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Cytogenetics is a branch of genetics concerned with the study of the structure of 
chromosomes and their role in heredity. Conventional chromosome analysis using 
G-banding is widely used for clinical diagnostics and genomic research. However, 
over the past 30 years the development of new techniques with increasingly higher 
resolution has led to the new field of molecular cytogenetics.
1.2 History of Cytogenetics
The field of human cytogenetics emerged in 1879 when Walther Flemming described 
the first human chromosomes and coined the term mitosis (Flemming, 1879). In 1888, 
Waldeyer introduced the word chromosome which comes from the Greek words 
chroma for colour and soma for body (Waldeyer, 1888). The term cytogenetics (from 
cytology and genetics) was formulated by Sutton in 1903 (Sutton, 1903). In the years 
that followed there were several publications on the human chromosome number 
(Von Winiwarter, 1912; Painter, 1923; Hsu, 1952). For a long time the chromosome 
number of humans was considered to be 48. Finally, in 1956 using improved tissue 
culture techniques, Tjio and Levan showed the correct human chromosome number in 
lung fibroblasts to be 46 (Tjio and Levan, 1956). This was soon confirmed on meiotic 
chromosomes from human testicular tissue (Ford and Hamerton, 1956). Three years 
later the first chromosomal aberration was discovered by Lejeune and his colleagues 
(1959) who identified an extra small chromosome in fibroblast cultures from patients 
with Down syndrome. Soon thereafter more chromosomal abnormalities were 
described involving both sex chromosomes and the autosomes: 45,X in Turner 
syndrome (Ford et al., 1959), 47,XXY in Klinefelter syndrome (Jacobs and Strong, 
1959), 47,XXX (Jacobs et al., 1959), trisomy 13 in Patau syndrome (Patau et al., 1960), 
trisomy 18 in Edwards syndrome (Edwards et al., 1960), and deletion of the short arm 
of chromosome 5 in Cri-du-chat syndrome (Lejeune et al., 1963). 
1.3 Chromosome banding and nomenclature
At first the chromosome pairs were classified into seven different groups (A-G), based 
on morphology (Patau, 1960). A system of nomenclature was proposed at a conference 
in Denver (Denver Conference, 1960). This classification was officially approved at 
a conference in London (London Conference, 1963). However, although certain 
chromosomes could be identified by their size and centromere position, it was not 
possible to identify individual chromosomes as we know them today. Furthermore, 
many structural abnormalities, such as inversions, that were suspected could not be 
proven. 
 In 1968, it was demonstrated that plant chromosomes, stained with fluorescent 
quinacrine compounds (Q-banding), showed a distinct staining whereby each 
chromosome could be identified by its unique banding pattern (Caspersson et al., 
1968). In 1970 the first human banded chromosomes were produced by this method 
(Caspersson et al., 1970). Q-banding proved to be very useful in identifying many 
chromosome abnormalities. However, as it requires a relatively expensive fluorescence 
microscope, and the fluorescence fades rapidly, Q-banding was largely replaced by 
G-banding. 
 For G-banding, which gives permanent staining, the chromosomes are treated 
with trypsin followed by staining with a Giemsa dye (Seabright, 1971). This method 
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is now the most commonly used banding technique in most laboratories worldwide, 
except in France. In France and many French speaking countries R-banding, which 
gives a banding pattern that is reverse to that of G-banding, is used as a standard 
technique (Dutrillaux and Lejeune, 1971). G-banding, a simple and an inexpensive 
technique, enabled rapid identification of many new chromosomal abnormalities, 
including deletions, duplications, translocations, inversions and insertions. In 1971, 
at the Paris Conference, a new system for the classification of chromosomes, based 
on Q, G, and R banding patterns, was introduced to identify individual chromosomes 
and chromosome regions (Paris Conference, 1971). This was followed in 1978 by a new 
document entitled “An International System for Human Cytogenetic Nomenclature” 
which included the major decisions of the Denver, London and Paris Conferences 
(ISCN 1978). This nomenclature for human chromosomes became widely used and 
is regularly updated (most recently in 2009, ISCN 2009). G-banding of long pro-
metaphase chromosomes gave high resolution banding (Yunis et al, 1980) and enabled 
the identification of subtle chromosome alterations. 
2. Chromosome morphology
2.1 Chromosome variants
Chromosomes consist of chromatin which is a combination of DNA and proteins. There 
are two types of chromatin, euchromatin and heterochromatin, which show different 
degrees of condensation. Euchromatin is the less condensed form, is generally rich 
in genes and is actively transcribed whereas heterochromatin is normally more 
condensed, poor in gene content, and rich in repetitive DNA. Even before the advent 
of banding it was known that the size and position of the heterochromatic segments 
could vary between individuals without a phenotypic effect. They were called 
heterochromatic variants. In recent years, variants of certain euchromatic chromosome 
segments have also been described. 
2.2 Heterochromatic variants
Already in 1960 it was evident that the Y chromosome could vary considerably 
between individuals (Patau, 1960). At the London Conference on ‘The normal human 
karyotype’ in 1963, it became apparent that also the secondary constrictions near the 
centromeres of chromosomes 1, 9 and 16 could vary in size. Although these so-called 
heteromorphisms had been widely reported, it was unclear whether or not they were 
associated with clinical abnormalities (Cooper and Hernits, 1963; Yunis and Gorlin, 
1963; Palmer and Schroder, 1971; Lobitz et al., 1972). It was only after large studies on 
consecutive newborns that it became clear that most of the heterochromatic variants 
were not disease-related (Sergovich et al., 1969; Lubs and Ruddle, 1970; Friedrich and 
Nielsen, 1973; Jacobs et al., 1974; Nielsen and Sillesen, 1975; Hamerton et al., 1975). 
Eventually, large scale population studies based on banded chromosomes revealed 
heteromorphisms on chromosomes 1, 3, 4, 6, 9, 13-16, 21, 22 and the Y (Geraedts and 
Pearson, 1974; Madan and Bobrow, 1974; Müller et al., 1975; McKenzie and Lubs, 1975; 
Madan and Bruinsma, 1979) and demonstrated that these were heritable (reviewed 
by Wyandt, 2004). The heritability of heteromorphisms was used in various ways, such 
as to demonstrate maternal contamination in prenatal samples (Olson et al., 1987), 
to determine paternity (Olson et al., 1983; Olson et al., 1986) and to determine the 
parental origin of chromosome abnormalities (Magenis et al., 1977; Mikkelsen et al., 




Deletions and duplications of euchromatic segments are usually pathogenic. However, 
several microscopically visible euchromatic deletions and duplications without any 
phenotypic consequences have been described. These euchromatic variants reflect 
copy number variation of chromosomal segments containing genes and pseudogenes. 
They can be polymorphic in the normal population and only reach a cytogenetically 
detectable level when the multiple copies are long enough to be observed under 
a microscope as constitutional cytogenetic amplifications. Euchromatic variants 
segregate in families without apparent phenotypic consequences. The first euchromatic 
variant was reported on the short arm of chromosome 9 in a G-banded chromosome 
study of live-born infants (Buckton et al., 1980). Other examples of regions with known 
euchromatic variants are 8p23.1, 9p12, 9q12, 9q13, 15q11.2 and 16p11.2 (reviewed by 
Wyandt, 2004; Barber et al., 2005; Hansson et al., 2007). In many cases it is difficult to 
decide whether a euchromatic deletion or a duplication is pathogenic or benign. Since 
most of the aberrations are initially detected in phenotypically abnormal individuals, 
their benign or pathogenic status can be established only after family studies. 
3. Molecular Cytogenetics
3.1 Overview
Although G-banding has improved substantially since its initial discovery in 1971, it 
enables the detection of deletions or duplications only in the order of 5-10 Mb. For 
the identification of smaller aberrations new techniques are needed. Fluorescence in 
Situ Hybridization (FISH) was the first of a series of methods that led to the emergence 
of the field of molecular cytogenetics, a combined application of cytogenetics and 
molecular biology. Some of the new methods are used only for the confirmation 
or further characterization of previously identified chromosomal aberrations 
(FISH, Multiplex Ligation-dependent Probe Amplification, MLPA and Quantitative 
Fluorescence-Polymerase Chain Reaction, QF-PCR ) whereas others are used for whole 
genome screening with different resolutions (array Comparative Genome Hybridization, 
aCGH and Single Nucleotide Polymorphism array, SNP array). Table 1.1 gives an 
overview of the (molecular) cytogenetic techniques and their possible resolutions. The 
techniques most commonly used in cytogenetic diagnostics are described below.
3.2 Fluorescence in Situ Hybridization 
In Situ Hybridization (ISH) was developed to detect specific DNA sequences on 
chromosomes and was initially based on radioactively labelled probes (Pardue and Gall, 
1969). This technique was used for the localization of genes to chromosomes (Harper 
et al., 1981; Gerhard et al., 1981). FISH, a locus-specific technique, was introduced in 
the 1980s (Prooijen-Knegt et al., 1982; Landegent et al., 1986). It allows the detection 
of chromosomal abnormalities directly on metaphase chromosomes and in interphase 
nuclei. A fluorescent labelled DNA probe hybridizes to its complementary sequence 
in chromosomes and is visualized with a fluorescent microscope. Probes used for FISH 
can be made from Bacterial Artificial Chromosome (BAC), P1 Artificial Chromosome 
(PAC), cosmid or fosmid clones, or from PCR products. The resolution depends on the 
size of the probe (>50 kb - 2 Mb). This method can be used to examine those regions 
of chromosomes that are suspected of carrying a specific abnormality based on the 
clinical picture of the patient, for instance microdeletion syndromes (Dauwerse et 



























chromosome abnormalities. However, it is relatively labour intensive and its use in 
diagnostics is limited because of its low resolution.
 Fiber FISH allows the detection of deletions and duplications of even just a 
few kilobases (Heng et al., 1992; Wiegant et al., 1992). This technique uses extended 
chromatin fibers and is able to resolve complex chromosomal rearrangements (Florijn 
et al., 1995; Giles et al., 1997). The preparation of fiber FISH samples, however, requires 
a highly skilled technician, and the technique is used only in specialized laboratories. 
Furthermore it is only used for a more detailed characterization of complex 
chromosomal aberrations that have been identified already.
 Other FISH applications use telomere-specific probes and whole-chromosome 
painting probes. Spectral karyotyping (SKY) and multicolour-FISH (M-FISH) are 
methods whereby in one experiment a whole karyotype can be produced in which 
each chromosome has a different fluorescent colour (Schröck et al., 1996; Speicher et 
al., 1996). These techniques allow the detection of interchromosomal aberrations such 
as translocations, insertions, complex chromosome rearrangements and the origin of 
marker chromosomes. The major disadvantage of SKY and M-FISH is that inversions, 
deletions and small duplications are not detectable.  
 While using different types of FISH for increasingly detailed analysis of 
chromosomes, it became apparent that techniques used for DNA analysis essentially 
also give information on chromosome morphology, albeit at another level of resolution. 
It was soon realized that these high throughput DNA techniques could also be used for 
studying chromosome morphology.
3.3 Array-CGH using BAC clones
Array comparative genome hybridization (aCGH) is a technique which compares 
DNA of a test sample with DNA of a reference sample and is generally seen as the 
first cytogenetic application of genomic (DNA-based) array technology. These arrays 
contained BAC and PAC clones covering the whole genome (BAC arrays) and were 
mostly in-house made by spotting (Solinas-Toldo et al., 1997; Pinkel et al., 1998). 
aCGH using BAC clones allows the detection of copy number variants (deletions 
and duplications) that are approximately 100 times smaller than those identifiable 
with conventional karyotyping. The resolution of these arrays depends on the 
distance between the probes as well as on the sizes of the probes. Initially, the BAC 
arrays contained approximately one clone per Mb (i.e. about 3500 BAC clones for the 
coverage of the full human genome) followed by a tiling path array with a resolution 
that is 10 fold higher (including 33000 BACs). The technique is based on competitive 
hybridization of test and reference DNA labelled with different fluorochromes (e.g. 
red for test and green for reference) on the spotted BAC clones. The array is imaged 
by a scanner and the relative fluorescence intensities are calculated. The chromosomal 
regions that are equally represented in the test and reference samples appear yellow, 
but those that are deleted in the test sample appear more green and those that are 
amplified appear more red. This results in intensity ratios for each mapped clone and 
reflects the copy number difference which can be visualized by a number of software 
packages. 
3.4 Array-CGH using oligonucleotides
The procedure for oligonucleotide CGH arrays is similar to that for BAC arrays, using 
differentially labelled test and reference DNA. However, these arrays are commercially 
manufactured by lithography, and consist of 45- to 85- mer oligonucleotide probes. 
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The major manufacturers are Agilent and Nimblegen. Their first arrays contained 44.000 
and 72.000 oligonucleotides respectively, but the latest released oligonucleotide CGH 
arrays contain 1 and 2.1 million probes respectively. 
3.5 Single Nucleotide Polymorphism (SNP) array 
A different type of oligonucleotide array is the SNP array which was initially developed 
for genome-wide linkage and association studies. This method allows the detection 
of SNP-genotype as well as the presence of deletions and amplifications. The major 
manufacturers of SNP arrays are Affymetrix and Illumina. These two companies use 
different technologies for the discrimination of alleles and their sensitivity for the 
detection of CNVs is different. A major advantage of this type of array is that it can be 
used both for genotyping studies and for copy number screening.
 Affymetrix
 The first SNP array produced by Affymetrix contained 10.000 (10K) SNP probes 
on a single array slide. This was followed by a 100K and 500K, the probes being 
distributed in the latter case over two array slides of 250K each. Later the 5.0 (500K) 
array combined the 500.000 probes on a single slide and the newer arrays 6.0 and 2.7M 
contain 1.8 and 2.7 million probes respectively on a single slide. These arrays include 
SNP probes and additional probes specific for the detection of copy number variation. 
 The Affymetrix method is a single color assay and is composed of multiple 
overlapping allele-specific hybridization probes that are complementary to SNP 
regions present in the reduced fraction of the genome amplified in the assay. Since the 
500K assay is now used for routine cytogenetic diagnostics in a number of laboratories, 
the method (adapted from www.affymetrix.com) is explained here in detail. The probes 
are 25-mer oligonucleotides with the variable SNP located at the 13th nucleotide. The 
probes present are for both possible alleles of each SNP, so-called ‘perfect match’ (PM). 
Besides these PM probes, mismatch (MM) probes are included for each allele to allow 
discrimination between signal and noise. Four additional probe quartets are present for 
each SNP where the probe sequences are different at four other positions. Additionally, 
all the quartets are present in both the forward and the reverse orientations. As a 
consequence, each SNP is represented by 40 distinct probe sequences. The probes are 
scattered over the array to diminish any effects of array variation and each probe has a 
fixed location on the array.  
 Approximately 250 ng of genomic DNA is digested with restriction enzymes 
and ligated to adaptors recognizing the overhangs (Figure 1.1). A universal primer, 
which recognizes the adaptor sequence, is used to amplify ligated DNA fragments 
and PCR conditions are optimized to preferentially amplify fragments in the 200-1000 
bp size range. These products are purified and fragmented to 50-200 bp products. 
The amplified and fragmented DNA is incorporated with biotine labeled nucleotides 
and hybridized to GeneChip arrays. After hybridization of 16-18 hours, the arrays are 
washed, fluorochromes are labeled to the biotine on the GeneChip fluidics station, 
and scanned on a GeneChip Scanner 3000. Signals from the allele-specific probes are 
analyzed to determine whether a SNP is AA, AB, or BB. The signal intensity is quantified 
and compared to signal intensities of normal individuals to determine SNP copy 
number. Several software packages have been developed to analyze SNP genotypes 
and to determine copy number.
15
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Figure 1.1 Schematic overview of the Affymetrix platform procedure
 Illumina
 The first SNP arrays from Illumina contained 317.000 probes (300K) on a single 
slide. The next generation contained twice the same 317.000 probes on a single slide, 
thus enabling hybridization of DNA from two individuals (317K-duo). This was followed 
by a 370K-duo and a 550K-duo. The latest SNP arrays from Illumina contain 650.000 and 
1 million probes.
 The concept of the Illumina assay is based on direct hybridization of whole 
genome-amplified genomic DNA to a bead array of 50-mer locus-specific probes. These 
probes end one nucleotide before the SNP. After hybridization each SNP is scored by 
a single base extension assay using different labeled nucleotides. These labels are 
visualized by staining with an immunohistochemistry assay. The A and T nucleotides 
are stained in one color and C and G in another. The signal intensity is used to 
determine copy number. On each array the beads are randomly assembled, therefore 
every array is provided with a file with the exact probe locations. A brief description of 
16
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the protocol (adapted from www.illumina.com) is described here. The first step in the 
Illumina assay is a whole genome amplification of 750 ng of genomic DNA (Figure 1.2). 
The amplified genomic DNA is fragmented to an average size of approximately 300 bp 
using an endpoint enzymatic fragmentation protocol. These fragments are precipitated 
and re-suspended in a hybridization buffer. The precipitated DNA is hybridized to a 
BeadChip in a humidified chamber. After 16-18 hours the hybridized arrays are washed 
and the next step is a single base extension with differentially labeled nucleotides. 
The BeadChips are scanned with a two-color confocal Illumina BeadArrayTM Reader. 
Image intensities are extracted and genotypes and copy number are determined using 
Illumina’s BeadStudio software. Several other software packages have been developed 
to analyze Illumina data.
Figure 1.2 Schematic overview of the Illumina platform procedure
17
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4. Copy number variants
As mentioned earlier, variation in chromosome morphology has been known from 
the earliest days of cytogenetics. It has now become possible to study variation in the 
composition of chromosomes right down to the nucleotide base level. Variation in the 
human genome takes many forms, ranging from the heterochromatic and euchromatic 
variants that have been described above to SNPs. With the advent of high-resolution 
whole-genome array technologies it has become evident that many submicroscopic 
copy number variants (CNVs), varying in size from kilobases to megabases, are 
present in all humans (Iafrate et al., 2004; Sebat et al., 2004; Sharp et al., 2005; Tuzun 
et al., 2005; Hinds et al., 2006; McCarroll et al., 2006; Locke et al., 2006; Feuk et al., 2006; 
Friedman et al., 2006; Redon et al., 2006; Conrad and Hurles, 2006). The identification of 
disease causing CNVs is hampered by our inability to distinguish between normal and 
causative variants. 
 New recurrent deletions and duplications for which the clinical significance is 
not directly evident have been reported. In 2007, a deletion of approximately 600 kb 
on 16p11.2 was reported in 1% of individuals with autistic features (Weiss et al., 2008). 
This was supported by two additional studies (Kumar et al., 2008; Marshall et al., 2008). 
However, in one of our studies we identified the same CNV in patients with mental 
retardation (MR) as well as in healthy individuals, both groups without autism (Chapter 
3.1). This indicates that the recurrent deletion of 16p11.2 gives rise to a broad and 
highly variable phenotype, including a normal phenotype. Another aberration which is 
detected in MR patients as well as in healthy individuals is a 253 kb deletion in 15q11.2 
(Murthy et al., 2007; Doornbos et al., 2009). This deletion was first reported in a boy 
with MR and dysmorphic features. He inherited it from his father, who had a history 
of developmental delay (Murthy et al., 2007). Doornbos and colleagues studied nine 
patients with the same deletion. In seven cases it was inherited from one of the parents. 
Only one of these parents showed an affected phenotype (the same developmental 
and behavioural problems as in the child). They concluded that a deletion in this region 
was associated with variable phenotypes, some of which could be explained by other 
genetic or environmental modifiers. 
 One of the consequences of the continuous increase in the resolution of the 
whole-genome arrays is that also the number of detected pathogenic, benign and 
potentially pathogenic CNVs has increased. Estimates indicate that approximately 
12% of the human genome may involve CNVs (Redon et al., 2006). The detected CNVs 
may be difficult to interpret in both clinical and research settings. Different workflows 
have been developed and are used to categorize CNVs into the different groups (Lee 
et al., 2007; Koolen et al., 2009; Chapter 2). In general, CNVs that overlap with known 
microdeletion or microduplication syndromes are likely to be pathogenic. Benign CNVs 
are mostly determined by comparing them with healthy or normal reference sets from 
one’s own laboratory or with the data in the Database of Genomic Variants (DGV). The 
DGV documents structural variants of 1 kb or more that were detected in apparently 
healthy individuals (http://projects.tcag.ca/variation). This database is still growing 
and laboratories that use high-resolution whole-genome arrays use it to screen for 
genomic deletions and amplifications to exclude the benign CNVs. Caution should be 
exercised when using this database as DGV is not always reliable. This is because many 
CNVs have been reported in single individuals, different platforms have been used in 
determining the CNVs and data submitted to this database is not subject to curation 
or an editorial screening. It is possible that ‘normal’ healthy individuals reported in the 
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DGV have phenotypic abnormalities which would have been noticed if the person had 
been seen by a clinical geneticist. Another example illustrating the need for caution is 
a case where a heterozygous deletion of 15q15.3 reported in the DGV turned out to 
be pathogenic in the homozygous state (Knijnenburg et al., 2009). Some heterozygous 
deletions could be pathogenic if there is a mutation on the other allele. Furthermore, 
there are CNVs such as 22q11.2 deletion that may show incomplete penetrance.
 CNVs that do not overlap with known microdeletion or microduplication 
syndromes and are not reported as benign variants are categorized as potentially 
pathogenic. Databases have been developed to collect cases of potentially pathogenic 
CNVs found in individuals seen in genetic clinics. DatabasE of Chromosomal Imbalance 
and Phenotype in Humans using Ensembl Resources (DECIPHER) collects clinical 
information about patients with microdeletions, microduplications, insertions, 
translocations and inversions (https://decipher.sanger.ac.uk). Another database 
with similar aims is the European Cytogenetics Association Register of Unbalanced 
Chromosome Aberrations (ECARUCA, http://www.ecaruca.net). CNVs that are not 
found in the DGV, should be compared with and added to one of these databases 
to create a platform of molecular cytogenetic and clinical data. This would enable 
collaboration between clinical genetic centres that have found (approximately) the 
same CNV in phenotypically similar patients and should make it possible to unravel 
new microdeletion and microduplication syndromes. The gene content, the size, and 
the inheritance pattern of potentially pathogenic CNVs are important factors that 
influence pathogenicity. 
 The implementation of high-resolution whole-genome arrays in cohorts with 
unexplained MR patients has resulted in the identification of new microdeletion and 
microduplication syndromes. These new syndromes were determined by screening 
large groups of patients with a similar clinical phenotype, mostly unexplained MR 
(reviewed by Slavotinek 2008; Vissers et al., 2009). 
 Chapter 2 describes the implementation of the SNP arrays in the diagnosis 
of MR. An increase from approximately 5% chromosomal aberrations found by 
conventional karyotyping to 22.6% aberrations by SNP array was noticed. However, 
most of the detected CNVs are neither described in the DGV nor are they known to 
be associated with microdeletion or microduplication syndromes. At present we do 
not know their clinical significance, so most of them have been classified as potentially 
pathogenic for the time being. More patients or healthy individuals with the same CNV 
are needed before we can understand their clinical significance. 
 We are seeing history repeat itself. Similar problems arose with the 
heterochromatic variants when karyotyping and banding were first introduced. The 
same was true for euchromatic variants identified by high resolution banding. In a 
few years one can expect that most of the potentially pathogenic CNVs will have been 
classified into either pathogenic or benign CNVs. We will then be faced with the same 
challenge at the base pair level with the introduction of the next-generation whole 
genome sequencing.
5. Clinical cytogenetic diagnostics
Patients are referred for chromosome analysis for various reasons which can be divided 
in three groups. 1) Postnatal diagnosis: this includes patients with multiple congenital 
abnormalities with or without mental retardation (MCA/MR), individuals with 
infertility and abnormal sexual development and couples with recurrent miscarriages. 
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2) Prenatal diagnosis: increased maternal age, ultrasound abnormalities in the foetus 
and chromosome abnormalities in the family. 3) Tumorcytogenetics: acquired 
chromosome abnormalities in tumor cells.
 Identification of chromosomal abnormalities is particularly important for a 
child with MCA/MR, for diagnosis and prognosis and for estimating the recurrence 
risk for the parents and other family members. Mental retardation is a highly diverse 
neurologic disorder with an incidence of 1-3% in the general population (Roeleveld et 
al., 1997; Leonard and Wen 2002). It is a lifelong disability characterized by impairment 
of cognitive and adaptive skills, with or without dysmorphic features. MR presents most 
often during infancy or in the first years of school. The cause of MR can be identified in 
only about 50% of all patients and is therefore one of the major unsolved problems in 
modern medicine (Battaglia and Carey, 2003). 
 The underlying causes of MR are extremely heterogeneous. There are non-
genetic factors that can act prenatally, perinatally or during early infancy to cause 
brain injury. These include infectious diseases (such as rubella, toxoplasmosis and 
cytomegalovirus during pregnancy and postnatal meningitis), oxygen deprivation 
(perinatal event), very premature birth and fetal alcohol syndrome, which is caused by 
excessive maternal alcohol consumption during pregnancy. Genetic factors include 
(1) single-gene disorders, such as Rubinstein-Taybi syndrome (CREBBP-gene) (Petrij et 
al., 1995) and Pitt-Hopkins syndrome (TCF4-gene) (Amiel et al., 2007), (2) chromosomal 
abnormalities, including presence of an extra chromosome, as in  Down syndrome 
(Lejeune et al., 1959), or a deletion or a duplication of a chromosome segment, 
for example 5p- in Cri-du-chat syndrome (Lejeune et al., 1963) and microdeletion 
in 22q11.2 in DiGeorge syndrome (de la Chapelle et al., 1981; Kelley et al., 1982), 
(3) multifactorial disorders, due to a combination of multiple genetic as well as 
environmental causes  and (4) mitochondrial disorders, caused by alterations in the 
small cytoplasmic mitochondrial chromosome (e.g. Leigh syndrome OMIM # 256000). 
 Patients with unexplained MR/MCA, who are referred to genetic laboratories, 
were screened initially with conventional karyotyping and if necessary with 
targeted FISH or MLPA analysis. The combined diagnostic yield of these analyses is 
approximately 5-10% (de Vries et al., 2005). Consequently, a clinical diagnosis is lacking 
in the majority of these patients and this impedes development of treatment strategies 
and adequate genetic counseling. Therefore, new high-resolution whole-genome 
technologies facilitating an increased detection rate of subtle chromosome imbalances 
have been developed to improve diagnosis of MR/MCA patients.
6. Scope of this thesis
The main aim of this thesis is to detect genome-wide submicroscopic CNVs at high 
resolution in a cohort of idiopathic MR patients to identify genomic regions or loci 
involved in developmental disorders. SNP arrays, from two manufacturers (Affymetrix 
and Illumina) were used to explore the possibility of identifying these abnormalities. 
The different arrays were directly compared for detection rate, accuracy, software, 
and costs. By applying these arrays, new regions involved in the etiology of MR were 
identified, resulting in an increase in the number of patients with a known cause for 
their developmental disorder. These methods have a significantly improved sensitivity 
as compared to the conventional karyotyping and FISH analyses. The Affymetrix array 
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High-density Single Nucleotide Polymorphism (SNP) genotyping technology enables 
extensive genotyping as well as the detection of increasingly smaller chromosomal 
aberrations. In this study we assess molecular karyotyping as first round analysis of 
patients with mental retardation and/or multiple congenital abnormalities (MR/MCA).       
 We used different commercially available SNP array platforms, the Affymetrix 
GeneChip 262K NspI, the Genechip 238K StyI, the Illumina HumanHap 300 and Human 
CNV 370 BeadChip, to detect copy number variants (CNVs) in 318 with unexplained 
MR/MCA. We found abnormalities in 22.6 % of the patients; including six CNVs which 
overlap known microdeletion/duplication syndromes, eight CNVs which overlap 
recently described syndromes, 63 potentially pathogenic CNVs (in 52 patients), four 
large segments of homozygosity, and two mosaic trisomies for an entire chromosome. 
 This study demonstrates that high density SNP array analysis reveals a 
much higher diagnostic yield as that of conventional karyotyping. SNP arrays have 
the potential to detect CNVs, mosaics, uniparental disomies (UPD) and loss-of-
heterozygosity (LOH) in one experiment. Furthermore, this study shows that two 
distinct SNP array platforms from different commercial suppliers can be readily used 
in a diagnostic setting. We therefore propose a novel diagnostic approach to all MR/
MCA patients by first analyzing every patient with a SNP array instead of conventional 
karyotyping.
Introduction 
Mental retardation (MR) is a life-long disability with a major impact on the lives of the 
patients and their families. The prevalence of MR is 2-3% and the underlying cause 
remains unknown in 65-80% of patients (Flint and Knight, 2003; Rauch et al., 2006; 
Hoyer et al., 2007). Diagnosing is a challenge due to the broad spectrum of potentially 
underlying disorders and the wide range of available tests. Knowing the cause is 
necessary in order to assess recurrence risk, short and long term prognosis and to 
decide on treatment options. 
 Changes in genetic dosage of one or more genes are common causes of 
MR (Rauch et al., 2006). Routine microscopic analysis of chromosomes isolated 
from peripheral blood lymphocytes has been used successfully to identify such 
genetic imbalances over the past 50 years. This conventional karyotyping has the 
advantage of surveying the entire genome for chromosome abnormalities in a single 
experiment, but it cannot detect imbalances smaller than approximately 5 Mb. Smaller 
chromosomal aberrations can be identified with Fluorescent In Situ Hybridization 
(FISH) and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. These 
techniques are used either to confirm a clinical suspicion by screening for well-known 
microdeletion syndromes associated with MR or for the analysis of all subtelomeric 
regions of the genome. The subtelomeric regions are known to be frequently affected 
in MR (Flint and Knight, 2003). The use of FISH and MLPA analysis is limited because 
only a few genomic regions can be screened in a single experiment and it can therefore 
not be applied genome wide. 
 Patients with unexplained MR with or without multiple congenital abnormalities 
(MR/MCA), whom are referred to genetic laboratories, are initially screened with 
conventional karyotyping and if required targeted FISH or MLPA analysis. The 
combined diagnostic yield of these analyses is approximately 5-10% (de Vries et al., 
2005). Consequently, a clinical diagnosis is lacking in the majority of these patients, 
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which impedes development of treatment strategies and adequate genetic counseling. 
Therefore, new high resolution whole genome technologies facilitating an increased 
detection rate of subtle chromosome imbalances are needed to improve diagnosis of 
MR/MCA patients.
 Recent developments in array technology allow whole genome analysis for copy 
number variation (CNV) at a resolution 10 to 10 000 times higher than that of routine 
chromosome analysis by conventional karyotyping. Comparative genome hybridization 
(CGH) studies using arrays with large insert clones (usually Bacterial Artificial Clones 
(BACs)) have demonstrated the potential of array technology to identify diagnostic 
CNVs in generally 16.7% of the unexplained MR/MCA patients (Vissers et al., 2003; 
Shaw-Smith et al., 2004; Schoumans et al., 2005; Tyson et al., 2005; Menten et al., 2006; 
Rosenberg et al., 2006; Fan et al., 2007). The pathogenic CNVs detected in CGH studies 
range in size from 0.25 Mb to 15 Mb (Kirov et al., 2008). Resolution is limited by the 
size of the probes and the distance between the clones, i.e. 100 kb-1 Mb. Therefore, 
the ideal technique would identify abnormalities with an even higher resolution. The 
single nucleotide polymorphism (SNP) arrays have been widely used for genotyping 
and can identify submicroscopic CNVs as well as low-level chromosomal mosaicisms 
and uniparental disomies (UPDs) (Altug-Teber et al., 2005; Friedman et al., 2006; Hoyer 
et al., 2007; Bruno et al., 2008).
 We performed SNP array analysis on DNA from 318 patients with unexplained 
MR/MCA and an apparently balanced karyotype to search for potentially pathogenic 
submicroscopic CNVs with two different commercially available SNP array platforms. In 
this study, we demonstrate the importance of implementing the SNP array analysis in 
a diagnostic setting and we advocate a whole-genome copy number screening using a 




A total of 318 patients referred for MR/MCA were recruited without further selection. 
Previously performed conventional karyotyping, targeted FISH or molecular tests 
revealed no etiological diagnosis. Detailed phenotypic information on all patients 
found to have a pathogenic or potentially pathogenic CNV is provided in Table 2.1. 
DNA was extracted from whole blood using a Gentra Puregene DNA purification Kit 
(Gentra Systems, Minneapolis, USA), following the manufacturer’s instructions. The 
study was approved by the Leiden University Medical Center Clinical Research Ethics 
Board, conforming to Dutch law and the World Medical association Declaration of 
Helsinki.
SNP Arrays
The Affymetrix GeneChip Human Mapping 262K NspI and 238K StyI arrays (Affymetrix, 
California, USA) contain 262 262 and 238 304 25-mer oligonucleotides respectively with 
an average spacing of approximately 12 kb per array. An amount of 250 ng DNA was 
processed according to the manufacturer’s instruction. SNP copy number was assessed 
using the software program CNAG Version 2.0 (Nannya et al., 2005). The Illumina 
HumanHap300 BeadChip (Illumina, Inc., San Diego, USA) contains 317 000 TagSNPs 
with an average spacing of approximately 9 kb. The Illumina HumanCNV370 BeadChip 
(Illumina, Inc., San Diego, USA) contains 317 000 TagSNPs and 52 000 non-polymorphic 
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markers to specifically target nearly 14 000 known CNVs. This array has an average 
spacing of approximately 7.7 kb. A total of 750 ng DNA was processed according to the 
manufacturer’s instruction. SNP copy number (log R ratio) and B allele frequency were 
assessed using the software programs BeadStudio Version 3.2 (Illumina, Inc., San Diego, 
USA) and Partek Genomics Suite Version 6.3 (Partek, Inc. St. Louis, USA).
Evaluation of CNVs
Deletions of at least five adjacent SNPs or of a minimum region of 150 kb and 
duplications of at least seven adjacent SNPs or of a minimum region of 200 kb were 
analyzed (Hehir-Kwa et al., 2007). This approach was adopted to minimise the number 
of false positive findings. The detected CNVs were classified in three different groups: 
I, known pathogenic CNVs (known microdeletion or microduplication syndrome); II, 
potentially pathogenic CNVs, not described in the Database of Genomic Variants (DGV; 
http://projects.tcag.ca/variation/); and III, known polymorphic CNVs described in the 
DGV, or observed in our in-house reference set (60 controls), whereby at least three 
individuals must be reported with the same rearrangement. All type III CNVs were 
further excluded from this study. All type II CNVs were assessed with Ensembl (http://
www.ensembl.org: Ensembl release 52 - dec 2008) and DECIPHER for gene content and 
similar cases respectively. All patients with a type II CNV were added to DECIPHER when 
consent was obtained.  
Validation of CNVs
The known and potentially pathogenic CNVs were confirmed with MLPA, FISH or 
another type of SNP array on a second independent sample. If parents were available 
segregation analysis was performed by MLPA, FISH or SNP array. 
 MLPA experiments were performed as described (White et al., 2004). At least two 
synthetic MLPA probes were designed within the CNV and probes were commercially 
obtained from Biolegio (Malden, the Netherlands). Amplification products were 
identified and quantified by capillary electrophoresis on an ABI 3130 genetic analyzer 
(Applied Biosystems, Nieuwerkerk aan de IJssel, the Netherlands). Fragment analysis 
was performed with the GeneMarker Software V1.51 (SoftGenetics, State College, USA). 
Thresholds for deletions and duplications were set at 0.75 and 1.25 respectively.
 FISH analysis was carried out by standard procedures as described (Dauwerse 
et al., 1990). BAC clones mapping to the CNVs were selected based on their physical 
location within the affected region (http://www.ensembl.org: Ensembl release 49 - mar 
2008). 
Results
A total of 318 patients were screened for submicroscopic CNVs. All patients had an 
apparently normal balanced karyotype and, if performed, targeted FISH or molecular 
tests revealed no rearrangements. The Affymetrix GeneChip was applied to 132 
patients and the Illumina BeadChip platform was applied to 186 patients. Eight (5.71 
%) Affymetrix and two (1.06 %) Illumina experiments failed. On average two CNVs per 
patient were obtained (Affymetrix 3 and Illumina 1.7).  All polymorphic CNVs were 
excluded from further research. Supplementary Table 2.1 shows a summary of all 
detected CNVs. Six patients showed a CNV that has a clear clinical significance since it 
overlaps a known microdeletion/duplication syndrome. In eight patients we detected a 
CNV that was recently described as a new microdeletion/duplication syndrome (Rauch 
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et al., 2005; Ballif et al., 2008; Courtens et al., 2008; Kumar et al., 2008; Weiss et al., 2008; 
Bijlsma et al., 2009; Hannes et al., 2009). 63 Potentially pathogenic CNVs were observed 
in 52 patients (16.4%). Four patients showed striking regions of loss-of-heterozygosity 
(LOH) (Table 2.1 and Figure 2.1). Regions of homozygosity, ranging in size from 200 
kb to 15 Mb are common in healthy individuals (Lencz et al., 2007). Here four patients 
showed regions of LOH extending more than 15 Mb. Two patients showed a single 
segment of LOH (BC227 and BC318), one patient a single segment, however in mosaic 
form (BC302) and one patient two segments (BC308). The parents of the patients were 
not related.
Figure 2.1 37.26 Mb region of LOH on chromosome 20q in case BC311 detected with the Illumina 317K 
BeadChip. Beadstudio logRratio estimate for each individual SNP in the first plot and genotype call for 
every SNP in the second plot. The X-axis shows the position on the chromosome.
 Two patients showed a low-level chromosomal mosaicism. Patient CR355 was a 
girl diagnosed with microcephaly, ventricular septum defect, diaphragmatic hernia, um-
bilical hernia and postaxial polydactyly of the left hand (Figure 2.2g and h). Pregnancy 
was conceived by in vitro fertilization and the girl was born at a gestational age of 36 5/7 
weeks with a birthweight of 2475 grams. Her psychomotor development was delayed 
and she failed to thrive. She developed severe respiratory insufficiency and died at the 
age of 7 months. Initial conventional karyotyping of five metaphases did not show re-
arrangements. SNP array analysis demonstrated a subtle increase in copy number for 
chromosome 13, suggesting an extra copy of chromosome 13 in 14% of the cells (Figure 
2.2a). FISH experiments confirmed the presence of trisomy 13 in 18% of cultured lym-
phocytes (Figure 2.2c and d) and supplementary karyotyping detected in seven of the 50 
(13%) metaphases an extra chromosome 13. 
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Figure 2.2 (a) CNAG copy number analysis for patient CR355 using the Affymetrix 262K GeneChip. LogRratio 
estimate for each individual SNP in the first plot and for an average of 10 SNPs in the second plot. Both 
plots show a slight increase in logRratio for whole chromosome 13. Blue line in first plot: copy-number 
estimate calculated with the Hidden Markov Model. The X-axis shows the position on the chromosome. 
Green stripes: heterozygous SNP calls. (b) CNAG copy number analysis output for patient CR377 using 
the Affymetrix 262K GeneChip. Both plots show a slight increase in logRratio for chromosome 14. (c) FISH 
experiment (probes LSI13 (green) and LSI21 (red), Vysis) showing a normal cell. (d) FISH experiment showing 
the presence of a mosaic trisomy 13 in 18% of the 200 cells analyzed.  (e) FISH experiment (probes LSI 
CCNDI, 11q13 (red) and LSI IGH, 14q32 (green), Vysis) showing a normal cell. (f ) FISH experiment showing 
the presence of a mosaic trisomy 14 in 9% of the 200 cells analyzed. (g) Facial picture of patient CR355. 
Facial dysmorphisms included upslant of palpebral fissures, a broad nasal bridge and uplifted earlobes. (h) 
Picture of postaxial polydactyly of the left hand of CR355. (i) Facial pictures of case CR377, 3 years and 7 
months (I, II), and 4 years and 8 months (III). Note marked asymmetry when smiling, asymmetric upslanted 
palpebral fissures, left sided epicanthus, hypertelorism, low-set and small right ear. 
a b
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 Patient CR377 was a boy referred at the age of 2 years and 9 months because of 
short stature, speech delay and motor delay (Figure 2.2i). Pregnancy had been unevent-
ful and the boy was born at a gestational age of 40 5/7 weeks after vacuum extraction, 
with a birthweight of 3610 grams. In early childhood, he suffered from recurrent respira-
tory infections and recurrent otitis media. At referral height was 84 cm (-3,4 SDS). He had 
a broad thorax, pectus excavatum, a right-sided simian crease and short 2nd phalanges 
of both digiti V. On follow up at the age of 3 years and 7 months height was even more 
compromised (-4.2 SDS). At the age of 4 years and 8 months a marked discrepancy in 
leg length was noted, the right being shorter. At that time the skin around both wrists 
and ankles showed an apparent reticular pattern of hypo- and hyperpigmentation. The 
body asymmetry combined with an abnormal skin pigmentation pointed in the direc-
tion of a mosaic condition. Conventional karyotyping on 31 metaphases had shown one 
cell with trisomy 14 which, confirming to professional guidelines, was interpreted as an 
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artifact. SNP array results displayed a subtle increase in copy number for chromosome 
14, suggesting an extra copy of chromosome 14 in 19% of the cells and mosaicism was 
confirmed with FISH experiments on cultured lymphocytes (9%) (Figure 2.2b, e and f ). 
UPD of chromosome 14 for the normal cells was excluded (results not shown).
Discussion
In this study SNP arrays were used to search for pathogenic CNVs in patients with 
unexplained MR/MCA. The detected CNVs can be divided into the following groups: 
clearly pathogenic CNVs which overlap known microdeletion/duplication syndromes, 
CNVs that overlap recently described syndromes, potentially pathogenic CNVs, and 
polymorphic CNVs (Supplementary Table 2.1). In total we detected known syndromes 
in six patients, recently described CNVs in eight patients and 63 potentially 
pathogenic CNVs in 52 patients (in total 20.7%). The polymorphic CNVs were excluded 
from further research. Six CNVs were considered pathogenic as they are associated 
with well-established microdeletion syndromes. These syndromes were recognized 
afterwards by a clinical geneticist, which underlines the difficulty of establishing a 
diagnosis by clinical observation. Eight patients showed CNVs that were recently 
identified in other studies. For these new syndromes no obvious phenotype has 
been established yet and more patients with the same abnormalities are needed to 
unravel the associated phenotype. The discovery of these ‘known’ CNVs highlights the 
advantage of the whole genome screening methods to detect a known deletion or 
duplication syndrome in one single experiment.      
 Unraveling the clinical relevance for the potentially pathogenic CNVs is a new 
challenge. Regions containing coding genes can be present in variable copy number 
without obvious clinical manifestations, which makes it very hard to determine 
whether a subtle CNV has a clinical significance. Recent papers have already 
presented flow schemes for the interpretation of these CNVs (Lee et al., 2007; Koolen 
et al., 2008). In this study, first all polymorphic CNVs were excluded by comparing 
against the DGV and our in-house reference set. Secondly, for all CNVs containing 
coding genes annotated by Ensembl (release 52, Dec 2008), the inheritance was 
determined by checking both parents (if available). 
 For 27 potentially pathogenic CNVs we could establish that the rearrangement 
was inherited from one of the unaffected parents. Several studies have shown 
that some CNVs are indeed polymorphisms contributing to common variation in 
healthy individuals (Iafrate et al., 2004; Sebat et al., 2004). A large number of small 
rearrangements, detected in patients with MR and inherited from phenotypically 
normal parents have been reported, whereby it was speculated that some of these 
imbalances may indeed be benign variations and others are likely to represent 
susceptibility loci for disease (Barber, 2005; de Ravel et al., 2006). A particularly 
intriguing example is the submicroscopic 1q21 deletion characteristic for 
thrombocytopenia absent radius (TAR) syndrome, which is found in all patients with 
the syndrome, but is inherited from a phenotypically normal parent in a subset of 
cases (Klopocki et al., 2007). It is becoming increasingly clear that many CNVs come 
with a highly variable phenotype, including what is considered as ‘normal’. Examples 
among many are the 22q11 deletion and duplication (Courtens et al., 2008), the 
16p11.2 deletion (Kumar et al., 2008; Weiss et al., 2008, Bijlsma et al., 2009), and the Xp 
deletions involving the neuroligin and VCX genes (Mochel et al., 2008). Mechanisms 
which can explain why some inherited CNVs occasionally result in abnormal 
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development have been postulated (Barber, 2005; Lesnik Oberstein et al., 2006). These 
mechanisms include: a mutation in the same region on the other chromosome; a 
mutation in one or more unlinked modifying genes; imprinting; mosaicism in one 
of the parents; or any other unidentified genetic, epigenetic or environmental factor 
(Barber, 2005; Hannes et al., 2008). Furthermore, it is frequently assumed that parents 
are phenotypically normal although closer inspection by a clinical geneticist might 
reveal subtle anomalies (Barber, 2005). 
 Twenty-two de novo potentially pathogenic CNVs are detected and are likely 
to be relevant for the phenotype of the patient. For 14 potentially pathogenic CNVs 
the inheritance could not be determined. Interpretation of these CNVs is even more 
difficult. Attempts should be made to receive DNA from the parents or alternatively 
other relatives. However, for all potentially pathogenic CNVs phenotypically concordant 
patients with the same abnormality need to be found to be sure of their pathogenicity. 
Therefore, databases like DECIPHER (https://decipher.sanger.ac.uk/) have been created 
in order to compile molecular cytogenetic data from clinical studies all over the world 
to provide the basis for understanding the role of different CNVs in genetic diseases. 
For the 63 potentially pathogenic CNVs detected in this study no complete overlapping 
cases were described in DECIPHER. More array data on MR patients and healthy 
controls will be needed to determine the clinical relevance of these CNVs.
 In 9 of the 26 de novo CNVs (pathogenic and potentially pathogenic), DNA from 
the parents was tested on SNP array, enabling us to determine the parental origin. 
Seven CNVs occurred in the paternally derived chromosome. Only two CNVs occurred 
in maternally derived chromosomes, giving a paternal maternal ratio of 6:2. Parental 
origins of microdeletions and duplications have been investigated in several genomic 
disorders. Deletions in Williams and DiGeorge syndrome were of paternal and maternal 
origin equally (Baumer et al., 1998). Deletions in Neurofibromatosis type 1 and in 
1p36 syndrome were predominant on the maternally derived chromosome (Lazaro 
et al., 1996; Wu et al., 1999). In contrast, duplications in Charcot-Marie-Tooth disease 
type I, deletions in Wolf-Hirschhorn syndrome and Cri Du Chat syndrome occur more 
frequently in the paternally derived chromosome (Lopes et al., 1997; Wieczorek et al., 
2000; Mainardi et al., 2001). Much more parent-of-origin data are needed to document 
the possible existence of regional parental bias. 
 ArrayCGH (aCGH) screenings performed on mentally retarded patients were 
found to be a powerful tool for the detection of CNVs (Vissers et al., 2003; Shaw-Smith 
et al., 2004; Schoumans et al., 2005; Tyson et al., 2005; de Vries et al., 2005; Menten et 
al., 2006; Rosenberg et al., 2006; Fan et al., 2007). These arrays consist of large-insert 
clones and the smallest pathogenic CNVs detected are approximately 0.25 Mb. The 
high-density whole-genome SNP arrays, which were initially developed for genotyping, 
are now widely used to search for smaller CNVs (Hoyer et al., 2007; Altug-Teber et 
al., 2005; Friedman et al., 2006; Bruno et al., 2008). In approximately 25% of patients 
with unexplained MR/MCA CNVs are detected by aCGH and SNP array studies. The 
array technology is the most effective method resulting in the most clinical diagnoses 
compared to conventional karyotyping, FISH analysis and mutation screening. 
Although cytogeneticists suspected that array analysis would not be able to detect 
mosaicisms, the aCGH and SNP array techniques actually appear to be more sensitive 
in detecting low-level mosaicism than conventional karyotyping (Ballif et al., 2006; 
Powis et al., 2007). If mosaicism is not suspected, the number of cells counted with 
conventional karyotyping may not be sufficient to detect the aberrant subset of cells, 
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and a single abnormal cell might be interpreted as an artifact of cell culture (Cheung 
et al., 2007). Two such cases of low-level mosaicism were reported in this study. Our 
patients with mosaic trisomy 13 and 14 have phenotypical characteristics which 
resemble the reported phenotypes of mosaic trisomy 13 and 14 (Figure 2.2). 
 A major advantage of SNP array analysis is the extra SNP genotyping 
information, which enables the detection of copy-number neutral chromosomal 
aberrations such as UPD and LOH (Zhang et al., 2008). UPD, which arises when an 
individual inherits two copies of a chromosome pair from one parent and no copy of 
the other parent, can result in rare recessive disorders, or developmental problems 
due to the effects of imprinting (Casidy et al., 2000). Examples of genetic diseases 
linked to UPD are Prader-Willi syndrome (MIM 176270), Angelman syndrome (MIM 
105830), Beckwith-Wiedemann syndrome (MIM 130650) and Silver-Russell syndrome 
(MIM 180860). SNP array analysis is able to detect uniparental isodisomy and 
uniparental heterodisomy (when both parents are included in the experiment), but 
the interpretation of new UPD regions is difficult and further research is required to 
confirm the clinical consequences. Recessive and normally non-penetrant alleles in 
isodisomic form (two copies of the same parental chromosome) may cause recessive 
diseases. Gene defects underlying autosomal recessive disorders can be localized and 
identified by homozygosity mapping. Furthermore, patients with consanguineous 
parents display many regions of homozygosity (LOH) that might result in a recessive 
disorder. In this study we identified an extended segment of LOH in four patients, with 
no consanguineous parents. To identify the responsible gene or genes is a challenge 
now, but may become a realistic possibility with next generation high throughput DNA 
sequencing technology. Finally, the information on the SNP genotype could be used to 
verify biological parentage and in cases of suspected incest. 
 Conversely, a disadvantage of using arrays instead of conventional karyotyping 
is the inability to detect balanced rearrangements. Around 6% of antenatal cases 
with balanced reciprocal translocations and inversions are associated with abnormal 
phenotypes (Warburton, 1991). In these cases the breakpoints of the rearrangement 
probably disrupt a gene, or small duplications or deletions beyond microscopic 
resolution are present. The SNP array analysis will (depending on the resolution) detect 
the small abnormalities, but the disruption of genes will remain unknown. A Dutch 
retrospective study showed that only approximately 0.78% potentially pathogenic 
balanced rearrangements of all referrals will be undetectable by array analysis without 
conventional karyotyping (Hochstenbach et al., 2009).
 The absence of an aberration or the presence of only polymorphic CNVs after 
SNP array analysis does not exclude a syndrome caused by a mutation at gene level. 
Therefore we emphasize that MR/MCA patients with normal array results should always 
be referred to a clinical geneticist to exclude such known syndromes. Furthermore, 
genomic data obtained from the SNP array analysis can be used in future research for 
association between genetic markers and specific phenotypes to hopefully diagnose 
even more patients. 
 In 2006, Rauch et al. compared the diagnostic yield of various techniques in 
MR/MCA patients (Rauch et al., 2006). These authors suggested targeted analysis in 
patients with a clear diagnosis and in the remaining patients conventional karyotyping 
and molecular screening (Rauch et al., 2006). Kriek et al. proposed another diagnostic 
approach to MR/MCA patients, suggesting a screening with MLPA first and based on 
the outcome additional aCGH or karyotyping (Kriek et al., 2007). However, more recent 
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studies already mentioned the partial replacement of conventional karyotyping by 
molecular karyotyping (Zhang et al., 2008). In addition, Koolen et al. described a 
workflow for the clinical interpretation of CNVs in individuals with MR (Koolen et al., 
2008). Our results demonstrate that high-density SNP arrays can be successfully used 
as tool for the detection of CNVs, low-level mosaicism and copy-number neutral 
abnormalities. Their high resolution and commercial availability make them attractive 
to implement into a routine diagnostic setting. 
 Here, we combine the flowcharts designed by Kriek et al. and Koolen et al. in 
a novel approach to the patient with MR/MCA (Figure 2.3) (Kriek et al., 2007; Koolen 
et al., 2008). We recommend testing every patient first with a SNP array instead of 
conventional karyotyping. The results will be classified in patients with polymorphic 
CNVs or no CNV (‘normal’), patients with CNVs which overlap known syndromes and 
patients with potentially pathogenic CNVs. The ‘normal’ patients could be screened 
for gene mutation in targeted genes or in the future with whole genome next 
generation high throughput DNA sequencing technology. The patients with CNVs 
overlapping known syndromes are diagnosed and family members could be checked 
for inheritance and recurrence risk. The inheritance of the potentially pathogenic CNVs 
should be tested and the patients should be reported in a database like DECIPHER. The 
clinical relevance for these CNVs can be determined when the specific CNV is reported 
in adequate numbers of healthy individuals or phenotypically concordant patients. 
Figure 2.3 Flow chart for the new diagnostic approach to patients with mental retardation. * If the CNV 
exceeds 200 kb we recommend additional FISH analysis to confirm the CNV in the patient and screen for 
balanced translocations or insertions in the parents. If the CNV is smaller than 200 kb we recommend a 
second array analysis on the patient to confirm the CNV and the parents to test heritability.
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 This new approach will diagnose a larger proportion of CNVs in the first round, 
however the interpretation of the CNVs will be the major challenge. Eventually, more 
families will be informed on the cause of the disease of their family member. This 
will improve medical care and genetic counseling. Furthermore, since the SNP array 
approach will make targeted FISH and MLPA analysis redundant, less laboratory tests 
will be needed which leads to a substantial reduction of cost. 
Acknowledgements
We are grateful to the patients and their parents, and to the clinicians of the Clinical 
Genetics Department of the Leiden University Medical Centre for referring the patients. 
We would further like to thank the technicians of the Laboratory of Diagnostic 
Genome Analysis, Leiden University Medical Centre for performing FISH experiments. 
In addition, we would like to thank Drs. Nicole de Leeuw and Rolph Pfundt from the 
Department of Human Genetics, Radboud University Nijmegen Medical Centre for 
sharing their knowledge about the implementation of arrays in their diagnostic setting. 
This work was supported by EuroGentest, an EU-FP6 supported NoE contract number 
512148.
References
Altug-Teber O, Dufke A, Poths S, Mau-Holzmann UA, Bastepe M, Colleaux L, Cormier-Daire V, Eggermann T, 
Gillessen-Kaesbach G, Bonin M, Riess O. 2005. A rapid microarray based whole genome analysis for 
detection of uniparental disomy. Hum Mutat 26:153-159.
Ballif BC, Rorem EA, Sundin K, Lincicum M, Gaskin S, Coppinger J, Kashork CD, Shaffer LG, Bejjani BA. 2006. 
Detection of low-level mosaicism by array CGH in routine diagnostic specimens. Am J Med Genet A 
140:2757-2767.
Ballif BC, Theisen A, Coppinger J, Gowans GC, Hersh JH, Madan-Khetarpal S, Schmidt KR, Tervo R, Escobar 
LF, Friedrich CA, McDonald M, Campbell L, Ming JE, Zackai EH, Bejjani BA, Shaffer LG. 2008. Expand-
ing the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the recipro-
cal microduplication. Mol Cytogenet 1:8.
Barber JC. 2005. Directly transmitted unbalanced chromosome abnormalities and euchromatic variants. J 
Med Genet 42:609-629.
Baumer A, Dutly F, Balmer D, Riegel M, Tukel T, Krajewska-Walasek M, Schinzel AA. 1998. High level of un-
equal meiotic crossovers at the origin of the 22q11.2 and 7q11.23 deletions. Hum Mol Genet 7:887-
894.
Bruno DL, Ganesamoorthy D, Schoumans J, Bankier A, Coman D, Delatycki M, Gardner MR, Hunter M, 
James PA, Kannu P, McGillivray G, Pachter N, Peters H, Rieubland C, Savarirayan R, Scheffer IE, Shef-
field L, Tan T, White SM, Yeung A, Bowman Z, Ngo C, Choy K, Cacheux V, Wong L, Amor D, Slater 
HR. 2009. Detection of Cryptic Pathogenic Copy Number Variations and Constitutional Loss of 
Heterozygosity using High Resolution SNP Microarray Analysis in 117 Patients Referred for Cytoge-
netic Analysis and Impact on Clinical Practice. J Med Genet 46:123-131.
Cassidy SB, Dykens E, Williams CA. 2000. Prader-Willi and Angelman syndromes: sister imprinted disorders. 
Am J Med Genet 97:136-146.
Cheung SW, Kolacki PL, Watson MS, Crane JP. 1988. Prenatal diagnosis, fetal pathology, and cytogenetic 
analysis of mosaic trisomy 14. Prenat Diagn 8:677-682.
Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, Bacino CA, Pursley A, Li J, Erickson R, Gropman AL, Miller 
DT, Seashore MR, Summers AM, Stankiewicz P, Chinault AC, Lupski JR, Beaudet AL, Sutton VR. 2007. 
Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenet-
ics. Am J Med Genet A 143A:1679-1686.
Courtens W, Schramme I, Laridon A. 2008. Microduplication 22q11.2: a benign polymorphism or a syn-
drome with a very large clinical variability and reduced penetrance? Report of two families. Am J 
Med Genet A 146A:758-763.
Dauwerse JG, Kievits T, Beverstock GC, van der KD, Smit E, Wessels HW, Hagemeijer A, Pearson PL, van Om-
men GJ, Breuning MH. 1990. Rapid detection of chromosome 16 inversion in acute nonlymphocytic 
39
Chapter 2
leukemia, subtype M4: regional localization of the breakpoint in 16p. Cytogenet Cell Genet 53:126-
128.
de Ravel TJ, Balikova I, Thienpont B, Hannes F, Maas N, Fryns JP, Devriendt K, Vermeesch JR. 2006. Molecu-
lar karyotyping of patients with MCA/MR: the blurred boundary between normal and pathogenic 
variation. Cytogenet Genome Res 115:225-230.
de Vries BB, Pfundt R, Leisink M, Koolen DA, Vissers LE, Janssen IM, Reijmersdal S, Nillesen WM, Huys EH, 
Leeuw N, Smeets D, Sistermans EA, Feuth T, van Ravenswaaij-Arts CM, van Kessel AG, Schoenmakers 
EF, Brunner HG, Veltman JA. 2005. Diagnostic genome profiling in mental retardation. Am J Hum 
Genet 77:606-616.
Delatycki M, Gardner RJ. 1997b. Three cases of trisomy 13 mosaicism and a review of the literature. Clin 
Genet 51:403-407.
Delatycki MB, Pertile MD, Gardner RJ. 1998. Trisomy 13 mosaicism at prenatal diagnosis: dilemmas in inter-
pretation. Prenat Diagn 18:45-50.
Fan YS, Jayakar P, Zhu H, Barbouth D, Sacharow S, Morales A, Carver V, Benke P, Mundy P, Elsas LJ. 2007. De-
tection of pathogenic gene copy number variations in patients with mental retardation by genom-
ewide oligonucleotide array comparative genomic hybridization. Hum Mutat 28:1124-1132.
Flint J, Knight S. 2003. The use of telomere probes to investigate submicroscopic rearrangements associ-
ated with mental retardation. Curr Opin Genet Dev 13:310-316.
Friedman JM, Baross A, Delaney AD, Ally A, Arbour L, Armstrong L, Asano J, Bailey DK, Barber S, Birch P, 
Brown-John M, Cao M, Chan S, Charest DL, Farnoud N, Fernandes N, Flibotte S, Go A, Gibson WT, Holt 
RA, Jones SJ, Kennedy GC, Krzywinski M, Langlois S, Li HI, McGillivray BC, Nayar T, Pugh TJ, Rajcan-
Separovic E, Schein JE, Schnerch A, Siddiqui A, Van Allen MI, Wilson G, Yong SL, Zahir F, Eydoux , 
Marra MA. 2006. Oligonucleotide microarray analysis of genomic imbalance in children with  
mental retardation. Am J Hum Genet 79:500-513.
Hannes FD, Sharp AJ, Mefford HC, de RT, Ruivenkamp CA, Breuning MH, Fryns JP, Devriendt K, Van BG, Vo-
gels A, Stewart HH, Hennekam RC, Cooper GM, Regan R, Knight SJ, Eichler EE, Vermeesch JR. 2009. 
Recurrent reciprocal deletions and duplications of 16p13.11: The deletion is a risk factor for MR/
MCA while the duplication may be a rare benign variant. J Med Genet 46: 223-232.
Hehir-Kwa JY, Egmont-Petersen M, Janssen IM, Smeets D, van Kessel AG, Veltman JA. 2007. Genome-wide 
copy number profiling on high-density bacterial artificial chromosomes, single-nucleotide poly-
morphisms, and oligonucleotide microarrays: a platform comparison based on statistical power 
analysis. DNA Res 14:1-11.
Hochstenbach R, van Binsbergen E, Engelen J, Nieuwint A, Polstra A, Poddighe P, Ruivenkamp C, Sikkema-
Raddatz B, Smeets D, Poot M. 2009. Array analysis and karyotyping: workflow consequences based 
on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. 
Eur J Med Genet 52:161-169.
Hoyer J, Dreweke A, Becker C, Gohring I, Thiel CT, Peippo MM, Rauch R, Hofbeck M, Trautmann U, Zweier C, 
Zenker M, Huffmeier U, Kraus C, Ekici AB, Ruschendorf F, Nurnberg P, Reis A, Rauch A. 2007. Molecu-
lar karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism 
arrays. J Med Genet 44:629-636.
Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. 2004. Detection of large-
scale variation in the human genome. Nat Genet 36:949-951.
Johnson VP, Aceto T, Jr., Likness C. 1979. Trisomy 14 mosaicism: case report and review. Am J Med Genet 
3:331-339.
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, O’Donovan MC, Erdogan F, Owen MJ, Ropers 
HH, Ullmann R. 2008. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in 
schizophrenia. Hum Mol Genet 17:458-465.
Klopocki E, Schulze H, Strauss G, Ott CE, Hall J, Trotier F, Fleischhauer S, Greenhalgh L, Newbury-Ecob RA, 
Neumann LM, Habenicht R, Konig R, Seemanova E, Megarbane A, Ropers HH, Ullmann R, Horn D, 
Mundlos S. 2007. Complex inheritance pattern resembling autosomal recessive inheritance involv-
ing a microdeletion in thrombocytopenia-absent radius syndrome. Am J Hum Genet 80:232-240.
Koolen DA, Pfundt R, de LN, Hehir-Kwa JY, Nillesen WM, Neefs I, Scheltinga I, Sistermans E, Smeets D, Brun-
ner HG, van Kessel AG, Veltman JA, de Vries BB. 2009. Genomic microarrays in mental retardation: a 
practical workflow for diagnostic applications. Hum Mutat 30:283-292.
Kriek M, Knijnenburg J, White SJ, Rosenberg C, den Dunnen JT, van Ommen GJ, Tanke HJ, Breuning MH, 
Szuhai K. 2007. Diagnosis of genetic abnormalities in developmentally delayed patients: a new 
strategy combining MLPA and array-CGH. Am J Med Genet A 143:610-614.
40
A new diagnostic workflow
Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, Gilliam TC, Nowak NJ, Cook EH, Jr., 
Dobyns WB, Christian SL. 2008. Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet 17:628-
638.
Lazaro C, Gaona A, Ainsworth P, Tenconi R, Vidaud D, Kruyer H, Ars E, Volpini V, Estivill X. 1996. Sex differ-
ences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 
patients. Hum Genet 98:696-699.
Lee C, Iafrate AJ, Brothman AR. 2007. Copy number variations and clinical cytogenetic diagnosis of consti-
tutional disorders. Nat Genet 39:S48-S54.
Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, Kane JM, Kucherlapati R, Malhotra AK. 2007. Runs 
of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A 
104:19942-19947.
Lesnik Oberstein SA, Kriek M, White SJ, Kalf ME, Szuhai K, den Dunnen JT, Breuning MH, Hennekam RC. 
2006. Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase. Am 
J Hum Genet 79:562-566.
Lopes J, Vandenberghe A, Tardieu S, Ionasescu V, Levy N, Wood N, Tachi N, Bouche P, Latour P, Brice A, 
LeGuern E. 1997. Sex-dependent rearrangements resulting in CMT1A and HNPP. Nat Genet 17:136-
137.
Mainardi PC, Perfumo C, Cali A, Coucourde G, Pastore G, Cavani S, Zara F, Overhauser J, Pierluigi M, Bricarelli 
FD. 2001. Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-pheno-
type correlation. J Med Genet 38:151-158.
Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J, Melotte C, de Ravel T, Van Vooren S, Balikova I, 
Backx L, Janssens S, De Paepe A, De Moor B, Moreau Y, Marynen P, Fryns JP, Mortier G, Devriendt K, 
Speleman F, Vermeesch JR. 2006. Emerging patterns of cryptic chromosomal imbalance in patients 
with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients 
and review of published reports. J Med Genet 43:625-633.
Mochel F, Missirian C, Reynaud R, Moncla A. 2008. Normal intelligence and social interactions in a male 
patient despite the deletion of NLGN4X and the VCX genes. Eur J Med Genet 51:68-73.
Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy 
GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucle-
otide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079.
Powis Z, Kang SH, Cooper ML, Patel A, Peiffer DA, Hawkins A, Heidenreich R, Gunderson KL, Cheung SW, Er-
ickson RP. 2007. Mosaic tetrasomy 12p with triplication of 12p detected by array-based comparative 
genomic hybridization of peripheral blood DNA. Am J Med Genet A 143A:2910-2915.
Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, Zenker M, Huffmeier U, Thiel C, Ruschendorf F, Nurn-
berg P, Reis A, Trautmann U. 2006. Diagnostic yield of various genetic approaches in patients with 
unexplained developmental delay or mental retardation. Am J Med Genet A 140:2063-2074.
Rauch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, Lascorz J, Huffmeier U, Weyand M, Singer H, Hofbeck 
M. 2005. Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 
22q11.2. J Med Genet 42:871-876.
Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, Otto PA, Kriek M, Hansson K, Krepis-
chi-Santos AC, Fiegler H, Carter NP, Bijlsma EK, van HA, Szuhai K, Tanke HJ. 2006. Array-CGH detec-
tion of micro rearrangements in mentally retarded individuals: clinical significance of imbalances 
present both in affected children and normal parents. J Med Genet 43:180-186.
Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M, Anderlid BM, Nordenskjold M. 2005. Detection of 
chromosomal imbalances in children with idiopathic mental retardation by array based compara-
tive genomic hybridisation (array-CGH). J Med Genet 42:699-705.
Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, 
Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 2004. 
Large-scale copy number polymorphism in the human genome. Science 305:525-528.
Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, Fiegler H, Firth H, Sanlaville D, Winter R, Colleaux L, 
Bobrow M, Carter NP. 2004. Microarray based comparative genomic hybridisation (array-CGH) de-
tects submicroscopic chromosomal deletions and duplications in patients with learning disability/
mental retardation and dysmorphic features. J Med Genet 41:241-248.
Shinawi M, Shao L, Jeng LJ, Shaw CA, Patel A, Bacino C, Sutton VR, Belmont J, Cheung SW. 2008. Low-level 
mosaicism of trisomy 14: phenotypic and molecular characterization. Am J Med Genet A 146A:1395-
1405.




Tyson C, Harvard C, Locker R, Friedman JM, Langlois S, Lewis ME, Van AM, Somerville M, Arbour L, Clarke 
L, McGilivray B, Yong SL, Siegel-Bartel J, Rajcan-Separovic E. 2005. Submicroscopic deletions and 
duplications in individuals with intellectual disability detected by array-CGH. Am J Med Genet A 
139:173-185.
Vermeesch JR, Fiegler H, de Leeuw N, Szuhai K, Schoumans J, Ciccone R, Speleman F, Rauch A, Clayton-
Smith J, Van Ravenswaaij C, Sanlaville D, Patsalis PC, Firth H, Devriendt K, Zuffardi O. 2007. Guidelines 
for molecular karyotyping in constitutional genetic diagnosis. Eur J Hum Genet 15:1105-1114.
Vissers LE, de Vries BB, Osoegawa K, Janssen IM, Feuth T, Choy CO, Straatman H, van der Vliet W, Huys EH, 
van Rijk A, Smeets D, van Ravenswaaij-Arts CM, Knoers NV, van der Burgt I, de Jong PJ, Brunner 
HG, van Kessel AG, Schoenmakers EF, Veltman JA. 2003. Array-based comparative genomic hybrid-
ization for the genomewide detection of submicroscopic chromosomal abnormalities. Am J Hum 
Genet 73:1261-1270.
Warburton D. 1991. De novo balanced chromosome rearrangements and extra marker chromosomes iden-
tified at prenatal diagnosis: clinical significance and distribution of breakpoints. Am J Hum Genet 
49:995-1013.
Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green 
T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, 
Gusella JF, Sklar P, Wu BL, Daly MJ. 2008. Association between microdeletion and microduplication 
at 16p11.2 and autism. N Engl J Med 358:667-675.
White SJ, Vink GR, Kriek M, Wuyts W, Schouten J, Bakker B, Breuning MH, den Dunnen JT. 2004. Two-color 
multiplex ligation-dependent probe amplification: detecting genomic rearrangements in heredi-
tary multiple exostoses. Hum Mutat 24:86-92.
Wieczorek D, Krause M, Majewski F, Albrecht B, Horn D, Riess O, Gillessen-Kaesbach G. 2000. Effect of the 
size of the deletion and clinical manifestation in Wolf-Hirschhorn syndrome: analysis of 13 patients 
with a de novo deletion. Eur J Hum Genet 8:519-526.
Wu YQ, Heilstedt HA, Bedell JA, May KM, Starkey DE, McPherson JD, Shapira SK, Shaffer LG. 1999. Molecular 
refinement of the 1p36 deletion syndrome reveals size diversity and a preponderance of maternally 
derived deletions. Hum Mol Genet 8:313-321.
Zhang ZF, Ruivenkamp C, Staaf J, Zhu H, Barbaro M, Petillo D, Khoo SK, Borg A, Fan YS, Schoumans J. 2008. 
Detection of submicroscopic constitutional chromosome aberrations in clinical diagnostics: a 
validation of the practical performance of different array platforms. Eur J Hum Genet 16:786-792. 
42






































































































































































































Interpretation of copy number variants

Chapter 3.1
Extending the phenotype of recurrent 
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Array CGH (comparative genomic hybridization) screening of large patient cohorts 
with mental retardation and/or multiple congenital anomalies (MR/MCA) has led to 
the identification of a number of new microdeletion and microduplication syndromes. 
Recently, a recurrent copy number variant (CNV) at chromosome 16p11.2 was reported 
to occur in up to 1% of autistic patients in three large autism studies.
 In the screening of 4284 patients with MR/MCA with various array platforms, 
we detected 22 individuals (14 index patients and 8 family members) with deletions 
in 16p11.2, which are genomically identical to those identified in the autism studies. 
Though some patients shared a facial resemblance and a tendency to overweight, 
there was no evidence for a recognizable phenotype. Autism was not the presenting 
feature in our series.
 The assembled evidence indicates that recurrent 16p11.2 deletions are 
associated with variable clinical outcome, most likely arising from haploinsufficiency of 
one or more genes. The phenotypical spectrum ranges from MR and/or MCA, autism, 
learning and speech problems, to a normal phenotype.
Introduction
Array CGH (comparative genomic hybridization) screening of large patient cohorts with 
mental retardation (MR) and/or multiple congenital anomalies (MCA) has lead to the 
identification of a number of new microdeletion and microduplication syndromes (for 
recent review see [20]). An additional and important outcome of this testing has been 
the discovery that several recurrent microdeletion and microduplication syndromes are 
caused by non-allelic homologous recombination (NAHR) between paired segmental 
duplications. As the short arm of chromosome 16 is rich in intrachromosomal 
segmental duplications (also known as low copy repeats, LCRs), it has previously 
been suggested that this region may harbour novel genomic disorders [19]. Indeed, 
a number of recent reports have provided evidence for this. Ballif et al. identified a 
microdeletion syndrome in 16p11.2-p12.2 involving a 7-8 Mb deletion [1]. Ullman et al. 
reported reciprocal 16p13.1 deletions and duplications which predispose to MR and/
or autism [21], while Hannes et al. found that this deletion was significantly associated 
with MR/MCA, and that the reciprocal duplication was a common variant in the 
general population [8]. Finally, copy number variants (CNVs) in the region of 16p11.2 
have been identified in up to 1% of autistic individuals [10, 13, 22], representing a 
substantial susceptibility risk to development of autism. The phenotypic spectrum of 
rearrangements in this genomic region remains to be fully characterized, especially in 
regard to their association with autism.
 By screening 4284 patients with MR/MCA, we detected 14 patients with 
deletions in 16p11.2, which are genomically identical to those identified in the autism 
studies [10, 13, 22]. Of these, six deletions were de novo and six were inherited from 
parents with a milder or normal phenotype; in one index case the inheritance could 
not be assessed, in another case segregation analysis is pending. We also detected an 
inherited smaller deletion of an adjacent region on 16p11.2. 
 Here we present clinical and molecular data on our patients with a 16p11.2 
deletion and compare them with previously reported cases. As autism was not the 
presenting symptom in our series of patients, our data indicate that the recurrent 
deletion of 16p11.2 gives rise to a broader phenotype than autism alone.
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Methods
Selection of patients tested by various array platforms. 
We studied 4284 patients with MR/MCA in several genetic centres. Patients were 
ascertained by clinical geneticists in Leiden, the Netherlands (n = 318), and through a 
collaborative effort with cytogenetic laboratories of Groningen, the Netherlands (n = 
600), Nijmegen, the Netherlands (n = 1525), Stockholm, Sweden (n = 560), Melbourne, 
Australia (n = 325), Madrid, Spain (n = 60), and Ghent, Belgium (n = 896).
Array platforms
Each of the genetic centres used one of the following array platforms to analyse their 
group of patients.
 The Affymetrix GeneChip Human Mapping 262K NspI and 238K StyI arrays 
(together 500K) (Affymetrix, California, USA) contain 262,262 and 238,304 25-mer 
oligonucleotides respectively, with an average spacing of approximately 12 kb per 
array. An amount of 250 ng DNA was processed according to the manufacturer’s 
instruction (http://www.affymetrix.com). Single nucleotide polymorphism (SNP) copy 
numbers were assessed using the software program CNAG Version 3.0 [15].
 The Affymetrix Genome-Wide Human SNP Array 6.0 features 1.8 million 
genetic markers, including more than 906,600 SNPs and more than 946,000 probes 
for the detection of copy number variation. DNA was processed according to the 
manufacturer’s instruction (http://www.affymetrix.com). SNP copy numbers were 
assessed using Genotyping Console™ version 3.0.2.
 The Illumina HumanHap300 BeadChip contains 317,000 TagSNPs with a mean 
resolution of approximately 9 kb. The Illumina HumanCNV370 BeadChip contains 
317,000 TagSNPs and 52,000 non-polymorphic markers to specifically target nearly 
14,000 known CNVs. This array has a mean resolution of approximately 7.7 kb. A total 
of 750 ng DNA was processed according to the manufacturer’s instruction (http://www.
illumina.com). SNP copy numbers (logRratio) and B allele frequencies were assessed 
using the software programs BeadStudio Version 3.2 (Illumina, Inc.) and Partek 
Genomics Suite Version 6.3 (Partek, Inc.).
 The 38K high-resolution CGH array contains 41,760 bacterial artificial 
chromosome (BAC) clones produced by the Swegene DNA Microarray Resource Centre, 
Department of Oncology, Lund University, Sweden (http://swegene.onk.lu.se) as 
previously described [17]. 
 The Agilent Human Genome CGH Microarray Kit 44K contains 42,433 probes 
and the assay was performed according to the manufacturer’s instructions with 
minor modifications. In brief, 400 ng of genomic DNA was labeled with Cy3 (patient) 
or Cy5 (control) (BioPrime Array CGH Genomic Labeling System, Invitrogen). After 
precipitation, patient and control samples were pooled together with Cot-1 DNA, 
Agilent 10X Blocking Agent and Agilent 2X Hybridization Buffer. This hybridization 
mixture was hybridized on the microarrays for 24 hours at 65°C. After washing, the 
slides were scanned with an Agilent DNA microarray scanner. The scan images were 
processed with Agilent Feature extraction software version 9 and further analysed 
with an in-house developed and freely available software tool arrayCGHbase (http://
medgen.ugent.be/arraycghbase/) [14]. Profiles were also evaluated by circular binary 
segmentation (CBS) to detect regions with aberrant copy number.
 The Agilent Human Genome CGH Microarray Kits 105K and 244K (Santa Clara, 
CA) contain respectively ~99,000 and ~237,000 probes, and the assays were performed 
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following the protocols provided by the manufacturer. The slides were scanned on an 
Agilent microarray scanner. Data analysis was performed using the Agilent Feature 
extraction software version 9 and Agilent CGH analytics version 3.5.14 software.
Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA experiments were performed as described previously [23]. MLPA probes were 
designed within the 16p11.2 region (located in the genes MVP, SPN, CORO1A (kit1); 
SEZ6L2, MVP, FAM57B (kit2); SPN, ALDOA (kit 3)). Amplification products were identified 
and quantified by capillary electrophoresis on an ABI 3130 genetic analyzer (Applied 
Biosystems, Nieuwerkerk aan de IJssel, the Netherlands). Fragment analysis was 
performed with the GeneMarker Software V1.51 (SoftGenetics, USA). Thresholds for 
deletions and duplications were set at 0.75 and 1.25 respectively.
Fluorescent In Situ Hybridisation (FISH)
FISH analysis was carried out by standard procedures as described previously [4]. BAC 
clones mapping to the 16p11.2 deletion region were used (RP11-114A14 and RP11-
301D18).  
Gene prioritisation and sequencing
The software tool Anni 2.0 (http://www.biosemantics.org/Anni) was used to search 
for candidate genes in the 16p11.2 region. For each gene a profile of related concepts 
is constructed that summarizes the context in which the gene is mentioned in the 
literature. Genes associated with similar topics are identified by hierarchical clustering 
of the corresponding gene concept profiles [9].The software was used according to the 
software’s manual. 
 Direct sequencing of genomic PCR products covering the coding regions 
of ALDOA, TBX6 and SPN was performed. Primers were selected using the Primer3 
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Sequencing was 
performed as described previously [12].
 
Case reports
Patients carrying a ~600 kb 16p11.2 deletion
Case 1 is a mildly retarded, 44-year old male with normal height (1.72 m, +0.2 SDS) and 
overweight (BMI 28.7 kg/m2). He does not have autistic behaviour, but has significant 
speech problems. He has some mild dysmorphic features: short palpebral fissures, 
dysplastic ears, retrognathia, a broad neck with sloping shoulders, and a unilateral 
simian crease. Parents were not available for testing, but were reported to be of normal 
intelligence.
Case 2 is a mildly retarded 18-year old male (Fig. 3.1.1a), born to a 30-year old mother 
and a 39-year old father. He was born at term with a birth weight of 4 kg. His motor 
development was normal (started walking at 13 months of age), however speech 
development was delayed (first words at 2.5 years of age). A formal test for autism in 
childhood showed no autism spectrum disorder (ASD).
 When first assessed at the age of 7 years and 3 months, his height was 1.36 
m (+2.3 SDS), and his head circumference 54.5 cm (+1.3 SDS). At the age of 17 years 
and 2 months his height was 1.80 m (-0.2 SDS), his weight was 130.5 kg (+4.2 SDS, BMI 
40.1 kg/m2) and his head circumference 60 cm (+1.8 SDS). He does not show autistic 
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behaviour. He has mild dysmorphic features: short and down-slanted palpebral fissures, 
mild malar hypoplasia, anteverted nares, simple external ears, retrognathia, a broad 
neck, and sloping shoulders. 
 An MRI at the age of 8 years showed an arachnoidal cyst with a diameter of 5 
cm, and partial agenesis of the left temporal lobe.
 His family history is negative for obesity or mental retardation. MLPA analysis of 
the 16p11.2 region (kit 1) showed normal copy numbers in both parents.
Case 3 is a mildly retarded, 10-year old girl, born to a 38-year old mother and a 31-year 
old father (Fig. 3.1.1b). She was born at term with a birth weight of 3300 g. In infancy 
she was treated for epilepsy. Her motor milestones were reached late and speech 
development was delayed (first words at the age of 20 months). A formal test for 
autism in childhood showed no ASD.
 On examination at the age of 8 years and 2 months her height was 1.30 
m (-0.4 SDS), her weight 45 kg, (+3 SDS for height, BMI 26.6 kg/m2) and her head 
circumference 54.5 cm (+1.7 SDS). She did not have autistic features. She speaks with a 
lisp. Apart from mild malar hypoplasia, she has no apparent facial dysmorphisms. She 
has a unilateral single palmar crease and mild syndactyly of the 2nd and 3rd toes.
 A brain MRI was reported normal.
 The paternal family history is positive for dyslexia and mild mental retardation. 
Only her parents and a paternal uncle could be examined with MLPA-analysis (kit 1). 
Other family members were not accessible.
 Her father carried the same microdeletion. He had speech retardation (first 
words at the age of 4 years) and is dyslectic. Because of this, he went to a special 
school. Apart from bilateral 4/5 syndactyly of his toes, he has no apparent dysmorphic 
features.
 The deletion was also found in the the paternal uncle. In infancy he was treated 
for pyloric stenosis. He is reported to have mental retardation and dyslexia. Dysmorphic 
features were not recorded. He lives in a sheltered home. 
Case 4 is a 13-year old boy. He is the only child of healthy, non-consanguineous 
parents. He was born at term after a normal pregnancy and delivery. His birth weight 
was 4.3 kg. In early childhood, he suffered from obstructive bronchitis. Enuresis was 
present till the age of 10 years. His motor and speech development were slightly 
delayed; he started to speak single words at 2 years of age. He was diagnosed with 
Attention Deficit Disorder (ADD) with motor immaturity and muscular hypotonia. His 
cognitive level was in the low normal range. On examination he was rather tall (+2 
SDS), and overweight (+3 SDS). He had no apparent dysmorphic features.
 FISH analysis for the 16p11.2 region showed normal copy numbers in both 
parents.
Case 5 is a 3-year old boy, the second in a sibship of three. His parents are first 
cousins. Pregnancy, delivery and neonatal period were reported as normal. His growth 
parameters are within normal limits (0 SDS for height and weight, -0.8 SDS for head 
circumference). His development (motor function, speech and cognitive function) 
was severely delayed. He walked independently at the age of 24 months. He has a 
disturbed sleeping pattern, with difficulties falling asleep as well as waking up in the 
middle of the night. 
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 At the age of 18 months he scored positive in the CHecklist for Autism in 
Toddlers (CHAT)-screening. Evaluation at the age of 20 months showed lack of eye 
contact, stereotypic behaviour and no speech. He had no dysmorphic features. Since 
the age of 18 months, he has had frequent periods with diarrhea.
 Psychological evaluation (Griffith and Merril Palmer R) revealed a cognitive level 
corresponding to the 4-10 months of age interval at a chronological age of 20 months, 
in addition to autistic symptoms. A brain MRI at 17 months of age was normal. 
 His family history is positive for speech retardation. MLPA analysis of the 
16p11.2 region (kit 2) in his parents and brother showed a normal copy number in 
his mother, and a deletion in his father and brother. As a child, his father had delayed 
speech development. At present he is working full time as a sailor. He has no apparent 
dysmorphic features.
 His 5-year old brother was born at term with good Apgar scores. At birth, his 
weight was 3055 g, his length 49 cm. His motor development was unremarkable 
(crawling at 8-9 months, walking independently at 19 months). He had a severe speech 
delay; at the age of 2 years he only spoke a few single words. Psychological evaluation 
at the age of 4 years and 6 months revealed a speech disorder. His cognitive function 
is in the low normal range. His growth parameters are at the median for weight and 
height. He has no apparent dysmorphic features.
Case 6 is a 7-year old mentally retarded girl (IQ 65), without autistic behaviour (Fig. 
3.1.1c). On examination, her height was 122 cm (-0.7 SDS), her weight 25 kg (0 SDS), 
and her head circumference 52.5 cm (+0.8 SDS). She has a nasal speech.
 She has several dysmorphic features: low frontal hairline, hypertelorism, bilateral 
epicanthic folds, short palpebral fissures, mild ptosis, a broad nasal bridge,  a broad 
based nose with upturned nares, a long philtrum, a tented mouth with thin upper lip, 
a high and narrow palate, a pointed chin, low set ears, a broad neck, widely spaced 
nipples, short fingers, broad and proximally implanted thumbs, and mild clinodactyly 
of both fifth fingers.
 Testing of the 16p11.2 region in the parents, using the 44K Agilent Human 
Genome CGH Microarray Kit detected the same deletion in the mother. She is a normal 
functioning female, with an IQ within normal limits, without speech problems or major 
health problems. The further family history is negative for mental retardation or autism. 
Case 7 is a 1 year and 8 month old boy, born after an uneventful pregnancy with a 
birth weight of 2770 g, a birth length of 46 cm and a head circumference of 34 cm. 
His neonatal period was uncomplicated. His neuromotor development was slow, with 
sitting independently at 13 months of age. At the age of 18 months he was able to 
crawl, roll over, and pull himself up to an upright position, but he could not yet stand 
unsuppported. He could speak two words. Formal developmental testing revealed a 
developmental level of 12 months at the age of 17 months. He had no major health 
problems. At the age of 18 months his height was 72 cm (-4 SDS), his weight 8.2 kg (-1.5 
SDS for height), and his head circumference 47.5 cm (-0.7 SDS). Physical examination 
revealed mild facial dysmorphism with sparse blond hair, anteverted nares, low-set 
ears, a broad mouth and a narrow nasal bridge. He has mild hypospadias with bilateral 
descended testis. He has small hands. Neurological examination showed symmetrical 
reflexes, axial hypotonia, and joint hyperlaxity.
 His family history is positive for developmental delay: his mother, father 
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and brother are all developmentally delayed. The probands brother had normal 
antropometric parameters at birth, but suffered from asphyxia and has convulsions and 
developmental delay. He has not been tested for the deletion.
 Analysis of the 16p11.2 region in the parents, using the 44K Agilent Human 
Genome CGH Microarray Kit detected the same deletion in the mother. She has short 
stature (height 1.50 m, -3.2 SDS). She attended a school for children with learning 
disabilities and works in a sheltered workshop. There is no further family history of 
developmental delay, other family members were not available for testing.
Case 8 is a 11-year old, mildly mentally retarded girl. She was born as the third child of 
healthy, non-consanguineous parents. Pregnancy and delivery were uneventful. At the 
age of 2 years speech retardation was evident. At the age of 2.5 years, she used about 
20 words and at the age of 3 years she spoke 2-word sentences. At the age of 3 years, 
she suffered from complex partial epilepsy, which was successfully treated.
 Psychological testing revealed mild mental retardation (total IQ (TIQ) 62) and a 
severe expressive language disorder. Apart from some hand stereotypies, she had no 
behavioural problems or autistic features. On examination, she had a normal height 
(146 cm, 0 SDS) and weight (42.8 kg, +0.7 SDS). Apart from mild truncal obesitas no 
abnormalities were noted, especially no dysmorphic features. A brain MRI showed no 
abnormalities.
 Despite intensive therapy, she did not achieve scholarly skills such as reading, 
writing and calculating. At the age of 11 years she still has poor expressive verbal skills.
 Her family history is positive for mental retardation. Her oldest sister is equally 
affected with mild mental retardation (TIQ 66), expressive language disorder and 
epilepsy. Their father had learning problems.  Analysis of the 16p11.2 region in the 
parents, using the 44K Agilent Human Genome CGH Microarray Kit detected the 
same deletion in the mother, who is of normal intelligence and without major health 
problems. Array analysis in the sister is pending.
Case 9 is a 34-year old mentally retarded male, reported as case 7 in a previously 
described series [2]. He was born at term after normal pregnancy and delivery. He was 
reported to be small for gestational age (2.8 kg). His developmental milestones were 
reached late. In childhood he had intensive speech therapy because of speech delay. 
On examination at the age of 34 years, he had slow speech and was overweight. Apart 
from mild malar hypoplasia, he had no apparent dysmorphisms. He had no autistic 
features. 
 Formal neuropsychological assessment indicated moderate mental retardation, 
with major difficulties with working memory, attention and self-monitoring. He does 
not live independently, but has been able to do simple (cleaning) jobs.
 FISH analysis in his parents confirmed a de novo deletion. 
Case 10 is an 8-year old girl with significant intellectual disability, born to a 30-year 
old mother and a 31-year old father. She has no speech, but she is socially interactive. 
She is able to walk and has a happy disposition. She is not toilet trained and has major 
sleeping problems. Apart from pyloric stenosis at the age of 5 weeks, she had no major 
health problems, especially no seizures.
 On examination she had normal height (128 cm, –0.5 SDS), weight (24 kg, –0.7 
SDS), and head circumference (53 cm, +1 SDS). She has subtle dysmorphic features 
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(Fig. 3.1.1d): a relatively flat nose and maxilla, prominent infra-orbital skin creases, small 
ears, an unusual hairline which extends over the lateral forehead, small hands with 
abnormal palmar creases and small feet.
 Her family history is negative for mental retardation. FISH analysis in the parents 
is ongoing.
Case 11 is a 4.5-year old boy, born to a 33-year old father and a 28-year old mother. He 
was born at term in poor condition, but quickly recovered from hypotonia and cyanosis 
using an oxygen mask (Apgar scores 5 and 9 at 1 and 5 minutes, respectively). 
 At birth, his weight was 3 kg, his length 49 cm, and his head circumference 35 
cm. In infancy and childhood he had failure to thrive. He has no autistic features. He 
loves water and music. He has normal hearing and vision. 
 His gross and fine motor development were delayed; he walked independently 
at the age of 2.5 years. At the age of 3 years and 8 months he had no comprehensible 
language, but only varied utterances mimicking sentences. Language comprehension 
was clearly present. At the age of 4 years and 4 months he was able to speak a few 
single words, with poor articulation.
 IQ-testing at the age of 3 years and 8 months showed scores in the slightly 
retarded range (non verbal IQ (tested with SON-R 2½-7) 74, language comprehension 
quotient (Reynell): 73, and expressive language quotients words/sentences 
(Schlichting): 58/55).
Physical examination at the age of 4 years showed a skinny boy with a height of 101.5 
cm (–0.5 SDS), a weight of 15 kg (–0.9 SDS for height), and a head circumference of 
51.5 cm (+0.1 SDS). He had mild facial dysmorphism: retrognathia, small teeth, and 
posteriorly rotated ears with a slightly larger ear on the left (Fig. 3.1.1e). Neurological 
examination showed clumsy walking, but was otherwise unremarkable. There was no 
indication of a specific motor deficit affecting articulation.
 A brain MRI was reported normal.
 The maternal family history is positive for mental retardation: two maternal 
uncles are mentally retarded. Analysis of the 16p11.2 region using the 105K Agilent 
Human Genome CGH Microarray Kit showed normal copy numbers in both parents.
Case 12 is a 3.5-year old girl, born as the third child of a 32-year old mother and 
the second child of a 31-year old father (Fig. 3.1.1f ). She presented prenatally with 
intrauterine growth retardation. In pregnancy, her mother had thrombosis and 
hypertension. Delivery was induced at 37 weeks of gestation. Birth weight was 2.5 kg 
(-1.3 SDS), and head circumference 31.5 cm (-2 SDS). In the first year, she had muscular 
hypertonia. Her development is within normal limits and she has no autistic features.
 Physical examination at the age of 11 months showed a length of 77.5 cm 
(+1.5 SDS), a weight of 8.4 kg (-0.9 SDS), and a head circumference of 45.5 cm (0 SDS). 
She had minor facial dysmorphisms: slightly deep-set eyes, a thin upper lip, a smooth 
philtrum, long and slender fingers, and camptodacyly of both fifth fingers.
At the age of 2 years and 9 months she was diagnosed with a Wilms' tumor with liver 
metastases. At the age of 3 years and 4 months she was fully recovered after standard 
treatment.
 The family history is positive for mental retardation. Her older brother is 
mentally retarded, with an estimated IQ of 60. He also had muscular hypertonia in 
infancy. He was not tested for the deletion. Her maternal half-sib is mentally retarded 
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and has attention deficit hyperactivity disorder (ADHD).
 The Wilms' tumor, combined with the family history and hypertonia in the 
neonatal period, were reason to perform array analysis.
 Analysis of the 16p11.2 region in her parents, using the 105K Agilent Human 
Genome CGH Microarray Kit, detected the same deletion in the father. He is of normal 
intelligence and has no apparent dysmorphic features (Fig. 3.1.1g). In childhood, he had 
neither learning problems nor speech problems. He had two episodes of meningitis, 
at the ages of 9 months and 31 years, respectively. During the latter episode he 
developed seizures due to post-viral cerebral damage. He has a full time job.
 He is the only child of healthy parents. Further family studies have not been 
performed.
Case 13 is a 4 years and 10 months old boy (Fig. 3.1.1h). He is the second child of a 
31-year old mother and a 33-year old father. He was born at term after a normal 
pregnancy, with a birth weight of 2790 g. At the age of 7 weeks he was diagnosed with 
short segment (~5 cm) Hirschsprung's disease, for which he underwent surgery. At the 
age of 2 years and 6 months he started to have seizures, for which he was successfully 
treated. He suffers from frequent infections, particularly otitis media and upper 
respiratory tract infections.
 His psychomotor development was delayed: he walked independently at the 
age of 21 months and spoke his first words at the age of 3 years and 9 months. At the 
age of 4 years and 6 months his IQ score was 83. A formal test for autism showed no 
ASD.
Figure 3.1.1 Phenotypical characteristics of cases with a 16p11.2 deletion. (a) case 2 (overview aged 16 
years (left), face aged 7 years (top) and 17 years, (b) case 3, (c) case 6, (d) case 10, (e) case 11, (f ) case 12, 
(g) father of case 12, (h) case 13,  (i) case 14 (at the age of 9 months (left) and 4 years). Some of the cases 
share facial characteristics (long nose in cases 6, 12 and, father of case 12) (c, f, g); narrow palpebral fis-
sures in cases 6 and 14(c, i); periorbital fulness in cases 2, 3, and 11(a, b, e); ptosis in cases 13 and 14 (h, i). 
Overall however, patients show no common facial features.
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Figure 3.1.2 Facial characteristics of cases with an atypical 16p11.2 deletion. (a) case 15, (b) father of case 
15. Note long narrow face, prominent forehead, downslanted and narrow palpebral fissures, and down 
turned corners of the mouth in both.
 On examination he had normal height (112 cm, 0 SDS) and weight (21 kg, +1 
SDS). He has a mild ptosis, a unilateral simean crease, and a pectus excavatum. He has 
a high forehead, but this is also observed in his unaffected brother and father.
 Analysis of the 16p11.2 region using the 500K Affymetrix GeneChip Human 
Mapping array, showed normal copy numbers in both parents.
Case 14 is a 4-year old girl with psychomotor and growth retardation. She is 
microcephalic with facial dysmorphisms: blepharophimosis, ptosis, epicanthus inversus, 
telecanthus, a flattened and broad nose with bifid tip, and large ears (Fig. 3.1.1i). She 
also has scoliosis and clinodactyly of her fingers. Autistic features are not reported.
 MLPA analysis of the 16p11.2 region (kit 3) showed normal copy numbers in 
both parents.
Patients carrying atypical 16p11.2 deletions
Case 15 is a 5-year old mentally retarded boy. He was born at term after an 
uncomplicated pregnancy. Birth weight and length were 3750 g and 53 cm, 
respectively. Both his motor and speech development were delayed; he started to 
walk at the age of 2 years, and at times speech is barely comprehensible. Because of 
behavioural problems he is on Risperdal. He has a normal sleeping pattern.
 On examination at the age of 5 years and 3 months he was hypotonic and 
had dysmorphic features: a long narrow face, a prominent forehead, downslanted 
and narrow palpebral fissures, an open mouth with down turned corners, and fleshy 
earlobes (Fig. 3.1.2a).
 A brain MRI was reported normal.
 Analysis of the 16p11.2 region in the parents, using the 44K Agilent Human 
Genome CGH Microarray Kit detected the same deletion in the father. As a child, 
his father had learning difficulties. He works as a truck driver. He has the same facial 
appearance as his son (Fig. 3.1.2b). Further family members were not accessible. The 
family history is negative for learning problems.
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Figure 3.1.3 Examples of array results showing a 16p11.2 deletion using various array platforms. (a) LogR-
ratio profile of a 500K Affymetrix array, showing a minimal deletion of ~525 kb in case 13. (b) LogRratio 
profile of a 317K Illumina array, showing a minimal deletion of ~522 kb in case 1. (c) LogRratio profile of 
a 244K Agilent array, showing a minimal deletion of ~505 kb kb in case 5. (d) LogRratio profile of a 44K 
Agilent array, showing a minimal deletion of ~526 kb kb in case 6. (e) LogRratio profile of a 38K BAC array, 
showing a minimal deletion of ~612 kb kb in case 4.
Results
Recurrent microdeletion of 16p11.2
Array analysis was performed on 4284 patients with MR/MCA. We detected 14 cases 
(0.3%) with a microdeletion of approximately 600 kb in the same area of 16p11.2, from 
genomic location 29.5 to 30.1 Mb (Ensembl release 52, Dec 2008) (Fig. 3.1.3). In case 
14 a de novo deletion of 16p11.2 was found in a mosaic state (Fig. 3.1.4). Table 3.1.1 
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summarizes all detected 16p11.2 deletions in the index cases (n =14). Of these, six 
occurred de novo, six were inherited (three paternal and three maternal), one could not 
be assessed, and one is still under study.
 Table 3.1.2 provides a summary of the phenotypic characteristics of the 14 
index cases with a 16p11.2 deletion. Twelve out of 14 had developmental delay, 
ranging from motor retardation to severe mental retardation. Ten were recorded to 
have speech problems. Autism was formally diagnosed in one index patient (case 5). 
In nine index cases dysmorphic features were noted. Five index cases had overweight 
or obesity. Major congenital malformations were not a frequent symptom, however 
pyloric stenosis was reported twice (uncle of case 3, case 10), but this co-occurence is 
most likely coincidental. The intracerebral cyst in case 2 is regarded a chance finding, 
as this anomaly is not known to be associated with (speech) retardation. Among the 
index cases, one patient had a malignancy (case 12, Wilms' tumor).
 In the six familial cases, three of the transmitting parents (two males, one 
female) had developmental problems of a varying degree (parents of cases 3, 5, and 7). 
Other family members carrying the deletion were also reported to have developmental 
problems (uncle and sib of cases 3 and 5, respectively). Three apparently normal 
transmitting parents were identified (in cases 6, 8, and 12).
In the common 600 kb recurrent microdeletion more than 25 genes are located. 
To determine whether the remaining intact 16p11.2 region harbored recessive 
mutations, which might be contributing to the phenotype in these individuals, we 
sought to identify gene candidates for sequence analysis. After analysing this region 
with the Anni tool, the genes ALDOA, TBX6 and SPN seemed good candidates to test 
for a mutation on the remaining allele. However, sequencing of genomic PCR products 
covering the coding regions of ALDOA, TBX6 and SPN in four of the deletion patients 
(cases 1-3, and the paternal uncle of case 3) showed no mutations.
Atypical deletion of 16p11.2
In addition to the common recurrent microdeletion of 16p11.2 observed in 22 
individuals (14 patients and 8 family members), an atypical rearrangement was 
detected in two related patients. In case 15, a 205 kb deletion in 16p11.2 was detected 
(28,74 Mb - 28,95 Mb) (Fig. 3.1.5). The same deletion was detected in his father. The 205 
kb deletion in 16p11.2 is flanking the common deleted region.
Figure 3.1.4 Mosaic 16p11.2 deletion. LogRratio profile (upper panel) showing a slight decrease in copy 
number and B-allele frequency plot (lower panel) showing ABB and AAB genotypes (317K Illumina array).
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Figure 3.1.5 Atypical 16p11.2 deletion. Array analysis with 44K Agilent array revealing a 205 kb atypical 
16p11.2 deletion from 28,74 Mb to 28,95 Mb.
Discussion
We describe 22 individuals (14 index patients and 8 family members) carrying a 
common deletion in 16p11.2 (from genomic location 29.5 Mb to 30.1 Mb), one of 
them in mosaic form. In addition, two related patients showed a smaller deletion of an 
adjoining region, presumably representing a rearrangement of adjacent LCRs.
 Previous reports have shown that the same (~ 600 kb) 16p11.2 deletion 
recurrently occurs in patients diagnosed with autism [10, 13, 22]. Weiss et al. reported 
a recurrent microdeletion on chromosome 16p11.2 in five of 751 families with one or 
more cases with ASD, in three of 299 ASD patients, in five of 512 children referred for 
MR and/or autism, and in two of 18,834 Icelandic controls who had not been screened 
for psychiatric or language disorders [22]. The reciprocal duplication was found in 
11 patients and in five controls. In another study, the same deletion was detected in 
four of 712 autistic patients and none of 837 controls [10]. This study identified the 
reciprocal duplication in one autism case and two controls. Similarly, Marshall et al. 
detected two de novo 16p11.2 deletions in 427 families with autism [13]. In this series, 
the reciprocal duplication was also found twice. The authors stated that deletions and 
duplications of 16p11.2 carry substantial susceptibility to autism, and that the deletions 
appear to account for approximately 1% of cases. In contrast, in our series autism was 
not a frequent symptom, only one of the cases had formally been diagnosed with 
autism. Although the other patients were not extensively assessed for autistic features, 
their behaviour and social interaction were not suggestive of autism.
 Additional, single reports of individuals with 16p11.2 microdeletions have been 
documented, mainly without autism. Rosenberg et al. reported a deletion in a patient 
with mild mental retardation, severe speech delay, and facial dysmorphism [16]. A 
~600 kb 16p11.2 microdeletion was reported in a pair of monozygotic twins with mild 
mental retardation, mild dysmorphism, a seizure disorder and aortic valve disease. 
Autistic features were not reported [7]. A similar de novo deletion was identified in a 
female with Asperger syndrome, without further details regarding her phenotype [18].
Comparison of the phenotypes is hampered by limited clinical data in previous 
reported series (Table 3.1.2). Dysmorphic features were not reported in the deletion 
cases in the series of Kumar et al. [10]. As further phenotypical data are not provided, 
these patients were not included in Table 3.1.2. Regarding behaviour, there was a trend 
towards aggression and overactivity in patients carrying the deletion [10]. This was not 
observed in our series.
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 Phenotypic data are available on two autism patients [13], five children referred 
for MR and/or autism (including a pair of monozygous twins), and three autism patients 
in the series of Weiss et al. [22]. Seven out of ten cases had developmental delay, and 
speech development was delayed in each case, when it was recorded (n = 9). Only 
one patient was reported with facial dysmorphisms, which were not further specified 
[13]. In our series, dysmorphic features were reported in nine of 14 index cases. Some 
patients have facial features in common (Fig. 3.1.1), however no specific pattern of 
dysmorphic features could be distinguished.
 Five of our 14 index cases were overweight, as were four out of ten autism cases 
[13, 22]. However, patients with a weight on the other side of the spectrum are also 
reported (case 12, [22]). Three of our index cases and four previously reported patients 
(including monozygous twins) had seizures [7, 22].
 In summary, though some of our patients show a facial resemblance and 
16p11.2 deletion patients share a tendency to overweight and obesity, there is no 
evidence in our group of index cases to suggest a recognizable phenotype.
 In the previous autism studies almost all microdeletions were de novo [10, 
13, 22]. Among a total of 20 cases (including monozygous twins), 18 were de novo 
and only one familial case was reported: an index patient with autism inherited the 
deletion from his father with ADHD [22]. In contrast, we identified six familial cases 
among 14 index patients. In half of familial cases, the transmitting parent (and other 
family members that carried the deletion) had developmental problems, which 
were frequently speech related. Interestingly, in a study of Icelandic subjects with a 
psychiatric or language disorder, the 16p11.2 deletion was found in a higher frequency 
than in the control population, 0,1% vs. 0,01%. For instance in patients with dyslexia, 
1 in about 750 carried the 16p11.2 deletion, suggesting an association between the 
deletion and this specific phenotype [22].
 In two families, the transmitting fathers were less affected than their children 
(cases 3 and 5). In one family with maternal transmission, the mother was mentally 
retarded and probably as affected as her child (case 7). As the region of chromosome 
16 is not known to be imprinted, it is unlikely that imprinting explains this phenotypic 
variability.
 Noticeably, in case 5 and his family clinical expression seems to include both 
ends of the phenotypic spectrum: case 5 is severely mentally retarded and the only 
patient in our series with autism; his father and brother are of normal intelligence but 
do have speech problems. It is possible that the consanguinity in this family plays a role 
in this variability. As his parents are first cousins, an additional effect of an autosomal 
recessive trait may be present. Homozygosity for this hypothetical trait in case 5, but 
not in his brother and father, would then explain the difference in expression in this 
family. Segregation studies however, point to considerable intrafamilial variability in 
expression in our non consanguineous families as well.
 Unexpectedly, the mosaic 16p11.2 deletion was identified in a patient with 
a severe phenotype (case 14), not observed in any other known carrier. Without 
knowledge about the full spectrum of the 16p11.2 deletion phenotype, it is difficult to 
presume a causal relationship between the mosaic deletion and the severe phenotype 
in this patient. As this patient seems to have dysmorphic features suggestive of BPES 
(Blepharophimosis, Ptosis, Epicanthus inversus Syndrome), this may well be caused by 
another genetic defect (FOXL2 gene mutations were excluded).
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 Likewise, it is difficult to speculate on the significance of the atypical deletion 
found in case 15 and his father. There are no previous reports about patients with this 
deletion. The deletion may be causal, since the father has a comparable phenotype and 
had learning problems. More evidence is needed however, and further family studies 
would have to be performed to gain more insight in the segregation of the deletion 
and the phenotype. The identification and characterization of additional deletions like 
the two described here are needed.
 In a previous paper, the question was raised whether the 16p11.2 microdeletion 
might be non-pathogenic, or a coincidental finding [10]. Given the negative results 
in their control group, the authors suggest that chance finding is unlikely. Further 
evidence to support pathogenicity for this microdeletion has come from several 
sources: in the autism studies, the deletion was almost always de novo [10, 13, 18, 22], 
and the deletion was found in only 2 of almost 18,900 non-characterized Icelandic 
controls [22]. In our series, six out of 14 deletion cases were familial, half of the 
transmitting parents however had a (mild) phenotype. Hence, it seems plausible that 
the 16p11.2 deletion is pathogenic.
 Kumar et al. suggested that the 16p11.2 microdeletion is not associated with 
MR, and is more likely to cause autism [10]. Our series proves that the deletion does 
not necessarily cause autism, but is associated with other developmental and speech 
disorders as well, and may even be found in normal individuals. Finally, the marked 
phenotypic variation in our series of deletion cases proves that the 16p11.2 deletion 
does not by itself cause ASD, as has been suggested previously [10].
 The assembled evidence indicates that recurrent 16p11.2 deletions are 
associated with variable clinical outcome, most likely arising from haploinsufficiency 
of one or more genes located between the two paired LCRs. Several well known 
microdeletion syndromes, such as the 22q11 microdeletion syndrome, show a wide 
range in phenotypic expression with non-obligatory MR, congenital anomalies, 
dysmorphisms and psychiatric disorders, including autism. The reciprocal 22q11 
duplication appears to be even more variable, including more ‘normal’ individuals with 
mild, but characteristic facial features [3, 5, 6]. 
 As an alternative explanation for the variability in phenotype in new 
microdeletion cases, it has been hypothesized that the deletion may unmask a 
mutation in a recessive gene on the homologous allele, and thus cause a more 
severe phenotype [11]. However, sequencing of three selected candidate genes in 
four patients described here, failed to detect any sequence alterations. As there are 
more than 25 genes in this region, one explanation for the negative findings could 
be the fact that we chose the wrong genes. However, the cellular functions of TBX6 
(a transcription factor) and ALDOA (a glycolytic enzyme) make them strong candidate 
genes, and it may be worthwhile to explore them in more detail. We may have missed 
mutations in the promotor regions, the untranslated regions or introns. Alternatively, 
we may have selected an inappropriate set of patients. Better still would be to screen 
patients with a more severe phenotype than their transmitting parent. Further studies 
of additional genes and patients are needed.
 In summary, a ~ 600 kb deletion in 16p11.2 is described in autistic patients 
without apparent dysmorphic features [10, 13, 18, 22], in mentally retarded patients 
with minor dysmorphic features ([7, 16], this series), and in individuals with normal 
intelligence (this series) who may have had isolated developmental problems such as 
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Apparently balanced chromosome abnormalities are occasionally associated with 
mental retardation (MR). These balanced rearrangements may disrupt genes. However, 
the phenotype may also be caused by small abnormalities present at the breakpoints 
or elsewhere in the genome. Conventional karyotyping is not instrumental for 
detecting small abnormalities because it only identifies genomic imbalances larger 
than 5-10 Mb. In contrast, high-resolution whole-genome arrays enable the detection 
of submicroscopic abnormalities in patients with apparently balanced rearrangements. 
 Here, we report on the whole-genome analysis of 13 MR patients with 
previously detected balanced chromosomal abnormalities, five de novo, four inherited, 
and four of unknown inheritance, using Single Nucleotide Polymorphism (SNP) arrays. 
In all the cases, the patient had an abnormal phenotype. In one familial case and 
one unknown inheritance case, one of the parents had a phenotype which appeared 
identical to the patient’s phenotype. Additional copy number variants (CNVs) were 
identified in eight patients. Three patients contained CNVs adjacent to one or either 
breakpoints. One of these patients showed four and two deletions near the breakpoints 
of a de novo pericentric inversion. In five patients we identified CNVs on chromosomes 
unrelated to the previously observed genomic imbalance.
 These data demonstrate that high-resolution array screening and conventional 
karyotyping is necessary to tie complex karyotypes to phenotypes of MR patients. 
Introduction
Recent advances in molecular cytogenetic technologies provide a resolution 
that exceeds that of conventional karyotyping and increased the detection of 
aberrations from 5% to approximately 17% in patients with mental retardation (MR) 
[13,16,17,19,23,28,31,32,34-36]. 
 A disadvantage of the array technique is the incapability to detect 
balanced structural abnormalities such as translocations and inversions. Balanced 
rearrangements have a prevalence of at least 1:500 and in approximately 6% of 
antenatal patients with a balanced rearrangement an abnormal phenotype is found 
[20,37]. The abnormal phenotype of these patients can be explained by (1) breakpoint 
regions directly disrupting genes or transcription regulatory regions [21], (2) indirectly 
by submicroscopic copy number variants (CNVs) near one or both of the breakpoints 
[4], (3) the rearrangement hosts ‘cryptic’ complex chromosomal rearrangements (CCRs) 
[24], (4) submicroscopic CNVs unrelated to the translocation or inversion [3,6,18], or (5) 
another unidentified genetic or environmental factor. 
 Reports of single patients or small series of patients with apparently balanced 
aberrations have identified unexpected complexity and instability of the human 
genome [3,6,18,24]. Some studies investigated the difference between additional CNVs 
in carriers of de novo ‘balanced’ reciprocal translocations and CCRs with normal and 
abnormal phenotypes [1,11]. In approximately 35% of the phenotypically abnormal 
patients additional candidate disease-causing CNVs were identified, mostly occurring 
around the breakpoints of the translocations. In the phenotypically normal cohort 
no additional genomic CNVs were identified. Sismani and colleagues studied 12 
MR patients both with de novo and familial apparently balanced translocations for 
the presence of cryptic CNVs [33]. Two de novo and one familial case had additional 
abnormalities. Recently, Schluth-Bolard and colleagues analysed 47 MR patients with de 
novo and familial apparently balanced chromosomal rearrangements [30]. All familial 
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rearrangements were inherited from phenotypically normal parents. Imbalances were 
detected in 16 de novo cases (48.5%) and in 4 inherited cases (28.6%).
 We report on 13 patients carrying an apparently balanced translocation or 
inversion detected with conventional karyotyping. High-resolution Single Nucleotide 
Polymorphism (SNP) array analysis was performed to search for cryptic CNVs. In eight 
patients additional CNVs were detected. Herein we focus on the interpretation of the 
detected CNV in relation to the phenotypes of the patients.
Materials and methods
Patients
This study included 13 patients with MR, with or without multiple congenital 
malformations, and an apparently balanced translocation or inversion observed 
with conventional karyotyping (five de novo, four inherited, and four of unknown 
inheritance). A summary of the clinical and cytogenetic data of all patients is shown in 
Table 3.2.1. Karyotyping on GTG-banded chromosomes from cultured lymphocytes of 
the patient was performed according to standard techniques. The study was approved 
by the Leiden University Medical Center Clinical Research Ethics Board, conforming to 
Dutch law and the World Medical association Declaration of Helsinki.
 
SNP arrays
DNA was extracted from whole blood by a Gentra Puregene DNA purification Kit 
(Gentra Systems, Minneapolis, USA), following the manufacturer’s instructions. The 
Affymetrix GeneChip Human Mapping 262K NspI, 238K StyI arrays (Affymetrix, Santa 
Clara, CA, USA) and Illumina HumanHap300, Human CNV370 BeadChips (Illumina Inc., 
San Diego, CA, USA) were performed following the manufacturers’ instructions and 
data was analyzed as described previously [17]. Table 3.2.1 shows which SNP array 
platform was used for each patient. 
Evaluation and validation of CNVs
Detected CNVs were evaluated as described previously [17]. The potentially pathogenic 
CNVs were confirmed with Fluorescence In Situ Hybridization (FISH) analysis or another 
type of SNP array using an independent DNA sample. If parents were available, 
segregation analysis was performed by FISH or SNP array analysis. FISH analysis was 
carried out by standard procedures as described previously [9]. BAC clones mapping 
to the unbalanced chromosome regions were selected based on their physical location 
within the affected region (http//: www.ensembl.org, Ensembl release 54 - May 2009, 
Genome build NCBI36). 
 All potentially pathogenic CNVs were assessed with Ensembl (Ensembl release 
54 - May 2009, Genome build NCBI36) and DECIPHER (https://decipher.sanger.ac.uk) for 
gene content and patients with similar CNVs respectively. Finally, data of all patients 
with (potentially) pathogenic CNVs was added to the DECIPHER database.
Results
SNP array analysis demonstrated 16 additional submicroscopic CNVs in eight of the 13 
patients (61.5%); five out of the five de novo, one out of the four familial and two out of 
the four unknown inheritance cases. In the remaining five patients no additional CNVs 
were detected. The 16 CNVs consisted of 15 interstitial deletions ranging in size from 
59 kb to 10.11 Mb and one interstitial duplication of 2.78 Mb. Results are described in 





































 The parental origin of the known de novo deletions could be determined in 
three patients (1, 3, and 8). In all these patients the deletions occurred on the paternal 
chromosome. In patients 4, 5, and 6 the breakpoints of the deletions were flanked by 
segmental duplications (according to the Database of Genomic Variants, DGV; http://
projects.tcag.ca/variation). 
CNVs at or near the breakpoint regions 
Eight CNVs in three patients were located at or near one of the breakpoints of the 
apparently balanced chromosome abnormalities (Table 3.2.1). Two of these patients (1 
and 3) had more complex chromosome abnormalities. 
Patient 1
The patient was a 1-year old boy with MR, sleeping problems, grand-mal seizures, 
sensorineural deafness, severe loss of vision, epicanthic folds, strabismus, ventricular 
septal defect (VSD) and general hypotonia. He was initially diagnosed with a de novo 
paracentric inversion of region 5q22q31.3 (Fig. 3.2.1a). Additional SNP array screening 
showed four de novo interstitial deletions on band 5q14.3 (Fig. 3.2.1b and c) and two 
de novo interstitial deletions on band 5q33.3 (Fig. 3.2.1b and d). The presence of the six 
deletions was confirmed by a different SNP array platform (NspI, Affymetrix). Based on 
the SNP array data the inversion breakpoints were revised to 5q14.3 and 5q33.3. These 
breakpoints were confirmed by high resolution G- banding. The 6 deletions contain 
eight known coding genes (COX7C, RASA1, CCNH, TMEM161B, MEF2C, EBF1, RNF145 and 
UBLCP1).
Figure 3.2.1 Cytogenetic and molecular results for patient 1. (a) Partial karyotype showing chromosome 
5. Right: abnormal chromosome 5 with inversion 5q14.3q33.3. (b) SNP array copy number plot (Illumina 
HumanHap 300 BeadChip) for chromosome 5. (c) Four deletions at 5q14.3 and (d) two deletions at 5q33.3
Patient 2 
The patient was a 61-year old male with MR and psychiatric problems. Conventional 
karyotyping showed a translocation between the long arm of chromosome 11 and 
the short arm of chromosome 12. The breakpoints were determined at 11q13.3 and 
12p12.3. In addition, a pericentric inversion of region 12p12.3q13.1 was observed in 
the derivative chromosome 12. Subsequent SNP array analysis identified an interstitial 
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deletion on band 12p12.3. The parents were not available for testing. The 2.51 Mb 
deleted region contains eight known coding genes (RERG, PTPRO, EPS8, STRAP, DERA, 
SLC15A5, MGST1 and LMO3).
Patient 3 
The patient was a 15-year old mentally retarded girl. She had a severe anxiety disorder 
and autistic features. The patient is described in detail by Dauwerse and colleagues 
[10]. Conventional karyotyping showed a de novo paracentric inversion of region 
7q31.3q34. However, FISH analysis in order to map the exact breakpoints identified an 
insertion of region 7q31.31q35 within band 7q21.3. SNP array screening demonstrated 
a de novo interstitial deletion at the insertion site from chromosome bands 7q21.11 to 
7q21.3. The deletion contains approximately 40 known coding genes. 
CNVs on unrelated chromosomes
Six CNVs in four patients were detected on chromosomes not related to the 
chromosomes involved in the balanced inversions or translocation (Table 3.2.1).
Patient 4 
The patient was a 42-year old male, diagnosed with MR and obesity. Conventional 
karyotyping showed a pericentric inversion of chromosome region 6p21.3q15 (Fig. 
3.2.2a). Additional SNP array analysis identified two interstitial deletions on the long 
arm of chromosome 18 in chromosome bands q21.31 and q21.32 (Fig. 3.2.2b and c). 
The patient’s mother and brother showed a normal karyotype and normal SNP array 
results. His father was not available for testing. The two deletions contain 13 known 
coding genes (NEDD4L, ALPK2, MALT1, ZNF532, SEC11C, GRP, RAX, CPLX4, LMAN1, CCBE1, 
PMAIP1, MC4R, CDH20).
Figure 3.2.2 Cytogenetic and molecular results for patient 4. (a) Partial karyotype showing chromosome 
6. Right: abnormal chromosome 6 with inversion 6p21.3q15. (b) SNP array copy number plot 





The patient was a 46-year old female with MR, deafness, heterochromia of the iris, a 
depigmented forelock, hypertension and hypothyroidism. Mutations in the coding 
region of MITF (Waardenburg syndrome) were excluded by sequencing. Conventional 
karyotyping showed a balanced translocation t(3;18)(p14.2;q23). SNP array analysis 
identified one additional deletion on the long arm of chromosome 22 between bands 
22q11.22 and q11.23. Conventional karyotyping and SNP array results of the father 
were normal. The mother was not available for testing. However a healthy sister of the 
proband showed the same t(3;18)(p14.2;q23). The 22q deletion contains four known 
coding genes (RTDR1, GNAZ, RAB36 and BCR).
Patient 6 
The patient was a 5-year old boy with mild MR and hyperactivity. He had several 
dysmorphic features, including microcephaly, coarse hair, hypotelorism, a narrow 
nasal bridge, a long columella, large ears, pectus excavatum, syndactyly of 2-3 toes, 
and patchy depigmentation of the skin. Conventional karyotyping identified a de 
novo balanced translocation t(2;6)(q37.1;q13). SNP array results revealed an interstitial 
deletion on the long arm of chromosome 13 band q12.3. In the 1.24 Mb deletion five 
known coding genes (KIAA0774, SLC7A1, UBL3, KATNAL1, HMGB1) are located. FISH 
analysis on the parents showed that the deletion occurred de novo. Parental DNA for 
SNP array analysis was not available.
Patient 7 
The patient was a 1-year old boy with mild developmental delay, a unilateral cleft 
palate and dysmorphic features, including protruding ears and a unilateral preauricular 
earpit, long eyelashes, prominent arched eyebrows and strabismus. On his philtrum 
he had a dimple. X-ray of the spine showed posterior fusion defects of several thoracic 
vertebrae. Conventional karyotyping showed a de novo balanced translocation 
t(2;6)(q24.1;p24.3). SNP array results revealed a de novo interstitial duplication on 
chromosome 1p32.3p32.2 that contains 23 known coding genes. The parental origin of 
this duplication could not be determined with SNP array analysis.
CNV at or near the breakpoint plus additional, unrelated CNV 
Patient 8 
The patient was a new born girl with low-set ears, a prominent forehead, pulmonary 
stenosis and a VSD. Conventional karyotyping showed a de novo translocation t(12;14)
(q21.3;q32.1). Subsequent SNP array analysis detected three de novo deletions on 
chromosome bands 3p12.3, 4q28.3q31.23, and 12q21.31q21.33, the latter at the 
breakpoint of the translocation. The deletions contain in total 52 known coding genes.
Discussion
The development of high-resolution array platforms allows the detection of CNVs 
in carriers of apparently balanced chromosome aberrations. In this study we have 
analyzed 13 MR patients with previously detected apparently balanced chromosomal 
rearrangements. Three of the patients had a breakpoint-associated imbalance, four had 
an imbalance on an unrelated chromosome and one patient had both an additional 
imbalance near the breakpoint of a translocation as well as cryptic deletions on 
unrelated chromosomes.  
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CNVs at or near the breakpoint regions 
 Three of the 13 patients showed additional CNVs at the breakpoints (patients 
1-3). The deletions in patients 1 and 3 are highly likely contributing to the patients’ 
phenotypes, since both are de novo and other patients have been reported with 
deletions in the same regions. 
 The 5q14.3 deletion region of patient 1 is recently described, five patients 
showed a 5q14.3 microdeletion and phenotypic similarities, including severe MR with 
absent speech, epilepsy, hypotonia and stereotypic movements [22]. The minimal 
overlapping region in their study encompassed the MEF2C gene. The phenotype of 
patient 1 is therefore most probably caused by haploinsufficiency of the MEF2C gene. 
None of the 12 breakpoint regions of the 6 de novo deletions in patient 1 contained 
low copy repeats (LCRs). It is therefore not likely that non-allelic homologous 
recombination (NAHR) underlies this complex single chromosome rearrangement. Poot 
and colleagues proposed that such a complex single chromosome rearrangement may 
be the result of mismatched repair of multiple double-strand breaks that co-localize in 
a chromosome at the time of DNA-damage induction [25].
 None of the genes in the 12p12.3 deletion of patient 2 could be directly related 
to the phenotype. To our knowledge, a deletion of the same region has not been 
reported yet. Since we were not able to investigate the parents, pathogenicity of the 
deletion remains uncertain.
 The phenotype of patient 3 overlaps with patients reported with de novo 
7q21.1q21.3 deletions [8]. As explained previously disruption of the C7orf58 gene in 
band 7q31.31, one of the insertion breakpoints, may explain anxiety disorder and/or 
autistic features [10]. 
CNVs on unrelated chromosomes
In four patients the translocation or inversion appeared balanced, but SNP array analysis 
detected cryptic CNVs on unrelated chromosomes (patients 4-7). Haploinsufficiency of 
one or more genes in the deletions of patients 4, 5, and 6 may have contributed to the 
patients’ phenotypes.  
 Partial deletions of the long arm of chromosome 18 lead to variable 
phenotypes. The region 18q12.1q21.33 could be associated with mild to severe MR 
[12,14], explaining the phenotype of patient 4. Furthermore, MC4R (melanocortin 
4 receptor) may have contributed to the obesity in this patient. The MC4R gene is a 
member of the melanocortin receptor family and represents a G-protein coupled seven 
transmembrane receptor. Genetic studies related melanocortin receptors to genetically 
determined obesity [5,7].  
 The deletion detected in patient 5 overlaps partly with a known microdeletion 
syndrome. The recurrent 22q11.2 distal deletions are either approximately 1.4 Mb or 
2.1 Mb in size with a common proximal breakpoint flanked by LCR22-4 [2]. They differ 
at the distal breakpoints flanked by either LCR22-5 for the smaller deletion or LCR22-6 
for the larger deletion [2]. The breakpoints for the deletion of patient 5 are LCR22-5 
and LCR22-6. The same deletion has been reported before in one patient and her 
healthy father [26]. This patient had a congenital heart defect, normal appearance and 
psychomotor development, and minimal dysmorphic features. The clinical features of 
patient 5 do not resemble the previously reported patient.  
 Patients with larger 13q deletions than patient 6 have been reported, but 
presented no recognizable phenotype [29]. One patient, with a deletion of 1.43 Mb on 
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13q12.3 (DECIPHER ref. 2154), is partly overlapping with the deletion in our patient. The 
common clinical features are MR, microcephaly, and large ears. The smallest region of 
overlap contains two genes, KATNAL1 and HMGB1, which might be responsible for the 
overlap in phenotype.  
 The clinical relevance of the de novo interstitial 1p duplication in patient 7 is 
not clear. Interstitial duplications of chromosome 1p are rare and are associated with 
a variable phenotype [15]. One patient has been described with a similar duplication, 
however this patient also carried a deletion within 1p36.32 [15]. 
CNVs at or near the breakpoint plus additional, unrelated CNV 
All three deletions in patient 8 occurred de novo and it is highly likely that 
haploinsufficiency of one or more genes have contributed to the patient’s phenotype. 
Each deletion partly overlaps with patients described in the DECIPHER database (refs. 
2059, 790 and 1020), although no similar phenotypes have been described.   
General discussion and conclusion
Since there is no applicable technique available yet to detect balanced chromosome 
rearrangements and cryptic imbalances in one experiment, both high-resolution 
array screening and conventional karyotyping were necessary to unravel the complex 
karyotypes described in this paper. In 61.5% of our patients with an apparently 
balanced aberration, we detected an additional cryptic CNV.
 In all five de novo cases an additional cryptic CNV was identified. Previous 
published data have shown cryptic imbalances in approximately 30-50% of MR 
patients with de novo apparently balanced chromosome rearrangements [11,33]. The 
high occurrence in our study is probably due to the small sample size. In only two 
of the four patients with an inherited translocation or inversion, one of the parents 
showed a similar phenotype as the proband. No additional CNVs were detected in 
these two cases. In one of the other familial cases an additional CNV not related to the 
translocation was detected (patient 4). Since, DNA of the mother was not available the 
inheritance of this CNV could not be determined.
 By SNP haplotype analysis we could determine for three of the patients that 
the deletions had occurred in the paternal allele. This observation is consistent with 
previous studies suggesting that male gametogenesis is more susceptible to this type 
of chromosome abnormalities [11]. 
 In the remaining patients where no additional abnormalities were detected 
the presence of cryptic imbalances explaining the phenotype obviously cannot be 
excluded. It is possible that higher resolution arrays may reveal smaller aberrations that 
could have been missed in our analysis. Alternatively, the breakpoints of the apparently 
balanced rearrangements might disrupt putative disease genes or cause a position 
effect giving rise to the abnormal phenotype.
 With the advent and application of high-resolution array screening it was 
demonstrated that man is more genetically variable than previously considered [27]. 
Each individual (healthy or not) presents multiple CNVs in its genome. Yet, unless 
reported in healthy individuals or patients with similar phenotypes, the pathogenicity 
of a substantial number of CNVs remains uncertain. The clinical interpretation of CNVs 
is even more difficult in patients with multiple chromosomal aberrations like the ones 
described in this paper, as the phenotypes might be the result of a combination of two 
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Abstract
Studies to identify copy number variants (CNVs) on the X-chromosome have revealed 
novel genes important in the causation of X-linked mental retardation (XLMR). Still, 
for many CNVs it is unclear whether they are associated with disease or are benign 
variants. We describe six different CNVs on the X-chromosome in five male patients with 
mental retardation (MR) that were identified by conventional karyotyping and Single 
Nucleotide Polymorphism (SNP) array analysis. One deletion and five duplications 
ranging in size from 325 kb to 12.5 Mb were observed. Five CNVs were maternally 
inherited and one occurred de novo. We discuss the involvement of potential candidate 
genes and focus on the complexity of X-chromosomal duplications in males inherited 
from healthy mothers with different X-inactivation patterns. Based on size and/or the 
presence of XLMR genes we were able to classify CNVs as pathogenic in two patients. 
However, it remains difficult to decide if the CNVs in the other three patients are 
pathogenic or benign.
Introduction
The prevalence of mental retardation (MR) in the general population is 2-3% (1, 2). As 
there are more males than females diagnosed with MR, the search for candidate genes 
or loci has been largely focused on the X-chromosome (3, 4). To date, there are 82 
genes for which mutations have been demonstrated in X-linked MR (XLMR) (5).
 However, in many XLMR families and sporadic cases the cause of MR remains 
unknown. Copy number variants (CNVs) involving one or more genes on the 
X-chromosome have been reported in patients with MR (6 - 8). Decrease in gene 
dosage due to deletions can be related to the phenotype in many cases. Although 
partial duplications in either arm of the X-chromosome are rare and difficult to 
interpret, it appears that an increase in gene dosage may be the cause of MR more 
often than expected (6 - 9). 
 In this report we describe the use of whole-genome Single Nucleotide 
Polymorphism (SNP) arrays to precisely map one previously detected large 
X-chromosomal aberration, and to identify novel X-chromosome abnormalities in 
patients with MR. In addition, we discuss the difficulty in determining whether an 
X-chromosomal aberration is pathogenic or a benign variant.
Materials and methods
Patients
Patients were selected from a series of idiopathic MR patients with or without multiple 
congenital abnormalities, which had been investigated with SNP array analysis. Some 
were previously found in a cohort of 318 idiopathic MR patients (10). For this study we 
selected only those patients that had an aberration on the X-chromosome. 
Conventional karyotyping and Fluorescence in Situ Hybridisation (FISH) 
Conventional cytogenetic analysis on GTG-banded chromosomes from cultured 
lymphocytes of the patients was performed according to standard techniques. FISH 
analysis was carried out by standard procedures as described previously (10). FISH 
analysis was performed on metaphase chromosomes of all patients to confirm whether 





The Affymetrix GeneChip Human Mapping 262K NspI (used for patients 2, 3 and 5), 
238K StyI (used for patient 4) and Affymetrix Genome-Wide Human SNP Array 6.0 arrays 
(used for patient 1) (Affymetrix, Santa Clara, CA, USA) were performed following the 
manufacturer’s instructions. The 262K and 238K arrays have an average probe spacing 
of 12 kb and were analyzed as described previously (10). The average probe spacing of 
the 6.0 array is 0.7 kb. SNP copy number was assessed in the patient using Affymetrix 
Genotyping Console 2.1 software. Aberrations of at least 100 kb were analyzed.
 All CNVs identified in this study were evaluated as described earlier (10). All 
patients with a (potentially) pathogenic CNV were added to the DECIPHER database.
 
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis
MLPA experiments were performed as described previously to narrow down the 
breakpoints of patient 2 (10).
X-inactivation 
X-inactivation was investigated with Southern blot analysis with a probe for the M27B 
(DXS255) locus for the mothers of patients 1 and 4. The intensity of the unmethylated 
(2.8 kb) and the methylated (5.2 kb) bands were compared to determine random or 
non-random X-inactivation. The ratio of active to inactive X could not be calculated by 
this method. X-inactivation was investigated with a methylation-specific PCR for family 
members of patients 2 and 3 (11). Inactivation was considered to be random if the ratio 
was less than 75:25 (12).
  
Results and discussion
We present six different CNVs, five interstitial duplications and one interstitial deletion, 
on the X-chromosome in five male MR patients (Table 3.3.1). Five CNVs were inherited 
from the mother (patients 1-4) and one had occurred de novo (patient 5). Clinical 
features of these patients are shown in Table 3.3.2 and an extended clinical description 
is provided as supplementary material.
 The array-based technology for the detection of CNVs in MR patients has 
proven to be a powerful tool. However, the main challenge is ranking these CNVs as 
pathogenic, potentially pathogenic or polymorphic variants. Here, CNVs were classified 
into these groups based on various factors, including size, gene content, and whether 
they were inherited or occurred de novo (13). 
Pathogenic CNVs
Conventional karyotyping of patient 1 (Fig 3.3.1a-c) and his brother (Fig 3.3.1d-f ) 
showed an interstitial duplication of Xp21.3p22.2, which was inherited from their 
healthy mother. SNP array analysis revealed a duplication of 12.5 Mb (Fig 3.3.1g). 
FISH analysis demonstrated that the duplication was present in tandem on the 
X-chromosome. Duplications of the individual XLMR genes in this region (AP1S2, 
CDKL5, SCML1, PDHA1, RPS6KA3, SMS and ARX) have so far not been associated with 
MR. One family with a partly overlapping duplication of Xp22.11p22.2 (from 15.0 Mb 
to 23.5 Mb) has been reported and the most striking similarities between the patients 
of that family and patient 1 and his brother are MR, long face and large ears (14). The 
large size of the duplication in patient 1 and his brother is expected to be associated 
with the abnormal phenotype due to a two-fold increase in dosage of the included 
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Figure 3.3.1 Patient 1 and his brother. (a) Patient 1 with elongated face and flat midface. (b) Scoliosis of 
patient 1. (c) Flat, thin and long feet of patient 1. (d) Brother of patient 1 with similar facial appearance. 
(e) Scoliosis and pectus excavatum of the brother. (f ) Flat, thin and long feet with long first digits of the 
brother. (g) SNP array (Affymetrix Genome-Wide Human SNP Array 6.0) results of patient 1 showing a 12.5 
Mb duplication. Log2ratios for each probe are plotted against the position on the X-chromosome. Intensity 
values are compared with normal males and females resulting in Log2ratios below zero for one copy of 
the X-chromosome for males. Duplicated regions have a Log2ratio of 0, including the pseudoautosomal 
regions 1 and 2 (PAR 1 and 2) at Xp22.3 and Xq28.
genes (7). Furthermore, pathogenicity of the CNV is supported by the fact that the 
phenotypically normal carrier mother showed a skewed X-inactivation pattern in which 
the X-chromosome with the aberration is most probably the one that is inactivated (12, 
15). 
 SNP array analysis of patient 3 showed a deletion of approximately 2.7 Mb in 
chromosome band Xp22.32p22.31 and a duplication of at least 6.3 Mb in chromosome 
band Xq27.3q28 (Fig 3.3.2b). SNP array analysis on the mother, who was slightly 
retarded, demonstrated that both aberrations had been inherited. The 2.7 Mb deleted 
region contains STS (steroid sulfatase), which is associated with X-linked ichthyosis, 
and can explain the very dry skin of the boy. Patients with X-linked ichthyosis often 
suffer from MR and VCX3A has been proposed as candidate gene for the MR, although 

















































































reported in a boy with autism and mental retardation (19). The 6.3 Mb duplicated 
region contains one known XLMR gene, FMR1 which is associated with the fragile 
X-syndrome. Recently, a familial interstitial Xq27.3q28 duplication has been reported 
partly overlapping the duplication of patient 3 (20). The phenotype of patient 3 shows 
no striking similarities with affected members of this family. The combination of the 
loss of these genes and the relative large size of the duplication in our patient most 
probably accounts for his cognitive phenotype as well as his other clinical features. 
Additionally, his slightly retarded mother, who carries the same X-chromosomal 
aberrations, showed a random X-inactivation (70:30) which might support the causative 
role of the aberrations. 
Figure 3.3.2 Patient 3. (a) Facial appearance showing oval eyes, short nose and a relative small chin. (b) 
SNP array (Affymetrix GeneChip Human Mapping 262K NspI and 238K StyI) results showing the 2.71 Mb 
deletion and 6.22 Mb duplication. Intensity values are compared with normal males resulting in Log2ratios 
of zero for one copy of the X-chromosome. Log2ratios for each probe are plotted against the position on 
the X-chromosome.  
Potentially pathogenic CNVs
High-resolution whole-genome screening arrays have enabled the detection of small 
abnormalities. Yet, the discovery of small CNVs in healthy individuals has revealed that 
many CNVs are not pathogenic (21-23). We found three CNVs of relatively small sizes 
(325 kb – 606 kb) in patients 2, 4 and 5. As these CNVs are neither described in the DGV 
nor do they contain known XLMR genes they could be potentially pathogenic. 
 SNP array analysis of patient 2 presented an interstitial duplication of at 
least 349 kb in chromosome band Xp22.12. The healthy mother and grandmother 
carried the same Xp22.12 duplication. The small duplication was located in the 
same duplicated region as observed in patient 1. However, the aberration contains 
only two genes, SH3KBP1 and MAP3K15. The SH3-domain kinase-binding protein, a 
multifunctional protein which is expressed in the nervous system (24), plays key roles in 
endocytic down-regulation of receptor tyrosine kinases, in apoptosis, in cell adhesion 
and in the rearrangement of the cytoskeleton. The MAP3K15 gene is a member of the 
Mitogen activated protein (MAP) kinase family. Although a mutation has been recently 
described in this gene in a patient with MR, the clinical significance of the mutation is 
not known (25). So far no MR patients with a similar duplication of these genes have 
been described. The unaffected carrier mother and grandmother of the patient showed 
skewed X-inactivation patterns (both ratios were 90:10), which could be an indicator 
for the functional effect of the aberration. 
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 SNP array analysis on patient 4 showed a duplication of approximately 606 
kb in chromosome band Xq28. SNP array analysis on the mother showed that the 
abnormality had been inherited. The duplication partially overlaps the duplication of 
patient 3, but contains no known XLMR genes. All seven duplicated genes located in 
this region overlap with patient 3. According to the DGV there are some copy number 
polymorphisms described in this region but the whole duplication in patient 4 is 
not covered by the variants. Only four of the seven genes were not located in one of 
these polymorphic regions. One gene belongs to the MAGEA-family (MAGEA9B), 
and members of this family may play a role in embryonic development, although 
they are better known for their expression in melanomas and other cancers (26). 
Mutations and deletions of IDS cause sex-linked mucopolysaccharidosis type II, which 
is a lysosomal storage disorder. No cases have been reported with a duplication of this 
gene. The other genes, HSFX1 (heat shock transcription factor family) and TMEM185A, 
are not known to be disease-related. The healthy carrier mother showed a random 
X-inactivation pattern indicating that the duplication might not be the cause of the 
phenotype. However, a CNV associated with an abnormal phenotype with random 
X-inactivation in a phenotypically normal carrier mother has been described (case 5 in 
reference 7).
 SNP array analysis on patient 5 revealed a de novo duplication of 325 kb in 
chromosome band Xq21.1, comprising almost the entire DACH2 gene, dachshund 
homolog 2 (Drosophila). The dachshund/Dach gene family is conserved in insects and 
vertebrates and encodes putative transcriptional cofactors (27). Dachshund is expressed 
in the developing eyes, brain, limbs and genital disc of the fly, however Dach1/2 
double homozygous newborn mice have intact eyes and limbs (28 -30). Mutations 
in DACH2 have been documented in patients with premature ovarian failure, but an 
association between DACH2 mutations and infertility has not yet been established (27, 
31). Since the duplication is intragenic it might result in gene disruption, leading to 
either absence of protein or a non-functional protein (32). Functional studies should 
be performed to check mRNA levels of this gene. Although the duplication is de novo it 
remains difficult to determine whether it is pathogenic or not. 
General discussion
In two of the five patients the CNVs could explain their phenotypes (1 and 3) based 
on size and/or the presence of XLMR genes. For patients 2, 4 and 5 it remains unclear 
whether the increase in gene dosage has contributed to the phenotype. Besides, 
establishing the pathogenicity of the duplication in patient 4 is difficult because of the 
random X-inactivation pattern in the healthy carrier mother. The X-inactivation pattern 
in females with an abnormal X-chromosome is usually skewed with the abnormal X 
being preferentially inactivated. In this way they are protected from genetic imbalance. 
Here, the X-inactivation pattern was measured only in peripheral blood which may 
not reflect the actual situation in the brain. In any case, the gene dosage in males 
with a duplication of a segment of the X will be higher than in females with random 
X-inactivation and therefore could explain the pathogenicity in our patient. 
 To gain more insight in the pathogenicity of the CNVs in patient 2, 4 and 5 
we checked our in-house reference set (including 118 healthy males and 82 healthy 
females) for the presence of these CNVs. None of the CNVs were found in this set. 
Additionally, family studies for the patients with the inherited potentially pathogenic 
CNVs could give a better indication of the pathogenicity if there are healthy or affected 
96
X-chromosome duplications
male carriers. Furthermore, the DGV should be regularly checked for these CNVs, since 
the data in this database is increasing rapidly. More patients or normal individuals with 
overlapping X chromosomal duplications will be needed to elucidate whether the 
CNVs that we have reported are pathogenic or benign variants
 In conclusion, this study highlights the difficulty in pinpointing the underlying 
causes of disease. Nevertheless knowing whether a CNV is pathogenic or benign is of 
major importance for counselling and diagnosis. 
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Supplementary material
Patient descriptions
Patient 1 was a 33-year old male. He was born by caesarian section at 43 weeks 
of gestation following a normal pregnancy. The parents were healthy and non-
consanguineous. Birth weight was 2460 g. He had bradycardia and hypotonia and 
assisted ventilation had been necessary for a short period. A submucous cleft of the 
palate was closed before the age of 1 year. As an infant he developed myoclonic jerks 
which stopped spontaneously after a few years. His psychomotor development was 
delayed, he was able to sit without support at 15 months. His dental development was 
abnormal: at the age of 11 he had only 5 teeth, several incisors and molars had never 
appeared.  
 Examination at the age of 20 showed: length 182 cm, span 170 cm and head 
circumference 56 cm. He had a friendly deposition and was able to speak a few single 
words. He had a long and slender habitus. The face was elongated with a relatively 
small mouth and a flat midface (Fig. 3.3.1a). The uvula was bifid. The maxillary lateral 
incisors were absent. His hands showed bilateral simian creases and long fingers. He 
had scoliosis (Fig. 3.3.1b). His feet were long and thin (Fig. 3.3.1c). 
 The 31-year old younger brother of patient 1 had a similar phenotype. He was 
born by caesarian section at 34 weeks. Birth weight was 1610 g. Assisted ventilation 
was necessary in the neonatal period because of respiratory distress syndrome. An 
open ductus Botalli closed after medication. Like his brother he developed myoclonic 
jerks, which ceased spontaneously before the age of four. Also as in his brother the 
psychomotor development was delayed, he walked independently at the age of four. 
Neurological examination at the age of 16 years showed a spastic gait.
 On examination at the age of 18 years his length was 190 cm, span 187 cm and 
head circumference 54 cm. He spoke a few words and communicated with signing. The 
face was somewhat asymmetric (Fig. 3.3.1d). The maxillary lateral incisors were absent. 
He had pectus excavatum and scoliosis (Fig. 3.3.1e). The hand creases were normal. The 
feet were flat, thin and long with long first digits (Fig 3.3.1f ). 
Patient 2 was a boy, born at term after an uncomplicated pregnancy. He had a normal 
birth weight. His development has been delayed form infancy, he was able to walk at 
the age of 4 years and he has no speech. He has a high threshold for pain. He has no 
sleeping problems.
 When first seen at the age of 4 years, he had a happy disposition and 
made stereotypic movements with his head and hands. Height, weight and head 
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Patient 3 was born at 41 weeks of gestation with a normal birth weight (3350 g). 
The pregnancy had been complicated by pre-eclampsia. He was admitted to the 
department of pediatrics for observation because of hypotonia. His skin was very dry. 
There were no feeding problems during infancy. He did not speak any words at the age 
of three. 
 At 13 years of age he was found to be severely retarded. He displayed palilalia 
and was not toilet-trained. His height was normal. His facial features were slightly 
dysmorphic with oval eyes, a short nose and a relatively small chin (Fig. 3.3.2a). He had 
inverted nipples, gynaecomastia, and an unusual subcutaneous fat distribution with 
large pads of fat above the buttocks.
Patient 4 was born at 41 weeks of gestation with a normal birth weigth (3930 g). He 
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Patient 5 was born at 40 weeks of gestation with a normal birth weight (3050 g). He 
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father with deep set small eyes, hypotelorism, narrow nose and small mouth.
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Abstract 
Mosaicism involving a normal cell line and an unbalanced autosomal translocation 
are rare. In this study we present three new cases detected by Single Nucleotide 
Polymorphism (SNP) array analysis in our routine diagnostic setting. These cases were 
further characterized using Fluorescence in situ Hybridisation (FISH) analysis and 
conventional karyotyping. 
 The first case is a mentally retarded male who carries an unbalanced 
translocation in 87% of his cells. Remarkably, the phenotypically normal mother 
carries the balanced form of the translocation in all her cells. The second case is a 
phenotypically normal female who has an unbalanced translocation in 52% of her 
cells. She passed the unbalanced translocation to her daughter who has mild mental 
retardation and serious behavior disturbance. The third case is a female referred for 
Rubinstein-Taybi syndrome who carries a complex unbalanced translocation in 60% of 
her cells. Her mother showed a normal karyotype. 
 The mechanisms that might be responsible for these mosaic karyotypes are 
discussed. Furthermore, we demonstrate that high-resolution whole-genome array is 
a powerful tool to reveal cryptic unbalanced translocations and mosaicisms, including 
the more rare cases.
Introduction
Mosaicism is the presence of genetically different cell lines in one individual derived 
from a single zygote. Mosaicism can be caused by several mechanisms, including 
chromosomal abnormalities and DNA mutations (reviewed by Youssoufian and Pyeritz, 
2002). Whether a mosaicism is disease-causing depends upon the abnormality, on 
which tissue is abnormal and on how much of a tissue is affected. If only a fraction of 
the soma is abnormal (somatic mosaicism), the phenotype is likely to be normal and 
will probably never be recognized (Gardner et al., 1994). If it involves a substantial part 
of the soma, it can cause dysmorphisms and malformation, and if the brain is included, 
mental retardation (MR). Abnormality involving only a part of the gonad (gonadal 
mosaicism) is not associated with an abnormal phenotype of the carrier and will usually 
only be recognized after two siblings are born with the same ‘de novo’ abnormality 
(Youssoufian and Pyeritz, 2002). 
 Chimerism is the presence of genetically different cell lines in one individual 
derived from two or more different zygotes. If both cell lines contain the same sex 
chromosomes, conventional karyotyping is generally not able to distinguish between 
mosaicism and chimerism. Support for the mechanism causing two or more different 
cell lines as a result of chimerism can be obtained by comparison of DNA microsatellite 
markers (Cotter and Hirschhorn, 1998).
 Somatic mosaicism with an abnormal cell line can be missed by conventional 
karyotyping if masked by a high percentage of normal cells or even dismissed as a 
culture artefact (Ballif et al., 2006). Additionally, healthy individuals with a mosaicism 
will in most cases not be investigated. The prevalence of mosaicisms is therefore 
difficult to establish. Lebbar et al. (2008) reviewed the literature for mosaicism with a 
normal cell line and a balanced rearrangement and reported 35 cases. Most of these 
carriers have a normal phenotype and were referred due to recurrent miscarriages, 
infertility or the birth of an abnormal child. Furthermore, they described the first two 
cases of mosaicism for a normal cell line and a complex chromosome rearrangement 
(CCR) in patients ascertained through infertility. Zaslav and colleagues (1999) reported 
104
Mosaicism
23 cases of mosaicism for a normal cell line and an unbalanced autosomal structural 
rearrangement (N/UASR). These UASRs included duplications, deletions, insertions, 
isochromosomes, and derivative chromosomes. In total they reported only 4 cases with 
a mosaicism for a normal cell line and an autosomal derivative chromosome (Zaslav et 
al., 1999). To our knowledge, only 3 additional mosaicism cases with a normal cell line 
and an unbalanced autosomal translocation have been described (Stallings et al., 1997; 
Kulharya et al, 2002; Petkovic et al., 2003). 
 The application of high-resolution whole-genome array technology to 
cytogenetic testing has improved the ability to detect smaller abnormalities and 
mosaicisms (Ballif et al., 2006; Gijsbers et al., 2009). We report on three unrelated 
cases with a mosaicism for a cryptic unbalanced reciprocal translocation detected 
by Single Nucleotide Polymorphism (SNP) array analysis and Fluorescence in situ 
hybridisation (FISH). Our results illustrate that array technology is a sensitive method 
for the detection of mosaicisms, unbalanced translocations and, as described here, a 
combination of these two. 
Material and methods
Patients
This study is based on results obtained from patients with MR submitted to our 
laboratory for SNP array screening. In this report we include three cases (two patients 
with MR and one healthy parent) in which a mosaicism with a normal cell line and an 
unbalanced autosomal translocation was detected. Pedigrees are shown in Figure 3.4.1.
Figure 3.4.1 Pedigrees of the three cases with a normal cell line and an unbalanced autosomal translocation. 
Arrow indicates case with the mosaicism.
Conventional karyotyping and FISH
Conventional cytogenetic analysis on GTG-banded chromosomes from cultured 
lymphocytes was performed according to standard techniques. FISH analysis was 
carried out by standard procedures as described (Dauwerse et al., 1990). Bacterial 
artificial clones (BAC) mapping to the affected chromosome regions were selected 
based on their physical location within the affected region (http//: www.ensembl.org, 
Ensembl release 54 - May 2009).
SNP arrays
DNA was extracted from whole blood by a Gentra Puregene DNA purification Kit 
(Gentra Systems, Minneapolis, USA), following the manufacturer’s instructions. The 
Affymetrix GeneChip Human Mapping 262K NspI array (Affymetrix, Santa Clara, CA, 
USA) was performed following the manufacturers’ instructions and data was analyzed 
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as described previously (Gijsbers et al., 2009). The Affymetrix Genome-Wide Human SNP 
Array 6.0 contains more than 1.8 million markers for genetic variation, including more 
than 906,600 SNP probes and more than 946,000 probes specific for the detection of 
copy number variation (Affymetrix). 500 ng of genomic DNA was processed according 
to the instruction provided in the Affymetrix Cytogenetics Copy Number Assay user 
guide. SNP copy number was assessed in the patient using Affymetrix Genotyping 




The patient was a 42-year old male with MR and dysmorphic features including 
coarse hair, small dysplastic low-set ears, deep-set eyes, hypotelorism and short 4th 
metatarsal of the left foot. He also had scoliosis, aortic stenosis, coarctation of the aorta, 
hypertension, anal stenosis, sensineural deafness and distal symphalangism of toes.
 SNP array analysis with the Affymetrix Genome-Wide Human SNP Array 6.0 
detected a terminal duplication of 10.11 Mb on the long arm of chromosome 10 and 
a 7.51 Mb deletion on the long arm of chromosome 11 (Fig. 3.4.2a and b). Additional 
FISH analysis showed in 87 of the 100 metaphases an unbalanced translocation 
between the long arm of chromosome 10 and the long arm of chromosome 11 (Fig 
3.4.2c. The karyotype of this patient was 46,XY,der(11)t(10;11)(q26.13;q24.2) [87]/46,XY 
[13]. DNA microsatellite markers showed no extra alleles.
 FISH analysis of the parents identified that the mother was a carrier of the 
balanced translocation between chromosomes 10 and 11. 
Figure 3.4.2 Case 1. (a) SNP array analysis revealed a duplication of 10.11 Mb on chromosome 10 and (b) a 





Case 2 was a 51-year old healthy female. The daughter of case 1 was referred because 
of developmental delay and serious behavioral problems. 
 SNP array analysis with the Affymetrix GeneChip Human Mapping 262K NspI 
array on the daughter of case 2 revealed a terminal duplication of 12.87 Mb on the long 
arm of chromosome 8. FISH analysis identified an unbalanced translocation between 
the long arm of chromosome 8 and the short arm of chromosome 22. Additional SNP 
array analysis for case 2 showed the same duplication, however with a lower intensity 
and FISH analysis confirmed this was due to a mosaic unbalanced t(8;22) resulting in 
a karyotype of 46,XX,der(22)t(8;22)(q24.2;p10) [15]/46,XX [14]. DNA microsatellite 
markers showed no extra alleles. 
 The parents of case 2 were not available for testing
Case 3
The patient was a female referred for Rubinstein-Taybi syndrome. FISH and sequence 
analysis for the CREBBP gene excluded the presence of a deletion or a mutation.
 SNP array analysis with the Affymetrix GeneChip Human Mapping 262K NspI 
revealed a terminal duplication of 6.8 Mb on the long arm of chromosome 6 and a 
terminal deletion of 11.2 Mb on the long arm of chromosome 11. Additional FISH 
analysis in the patient confirmed the presence of an unbalanced translocation between 
the long arm of chromosome 6 and the long arm of chromosome 11 in 6 of the 10 cells. 
The karyotype of this patient was 46,XX,der(11)t(6;11)(q26;q24.1) [6]/46,XX [4]. DNA 
microsatellite markers showed no extra alleles. In addition, the SNP analysis showed 
large stretches of homozygosity, suggesting consanguinity of the parents.
 FISH results for the parents were normal. The parents are first cousins once 
removed.
Discussion
Mosaicism involving a normal cell line and an unbalanced autosomal translocation is 
rare. To our knowledge, only 7 cases have been reported (Table 3.4.1) (Stallings et al., 
1997; Kulharya et al, 2002; Zaslav et al., 1999; Petkovic et al., 2003). Zaslav et al. (1999) 
reported a mosaicism for three cell lines, present in fibroblasts and lymphocytes and 
a patient with mosaicism for two cell lines in both lymphocytes and fibroblasts. Two 
cases are described with normal cell line in lymphocytes and mosaicism in fibroblasts 
(Stallings et al., 1997; Kulharya et al, 2002). The last three cases are mentioned with 
mosaicism in their lymphocytes only (Zaslav et al., 1999; Petkovic et al., 2003). The 
inheritance was unknown for three cases (Zaslav et al., 1999; Petkovic et al., 2003), 
three were de novo (Tsien et al., 1991; Stallings et al., 1997; Zaslav et al., 1999), and for 
one case the mother was carrier of the balanced translocation (Kulharya et al, 2002). 
In this study we reported three new cases with a normal cell line and an unbalanced 
autosomal translocation identified in lymphocytes. Other tissues were not analyzed. 
 The presence of a normal cell line and an unbalanced translocation can arise 
in several ways. 1) A mitotic exchange of nonhomologous chromatids followed by 
the loss of one of the translocated chromatids, subsequent segregation would result 
in a normal and an unbalanced cell line (Zaslav et al., 1999). 2) An unbalanced zygote 
followed by loss of the abnormal chromosome, a subsequent monosomy rescue event 
and a duplication of the normal chromosome. This would result in an isodisomy for 
this chromosome (Cotter and Hirschhorn, 1998). 3) 3:1 segregation with the derivative 
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chromosome and two normal associated chromosomes. Loss of a normal chromosome 
in one cell and loss of the derivative chromosome in the other cell will result in two 
different cell lines (Kulharya et al, 2002). Depending on the stage of development the 
abnormal cell line involves a greater or lesser fraction of the embryo for these three 
mechanisms. 4) Chimerism (Nyberg et al, 1992).  
 Here, we report on three unrelated cases of mosaic unbalanced translocations 
detected by SNP array and FISH analysis. Case 1 inherited the unbalanced translocation 
from his mother who carried the balanced translocation. To our knowledge this is only 
reported once (Kulharya et al., 2002). This mosaicism could only be explained by events 
2, 3 or 4. No extra alleles were detected with DNA microsatellite marker study and the 
genotype information was not suggestive for isodisomy. Since there was approximately 
in only 10% of the cells a normal karyotype this might be under the detection level of 
both techniques, and therefore mechanism 2 and 4 could not be excluded. For case 2, 
we were not able to determine the inheritance of the unbalanced translocation since 
the parents were not available for testing. Case 3 showed a de novo mosaic unbalanced 
translocation. The origin of these mosaicisms is most likely postzygotic. Chimerism was 
excluded for both cases and genotype information derived from SNP array analyses 
showed no allele differences suggestive for isodisomy. The first mechanism seems to 
be most likely in these cases. 
 To detect low-level mosaicisms with conventional karyotyping, large cell 
numbers need to be examined. Therefore, mosaicism screening is time consuming and 
expensive (Ballif et al., 2006). The application of high-resolution whole-genome arrays 
in a diagnostic setting has the potential to improve the identification of mosaicisms 
(Ballif et al., 2006; Gijsbers et al., 2009). Furthermore, the increased resolution of arrays 
enables the detection of smaller deletions and duplications. The gains and losses 
detected in this study were all larger than 5 Mb, which should be identifiable with 
conventional karyotyping. This highlights that the subtelomeric regions are more 
difficult to characterize by conventional karyotyping due to their G-negative staining. 
Therefore, unbalanced translocations could be easily masked and missed by routine 
cytogenetic testing.
 This study reports three new cases of a mosaicism with a normal cell line 
and an unbalanced autosomal translocation, which is a rare phenomenon. The 
exact mechanism responsible for these karyotypes is not clear. We demonstrate that 
high-resolution whole-genome arrays will reveal more mosaicisms, unbalanced 
translocations and a combination of both.
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Abstract
The presence of a duplication as well as a triplication in one chromosome is a rare 
rearrangement and not easy to distinguish with routine chromosomal analysis. Recent 
developments in array technologies, however, not only allow screening of the whole 
genome at a higher resolution, but also make it possible to characterize complex 
chromosomal rearrangements in more detail. Here we report a molecular cytogenetic 
analysis of a 16-year old female with severe mental retardation and an abnormality on 
the end of the long arm of chromosome 9. Subtelomeric multiplex ligation-dependent 
probe amplification (MLPA) analysis revealed that the extra material originated from 
the telomeric end of chromosome 9q. Fine mapping using a high-resolution single 
nucleotide polymorphism (SNP) array detected a duplication of ~400 kb upstream of 
a ~2.4 Mb triplication followed by a duplication of ~130 kb of chromosome 9q34.3. 
This study underscores the value of combining conventional karyotyping with novel 
array technologies to unravel complex chromosomal alterations in order to study their 
phenotypic impact. 
1. Methods of detection
1.1 Cytogenetic analysis
Conventional cytogenetic analysis on GTG-banded chromosomes from cultured 
lymphocytes of the patient was performed according to standard techniques. All 
metaphases studied demonstrated a 46,XX, add(9)(q34) karyotype (Fig. 4.1.1a). 
1.2 MLPA
Two specifically designed sets of probes for testing subtelomeric chromosomal 
imbalances, SALSA P036B and P070 Human Telomere Test Kit (MRC Holland, 
Amsterdam, The Netherlands), were used for subtelomere screening of the patient 
and the parents. MLPA experiments were performed as described by MRC Holland 
(http://www.mlpa.com/pages/indexpag.html) with slight modifications. Amplification 
products were identified and quantified by capillary electrophoresis on an ABI 3130 
genetic analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). 
Peak analysis was performed with the GeneMarker Software V1.51 (SoftGenetics, USA). 
1.3 SNP- array 
The Affymetrix GeneChip Human Mapping 238K StyI array was used. This SNP array 
contains ~238.000 25-mer oligonucleotides with a ~12 kb resolution. A sample of 
250 ng DNA was processed according to the instruction provided in the Affymetrix 
GeneChip Human Mapping 500K Manual (http://www.affymetrix.com). SNP copy 
number was assessed in the patient using DNA-Chip Analyzer (dChip) software (version 
release 02-16-06) [8]. Regions of copy number gain and loss were detected using the 
hidden Markov model output of dChip.
1.4 Chromosomal anomaly
To further characterize the extent of the aberration found by karyotyping, subtelomeric 
MLPA was performed. A duplication of both 9q probes, located in the MRPL41 gene 
and EHMT1 gene, was observed (Fig. 4.1.1b). 
 Fine mapping of the duplication was performed with a 238K SNP array. This 
array illustrated a terminal duplication of ~2.93 Mb (Fig. 4.1.1c). Due to exceptional 
high intensity values from both, the MLPA and the SNP array analyses, a 9q34.3 
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triplication was suggested.  Detailed analysis of the SNP array data revealed a ~400 kb 
duplication followed by a ~2.4 Mb triplication and a ~130 kb duplication (Fig. 4.1.1d). 
The proximal breakpoint is mapped in 9q34.3 with the last SNP (rs11103754) normal 
located in 137.24 Mb and the first SNP (rs7043655) duplicated in 137.26 Mb. The second 
breakpoint is mapped between the duplicated SNP (rs3849220) located in 137.62 Mb 
and the triplicated SNP (rs7873626) in 137.63Mb. The most distal breakpoint in 9q34.3 
is mapped with the last SNP (rs7848769) triplicated in 140.075 Mb and the first SNP 




Figure 4.1.1 Cytogenetic and molecular results. (a) Partial karyotype showing both chromosomes 9. Right: 
abnormal chromosome 9. (b) MLPA analysis revealing an aberration of the 9q probe. Red peaks: control 
panel; blue peaks: patient. (c) SNP array analysis of the patient revealed an aberration on the long arm of 
chromosome 9 of approximately 2.93 Mb. The threshold for deletions and duplications is, respectively, 1.6 
and 2.4. (d) SNP array copy number plot focused on the duplicated region of chromosome 9, showing a 
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1.5 Methods of confirmation
To verify these results additional MLPA probes were developed within the 2.93 
Mb critical interval for 9q. MLPA probes for the duplicated and triplicated region 
of chromosome 9q34.3 (located in genes MRPS2, CAMSAP1, LHX3, PTGDS, ANAPC2, 
COL5A1, OLFM1, CACNA1B) and control probes (genes GPR64 and FAM46D located 
on chromosome X) were designed at our laboratory and commercially obtained 
from Biolegio (Malden, The Netherlands). The MLPA experiments were performed as 
described [15].
 Furthermore BAC clones specific for human chromosome 9q were selected 
based on their physical location within the affected 9q region (http://www.ensembl.
org). Fluorescent in situ hybridization (FISH) experiments were performed by standard 
procedures [2]. BAC clones RP11-270D17 and GS-135I17 were used to confirm both 
duplications (Fig. 4.1.2a). To determine the precise orientation of the fragments 
involved in the triplication, BAC clones RP11-413M3 and RP11-48E05 were used and 
labeled with different fluorochromes (Fig. 4.1.2b, c). 
Figure 4.1.2 (a) FISH analysis with RP11-270D17 (green) and GS-135I17 (red) observed a duplication for 
both the probes confirming the 400 kb and 130 kb duplication, respectively. (b) Hybridization with RP11-
413M3 (green, centromeric side of chromosome 9q) and RP11-48E05 (red, telomeric side of chromosome 
9q) revealed the presence of four red and four green signals. The signals for the chromosome with the 
triplicated region showed that the middle repeat is inverted (green-red-red-green-green-red). (c) For probe 
RP11-48E05 the centromeric signal was of double intensity as compared to the telomeric signal. For probe 
RP11-413M3 (green) the telomeric signal was stronger than the centromeric signal. This indicates that the 
repeats of the triplication are normal in the proximal and distal region and inverted in the central region.
1.6 Causative of the phenotype
Conventional karyotyping of the parents presented a normal karyotype. Furthermore 
the parents showed normal subtelomeric MLPA, FISH and SNP array results. These 
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2. Clinical description
The female patient was born after an uncomplicated pregnancy, weighing 2750 g. She 
is the youngest child in a sibship of three. Parents are healthy and non-consanguineous. 
A previous pregnancy had resulted in unexplained stillbirth around 38 weeks gestation. 
She has one healthy older sister.
 In early infancy, psychomotor retardation was noted (walking after 2.5 years of 
age, no speech development). At physical examination at the age of 2.5 years height 
was 89 cm (10th centile), head circumference 47.5 cm (25th centile). She was reported 
to have no apparent facial dysmorphism, and apart from tapering fingers and a sacral 
dimple no phenotypic anomalies were present. Despite extensive investigations at 
the time, no reason for the developmental delay was found. At the age of 6 years she 
underwent surgery because of convergent strabismus.
 At the age of 16 years she was referred to our department for re-evaluation (Fig. 
4.1.3). She was severely mentally retarded. She had limited speech; she only used a few 
words and was dysarthric. There was constant drooling. She had hearing loss. She was 
able to communicate using signs and pictures. She had a high threshold for pain. There 
was no history of sleep disturbance, seizures or constipation. Recently, she developed 
aggressive behaviour and was found to have more difficulties with walking.
 At physical examination her growth parameters were within normal limits. Her 
facial features showed narrow palpebral fissures and a wide/large mouth. Both earlobes 
were upturned. Apart from slender fingers with clinodactyly of both fifth fingers and 
bilateral pes cavus, no dysmorphic features were present.
 DNA analysis for Angelman syndrome and Mowat-Wilson syndrome showed 
a normal methylation pattern and no mutation in the ZFHX1B gene, respectively. MRI 
and metabolic screening showed no abnormalities. 
 We obtained samples from the patient and family members after acquiring 
informed consent approved by the Institutional Review Board at the Leiden University 
Medical Center, Leiden.
Figure 4.1.3 Picture of the female patient at the age of 16 years. Note mild facial asymmetry and narrow 
palpebral fissures.
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3. Discussion
Cytogenetic karyotyping was performed on a female patient with unexplained 
severe mental retardation and showed an abnormal karyotype, 46,XX,add(9)(q34). 
To determine the extent of the aberration on chromosome 9, subtelomeric MLPA 
analysis was performed showing an abnormality for both probes on chromosome 9q. 
Subsequent SNP array analysis revealed a ~400 kb duplication followed by a ~2.4 Mb 
triplication and a duplication of 130 kb of chromosome 9q34.3 demonstrating the 
added value of this technique to conventional karyotyping.
 To the best of our knowledge, this is the first report on a case with a partial 
duplication and partial triplication of chromosome 9q34.3. In the literature a few cases 
of duplication 9q are described. In 1975 the first association between clinical features 
and a partial duplication of chromosome 9q in two patients was reported [12]. Later 
four families with seven affected children, presumably descending from a common 
ancestor, in which an inverted insertion (9)(q22.1q34.3q34.1) chromosome was 
segregating were described [1]. Meiotic recombination led to the duplication of the 
9q34 region, and to a phenotype they called the duplication 9q34 syndrome. Recently 
a new case with a duplication of chromosome 9q34 was described [4]. Furthermore, 
patients with a duplication of the 9q34 region and an additional aberration elsewhere 
in the genome were reported [6,9,10]. It may be expected that in those cases the 
phenotype is also affected by the other observed deletions and duplications in the 
genome. Nevertheless, the authors recognized a clinical syndrome similar to the 
duplication 9q34 syndrome [1]. Phenotypic similarities are observed between patients 
with a duplication of chromosome 9q34 and patients with larger duplications of 
chromosome 9q [10]. Larger duplications of chromosome 9q appear to be associated 
with a more severe developmental delay. 
 Although there are no cases described of partial triplication of this region 
before, it would be logical to compare the clinical phenotype of our patient with cases 
with duplication of chromosome 9q34 (Table 4.1.1). Only one study described patients 
with a pure 9q34 duplication overlapping the 9q34.3 abnormality in our patient [1]. In 
their patients common clinical features were dolichocephaly, facial asymmetry, deep-
set eyes, narrow horizontal palpebral fissures, prominent nasal bridge, beaked nose, 
small mouth, retrognathia, arachnodactyly, camptodactyly, joint contractures, and 
scoliosis. The facial phenotype seemed to change with age. Reported medical problems 
were feeding difficulties and failure to thrive in infancy, strabismus and ptosis. All 
patients had psychomotor retardation and speech development was frequently 
impaired. Several patients were reported to have behavioral problems (hyperactivity, 
tantrums). Our patient seems to have some of the reported facial features. Furthermore, 
her arachnodactyly, limited speech and behavioral problems may be explained by the 
chromosome aberration.
 It has been described that a microdeletion syndrome can show overlapping 
features with a microduplication syndrome of the same region, e.g. 22q11 [3]. Patients 
with a deletion 9q34 however, show a distinct phenotype that does not bear a 
resemblance to our patient [5]. As yet there are no arguments for overlapping clinical 
features in microduplication and microdeletion in the 9q34 region. 
 In the 9q34.3 deletion syndrome, haploinsufficiency of EHMT1 (MIM 607001) is 
recognized as the causative gene [7]. The EHMT1 gene belongs to the histone-lysine 
methyltransferase family and plays a role in the central nervous system development 
and function through epigenetic histon modification (http://www.dsi.univ-paris5.fr/
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Table 4.1.1 Comparison of clinical features with other reported cases with 
duplication 9q34
genatlas/). It is unknown whether duplication or triplication of this gene results in an 
equal disturbance of function.
 In our case the most distal breakpoint disrupts the CACNA1B gene. CACNA1B 
is a calcium channel, voltage dependent, N-type, alpha subunit gene (MIM 601012). 
It encodes an N-type calcium channel, which controls neurotransmitter release from 
neurons. It has been suggested that a heterozygous deletion of CACNA1B may result in 
the reduction of N-type channel activity [5]. In this way, in addition to the triplication 
of EHMT1, haploinsufficiency of CACNA1B may be a contributing factor for mental 
retardation and/or epilepsy. However, FISH analysis revealed the orientation of the 
triplication and supports an inverted orientation of the middle fragment (Fig. 4.1.3b, 
c). This results in two normal functioning copies of the CACNA1B gene and three 
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interrupted copies. 
 In short, copy number variations of the EHMT1 gene may probably explain 
some features of the phenotype of this patient. However, according to the Ensembl 
Genome Browser (http://www.ensembl.org/index.html) release 44 based on the NCBI 
36 assembly of the human genome (November 2005), the 2.93 Mb duplicated and 
triplicated regions of our patient contains approximately 100 genes. It is therefore 
unlikely that the clinical features in our patient are the result of a copy number change 
in just one gene. We expect that the phenotype associated with this rearrangement 
will be clarified when other cases with comparable rearrangements are disclosed. 
 According to the Database of Genomic Variants (http://projects.tcag.ca/
variation/) the 9q34.3 region corresponds to a copy number variation region (CNVR), 
which is an artificial grouping of CNVs overlapping or in close proximity of each other 
[16]. This CNVR consists of 3 individual CNVs (gains) detected in 1190 controls (0.3%). 
Since this aberration is repeatedly described as disease causing [1,4,12], it is likely that 
the complex rearrangement described here causes the phenotype. 
 The three breakpoint regions of the 9q aberration present no architectural 
features that might be involved in the mediation of duplications and triplications. We 
speculate that first a 2.93 Mb duplication occurred and subsequently, an interstitial 
triplication in the duplicated region. Intrachromosomal triplications are rare and most 
of them concern the proximal 15q region [13]. Most of the reported triplications seem 
to result from a common mechanism as indicated by the inverted orientation of the 
middle repeat [14]. However, it is not clear which mechanism can explain the genesis 
of these triplications. 
 In conclusion, using conventional karyotyping characterization of complex 
rearrangements and identification of the origin of extra chromosomal material is 
often difficult. The introduction of new molecular cytogenetic methods such as 
MLPA analysis and SNP arrays provides cytogenetics with new approaches to define 
these abnormal chromosomes. The resolution of chromosome studies is markedly 
improved by the availability of SNP arrays that enable high-resolution genome 
analysis. This technique proves to be a more accurate method for the identification and 
delineation of chromosomal rearrangements. As a result, precise definition of complex 
rearrangements can be better established. It is, however, noteworthy that current array 
technologies are incapable of detecting balanced alterations such as inversions, and 
only give information regarding genomic gains and losses. In this study we underline 
the added value of array technologies in defining chromosomal aberrations observed 
with conventional chromosome analysis. 
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Abstract
Here we report on the clinical and cytogenetic results in a family carrying a cryptic 
translocation involving chromosome 3pter and 21qter detected by Single Nucleotide 
Polymorphism (SNP) array and subtelomeric Fluorescent In Situ Hybridisation (FISH) 
analysis. The index patient, with mild mental retardation (MR) in combination with 
minor dysmorphic features, inherited the derivative chromosome 21 resulting in a 
partial trisomy of the short arm of chromosome 3 and a partial monosomy of the 
long arm of chromosome 21. Her apparently healthy brother inherited the derivative 
chromosome 3 resulting in a terminal deletion of the short arm of chromosome 3 and 
a terminal duplication of the long arm of chromosome 21. We discuss the different 
phenotypes for the two genotypes and argue for the importance of reporting these 
imbalances to achieve accurate genetic counseling in prenatal and postnatal diagnosis. 
Introduction
Several patients with chromosome aberrations involving chromosomes 3pter 
and 21qter have been reported. The first case with the 3p deletion syndrome was 
described in 1978 (Verjaal and De Nef, 1978), and is characterized by low birth weight, 
developmental delay, growth retardation and dysmorphic facial features (Malmgren 
et al., 2007; Barber et al., 2008; Fernandez et al., 2008). The smallest region of overlap 
for all reported 3p deletion patients is 1.5 Mb on chromosome band 3p26, including 
the candidate genes CHL1 (MIM# 607416), CNTN4 (MIM# 607280) and CRBN (MIM# 
609262) (Cargile et al., 2002; Dijkhuizen et al., 2006). The clinical manifestations of the 
trisomy 3p syndrome are quite variable depending on the size of the duplication (for 
review see Schinzel, 2001). The syndrome includes psychomotor retardation, mental 
retardation (MR) and minor dysmorphic features.
 Genotype-to-phenotype correlations for partial monosomy and partial 
trisomy of chromosome 21 have recently been reviewed (Lyle et al., 2009). Deletions 
of the terminal 21q22.2q22.3 region produce a mild phenotype including MR and 
holoprosencephaly (Lyle et al., 2009). Cases with terminal duplications of 21q22 are 
rare. Most patients have a Down syndrome phenotype including cognitive impairment, 
congenital heart disease and characteristic facial and physical appearance (Lyle et al., 
2009). 
 Conventional karyotyping can detect chromosomal abnormalities larger 
than approximately 5 Mb. For detection of smaller abnormalities Fluorescent In Situ 
Hybridisation (FISH)-, Multiplex Ligation-dependent Probe Amplification (MLPA)-,and 
whole genome high resolution array - analyses are necessary (Knight and Flint, 2000; 
de Vries et al., 2005; Rauch et al., 2006; Hoyer et al., 2007; Kriek et al., 2007; Gijsbers et 
al., 2009). In 5% of patients with MR with or without multiple congenital abnormalities 
subtelomeric abnormalities are identified (Flint et al., 1995; Knight et al., 1999; de 
Vries et al., 2003). Nevertheless, there are subtelomeric rearrangements reported 
in unaffected normal individuals and therefore considered to be not pathogenic 
(Hengstschläger et al., 2005; Balikova et al., 2007). Hence it is of great importance 
to report these polymorphisms for genetic counseling in prenatal and postnatal 
screening. 
 Here we report on the segregation of a submicroscopic familial reciprocal 
translocation between the subtelomeric regions of the short arm of chromosome 3 and 
the long arm of chromosome 21, and describe the different phenotypes in two siblings 
who inherited the different unbalanced products.
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Materials and methods
Index patient
The index patient in this family was a 5-year old girl (Fig. 4.2.1a and b), the first child of 
healthy, unrelated parents. She was born after an uneventful pregnancy after 42 weeks 
of gestation with a birth weight of 2500 g and birth length of 43 cm. She spoke her first 
words before her first year and walked unsupported at the age of 2 years. At 2 years 
and 8 months delayed motor and speech development was noted. She had mild MR 
(IQ 65) and clinical examination showed frontal bossing, hypotelorism, thin and long 
face, hoarse voice and laxity of all joints.
 Williams syndrome was excluded by FISH analysis with the DNA probe LSI ELN/
LSI D7S486, D7S522 (Vysis, Il, USA). 
Brother of index patient
The 2.5-year old, younger brother (Fig. 4.2.1c) of the index patient was born after an 
uneventful pregnancy after 40 weeks of gestation. His birth weight was 3350 g. He 
walked unsupported at 14 months. His motor and speech development was normal. 
Clinical examination showed no dysmorphic features. At 14 months mild strabismus 
was noted. Before the age of 2 years he was able to count and to recognize figures. He 
will be kept under review in case later onset health problems emerge.    
Figure 4.2.1 Pictures of the index patient and her apparently healthy brother. (a) (b) Facial picture of the 
index patient at the age of 3 (a) and 4 (b) years. Note frontal bossing, hypotelorism and thin and long face. 
(c) Facial picture of her brother at the age of 2 years.
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Conventional karyotyping and FISH analysis
Conventional cytogenetic analysis on GTG-banded chromosomes from cultured 
lymphocytes and FISH analysis were performed according to standard techniques 
(Dauwerse et al., 1990).
SNP arrays
DNA was extracted from whole blood by a Gentra Puregene DNA purification Kit 
(Gentra Systems, Minneapolis, USA), following the manufacturer’s instructions. 
The Affymetrix GeneChip Human Mapping 262K NspI array contains 262.262 25-
mer oligonucleotides, with an average spacing of approximately 12 kb (Affymetrix, 
Santa Clara, CA, USA). An amount of 250 ng DNA was processed according to the 
manufacturer’s instruction. SNP copy number was assessed using the software program 
CNAG Version 2.0 (Nannya et al., 2005).
 The result of the index patient was added to the DECIPHER database (Wellcome 




Conventional karyotyping showed no abnormalities in the index patient (Fig 4.2.2a). 
SNP array screening, however, revealed a terminal duplication on the short arm of 
chromosome 3 and a terminal deletion on the long arm of chromosome 21 (Fig 4.2.2b). 
The size of the aberrations was 3 Mb (from probe SNP_A-1971271 to SNP_A-2081957, 
respectively at 73.603 bp and 3.085.004 bp according to http//:www.ensembl.org, 
Ensembl release 56 – Sept 2009) and 5 Mb (from probe SNP_A-2019989 to SNP_A-
2020813, respectively at 43.020.221 bp and 48.069.930 bp). FISH analysis confirmed the 
presence of a derivative chromosome 21, originating from a translocation between the 
short arm of chromosome 3 and the long arm of chromosome 21 (Fig 4.2.2c).        
 FISH analysis revealed a normal karyotype for the father, while the mother was 
carrier of a de novo balanced t(3;21)(p26.3;q22.3) (Fig 4.2.2d). The brother of the index 
patient inherited the derivative chromosome 3 resulting in a 3 Mb deletion of the 
terminal part of the short arm of chromosome 3 and a 5 Mb terminal duplication of the 
long arm of chromosome 21 (Fig. 4.2.2e). 
Discussion
The presence of a double chromosome imbalance complicates genotype-phenotype 
correlations in patients. Our index patient carrying the derivative chromosome 21, 
resulting in a partial trisomy of 3p and a partial monosomy of 21q, presented mild 
MR, frontal bossing, hypotelorism, thin and long face, hoarse voice and laxity of all 
joints. The phenotype of trisomy 3p patients is quite variable and depends on the 
size of the duplication (Schinzel, 2001). The duplication of 3p in the index patient is 3 
Mb and contains three genes: CHL1, CNTN6 and CNTN4. In the Database of Genomic 
Variants (DGV, http://projects.tcag.ca/variation/), all these genes are reported as gains 
in normal individuals. Therefore we suggest that the 3p duplication in our patient is 
probably not contributing to the phenotype. The 5 Mb deletion on chromosome 21, 
however, contains approximately 88 genes and is not described in normal individuals 
according to the DGV. Despite the phenotypic variability in partial monosomy 21, there 
are some common features among the reported cases including craniofacial, skeletal 
and cardiac effects, genital malformations and severe MR (Lyle et al., 2009). Yet, most 
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Figure 4.2.2 Cytogenetic and molecular analysis of the familial t(3;21)(p26.3;q22.3). (a) Conventional 
karyotyping revealed no abnormalities for chromosomes 3 and 21 in the index patient. The arrow indicates 
the aberrant chromosome 21. (b) SNP array analysis (Affymetrix GeneChip Human Mapping 262K NspI) 
results for the index patient demonstrating a 3 Mb duplication on the short arm of chromosome 3 and a 5 
Mb deletion on the long arm of chromosome 21. Genes involved on both regions, UCSC Human Genome 
Browser (http://genome.ucsc.edu), Mar 2006 build (hg18). (c) FISH analysis confirmed the presence of the 
derivative chromosome 21 (black arrow), originating from a translocation between 3p (green; GS-1186B18; 
Flint) and 21q (red; GS-63H24; Flint). Control probes used for centromere chromosome 3 (red; CEP3; Vysis) 
and satellites of chromosome 13 and 21 (green; a-sat 13/21; Cytocell). (d) FISH analysis for the mother 
of the index patient demonstrated that she is carrier of the balanced t(3;21)(p26.3;q22.3) (black arrows) 
(probes: GS-1186B18, GS-63H24, CEP3 and a-sat 13/21). (e) FISH analysis for the brother of the index patient 
showing the derivative chromosome 3 (black arrow) (probes: GS-1186B18, GS-63H24, CEP3).
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of these patients have a larger deletion than our patient. The most terminal 10 Mb 
of chromosome 21 contains approximately 130 genes and monosomy of this region 
contributes to a milder phenotype (Lyle et al., 2009). Accordingly the relative mild 
phenotype of our index patient is most likely explained by the even smaller distal 21q 
deletion. The phenotype might be the result of a gene-dosage effect of a combination 
of genes. Moreover, five of the 88 genes have been associated with MR; CBS (MIM# 
236200), COL6A1 (MIM# 120220), CSTB (MIM# 601145), S100B (MIM# 176990) and 
SLC19A1 (MIM# 600424) (http://www.ncbi.nlm.nih.gov/sites/entrez).  
 The brother of the index patient, carrying the derivative chromosome 3, 
resulting in a terminal deletion of the short arm of chromosome 3 and a terminal 
duplication of the long arm of chromosome 21, shows an apparently healthy 
phenotype. The distal 3p deletion syndrome is reported with a recognizable 
phenotype, including developmental delay, low birth weight, growth retardation and 
several dysmorphic features (Malmgren et al., 2007; Barber et al., 2008; Fernandez et 
al., 2008). The critical region was defined as a 1.5 Mb region on chromosome 3p26, 
containing the candidate genes CHL1, CNTN4 and CRBN (Cargile et al., 2002; Dijkhuizen 
et al., 2006). The genes CHL1 and CNTN4 map within the brother’s deletion excluding 
haploinsufficiency of these genes as a cause for MR. Nevertheless, cases have been 
reported with a deletion of the distal 3p region without any phenotypic effects (Knight 
et al., 1995; Shrimpton et al., 2006; Takagishi et al., 2006; Hoo et al., 2008). Shrimpton 
et al (2006) even postulated that the distal 3p26 deletion is probably associated 
with normal intelligence and normal physical features. However, it is possible that 
mutations in one of the candidate genes on the normal chromosome 3 are responsible 
for an abnormal phenotype. This could also be suggested for the candidate gene 
CRBN, which was not deleted in our patient, but in both phenotypically abnormal 
and normal previously reported cases (Knight et al., 1995; Dijkhuizen et al., 2006). 
Another explanation might be that the distal 3p region is a susceptibility locus for 
MR, and therefore the deletion is not presenting MR in all 3p- cases. A further possible 
explanation might be the involvement of epigenetic and environmental factors.
 Since terminal deletions of the 3p26 may be associated with a normal 
phenotype we suggest that prenatally detected de novo distal 3p deletions may 
warrant further molecular analysis to accurately size the deletion. 
 Patients with partial trisomy 21 are rare and the Down syndrome phenotype in 
most of these cases has been associated with duplication of 21q22 (Horn et al., 2003). 
A 250 kb trisomy of the distal subtelomeric region of 21q22.3 was reported as a benign 
variant (Bonaglia et al., 2007). Here we show that a terminal duplication of at least 5 Mb 
on distal 21q22.3q22.3 is not related with an abnormal phenotype. While a deletion of 
this region is associated with an abnormal phenotype in our index patient.
 In conclusion, a genotype-phenotype correlation is difficult to make in regions 
with large number of genes and in regions in which deletions as well as duplications 
have been reported in healthy individuals. Yet, reporting these pathogenic and 
polymorphic rearrangements is of great importance for genetic counseling and 
prenatal screening.  The detailed clinical description of our cases, along with a precise 
cytogenetic designation of chromosome breakpoints, allows further refinement of 
genotype-phenotype correlation for terminal imbalances in 3p and 21q.
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Abstract
Blepharophimosis-Ptosis-Epicanthus inversus Syndrome (BPES) is a well characterized 
rare syndrome that includes an eyelid malformation associated with (type I) or 
without premature ovarian failure (type II). Patients with typical BPES have four 
major characteristics: blepharophimosis, ptosis, epicanthus inversus and telecanthus. 
Mutations in the FOXL2 gene, encoding a forkhead transcription factor, are responsible 
for the majority of both types of BPES. However, many patients with BPES-like features, 
i.e. having at least 2 major characteristics of BPES, have an unidentified cause. Here, 
we report on a group of 27 patients with BPES-like features, but without an identified 
genetic defect in the FOXL2 gene or flanking region. These patients were analyzed with 
whole-genome high-density arrays in order to identify copy number variants (CNVs) 
that might explain the BPES-like phenotype. In 9 out of 27 patients (33%) CNVs not 
previously described as polymorphisms were detected. Four of these patients displayed 
psychomotor retardation as an additional clinical characteristic. In conclusion, we 
demonstrate that BPES-like phenotypes are frequently caused by CNVs, and we 
emphasize the importance of whole-genome copy number screening to identify the 
underlying genetic causes of these phenotypes.
Introduction
Blepharophimosis and ptosis are a reduction in the horizontal and vertical dimensions 
of the palpebral fissures respectively (Guercio et al. 2007). From the 135 syndromes in 
the London Dysmorphology Database with blepharophimosis and ptosis, 6 are known 
to be associated with a chromosomal microdeletion (Winter et al. 2008). In addition, a 
recent literature review illustrates that chromosomal aberrations are probably the most 
important underlying cause in patients with blepharophimosis and mental retardation 
phenotypes (Bartholdi et al. 2008). Only a few blepharophimosis syndromes have 
known causative genes: the Schwartz-Jampel syndrome (OMIM 255800), Freeman 
Sheldon syndrome (OMIM 193700), Hereditary neuralgic amyotrophy syndrome 
(HNA; OMIM 162100) (Laccone et al, 2008) and Blepharophimosis-Ptosis-Epicanthus 
inversus syndrome (BPES) (OMIM 110100). BPES is a rare autosomal dominant disorder 
characterized by a dysplasia of the eyelids. There are two types of clinical presentation: 
type I is associated with premature ovarian failure, whereas type II has no associated 
symptoms (Zlotogora et al. 1983). The typical BPES phenotype is characterized by 
four major features blepharophimosis, ptosis, epicanthus inversus (a small skin fold 
which arises from the lower eyelid and runs inwards and upwards) and telecanthus 
(increased distance between the medial lid margins). Haploinsufficiency of the FOXL2 
gene, encoding a putative forkhead transcription factor located at chromosome 
3q23, is responsible for both types of BPES (Crisponi et al. 2001; De Baere et al. 2001; 
De Baere et al. 2003). Using a combined mutation detection approach, it is possible 
to reveal the causal genetic defect in 88% of typical BPES patients. Molecular defects 
include chromosomal rearrangements (2%), intragenic mutations (81%) and genomic 
rearrangements comprising both deletions encompassing FOXL2 (12%) and deletions 
located outside its transcription unit (5%) (Beysen et al. 2005; Beysen et al. 2008). The 
lack of a detectable genetic FOXL2 defect might be explained by several grounds, 
including subtle extragenic rearrangements, epigenetic changes and referral bias by 
the different clinicians (Beysen et al. 2008). Here, we focus on series of 27 patients with 
BPES-like features (i.e. having at least two main characteristics of typical BPES), who 
tested negative for FOXL2 mutations and deletions of the FOXL2 region, and in whom 
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the causal defect remains to be elucidated (Beysen et al. 2008).
 Novel whole-genome array-based technologies can detect copy number 
variants (CNVs) at much higher resolution than conventional cytogenetic methods, 
and hence might reveal CNVs that were previously unidentified. These techniques have 
been used with considerable success to reveal de novo CNVs in several phenotypes, 
including mental retardation and dysmorphism (Stankiewicz and Beaudet 2007; 
Slavotinek 2008).Yet, the association between CNVs and BPES-like phenotypes has not 
been investigated. We performed whole-genome high-density arrays in the group of 
27 FOXL2 mutation-negative patients with a BPES-like phenotype in order to identify 
the underlying genetic cause explaining the phenotypes. 
Methods
Patients
Genomic DNA was obtained from 27 patients with a BPES-like phenotype, 
being patients for whom at least two of the four diagnostic criteria of BPES (i.e. 
blepharophimosis, ptosis, epicanthus inversus and telecanthus), were mentioned on 
a clinical questionnaire. In 11 of the patients psychomotor retardation was identified 
as an additional clinical feature. Furthermore, all patients were clinically assessed by 
different clinicians. The patients were recruited in three genetic centers: (1) 22 patients 
from the Center for Medical Genetics, Ghent University Hospital, Belgium. Genomic 
patient DNA was used that was available from previously approved mutation studies 
(De Baere et al. 2001; De Beare et al. 2003; Beysen et al. 2005; Beysen et al. 2008); (2) 
3 families from the Department of Clinical Genetics, Amsterdam Medical Centre, The 
Netherlands; (3) 2 patients from the Department of Clinical Genetics, Leiden University 
Medical Center, The Netherlands.
 All patients were initially referred for FOXL2 screening. Intragenic FOXL2 
mutations and copy number variants of the FOXL2 gene and surrounding region were 
excluded in all patients by sequencing of the coding region and multiplex ligation-
dependent probe amplification (MLPA) (P054, MRC Holland). In addition, conventional 
karyotyping was performed in 13 patients and considered normal.
Single Nucleotide Polymorphism arrays
Affymetrix GeneChip Human Mapping 262K NspI. This array was used for one patient 
and his parents. This SNP array contains ~262,000 25-mer oligonucleotides with 
an average spatial resolution of ~12 kb. An amount of 250 ng DNA was processed 
according to the manufacturer’s instruction (http://www.affymetrix.com). SNP copy 
number was assessed in the patient using DNA-Chip Analyzer (dChip) software (version 
release 02-16-06) (Li and Wong, 2001). 
Illumina’s Sentrix HumanHap300 Genotyping Beadchip. This platform was used for 
23 patients. This array contains ~317,000 TagSNPs with a mean spatial resolution 
of approximately 9 kb. A total of 750 ng DNA was processed according to the 
manufacturer’s instruction (http://www.illumina.com). SNP copy number (logRratio) 
and B allele frequency were assessed in the patients using BeadStudio Version 3.2 
(Illumina, Inc.). 
Illumina’s HumanCNV370-Duo BeadChip. For three patients this platform was used. This 
array contains ~317,000 TagSNPs and 52,000 non-polymorphic markers to specifically 
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target nearly 14,000 known copy number variants with a mean spatial resolution of 
approximately 7.7 kb. The experiment was performed as described above. SNP copy 
number and B allele frequency were assessed in BeadStudio, Version 3.2 (Illumina, Inc.).
Evaluation of CNVs
Based on in-house validation studies deletions of at least 5 adjacent SNPs or with 
a minimum size of 150 kb and duplications of at least 7 adjacent SNPs or with a 
minimum size of 200 kb were considered significant. All CNVs identified in this study 
were assessed by screening them against the Database of Genomic Variants (DGV) 
(http://projects.tcag.ca/variation/) and against our in-house available reference set of 
approximately 1000 individuals. All regions that significantly overlapped with known 
polymorphic CNVs were excluded from further research.
MLPA
MLPA experiments were carried out to validate the presence of deletions and 
duplications identified by the arrays. When an aberration was confirmed by MLPA, 
the same probe set was used to perform segregation analysis in the parents (if 
available).  At least two synthetic MLPA probes were designed within the aberration 
and MLPA experiments were performed as described (White et al. 2004). Probes 
were commercially obtained from Biolegio (Malden, The Netherlands). Amplification 
products were identified and quantified by capillary electrophoresis on an ABI 3130 
genetic analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). 
Fragment analysis was performed with the GeneMarker Software V1.51 (SoftGenetics, 
USA). Thresholds for deletions and duplications were set at 0.75 and 1.25 respectively 
(White et al. 2004).
Fluorescent In Situ Hybridisation Analysis (FISH)
FISH analysis was carried out by standard procedures as described (Dauwerse et 
al. 1990). FISH analysis was performed to verify the imbalances found with the array 
experiments and to exclude more complex rearrangements. BAC clones mapping to 
the unbalanced chromosome regions were selected based on their physical location 
within the affected region (http://www.ensembl.org: Ensembl release 48 - dec 2007). 
Gene prioritisation
The software tool Anni 2.0 (http://www.biosemantics.org/Anni) was used to search for 
potential candidate genes for BPES-like features in the CNVs found. For each gene a 
profile of related concepts is constructed that summarizes the context in which the 
gene is mentioned in the literature. Genes associated with similar topics are identified 
by hierarchical clustering of the corresponding gene concept profiles. The software was 
used according to the software’s manual (Jelier et al. 2007).
Results and discussion
Identification and confirmation of 12 significant CNVs 
In this study we included 27 patients based on the following criteria: (1) BPES-
like phenotype (i.e. 2 or more major features of BPES, with or without additional 
dysmorphic features and psychomotor retardation); (2) exclusion of a FOXL2 mutation 
or deletion of the FOXL2 region. These patients were analyzed with whole-genome 
high-density arrays with an average spatial resolution of approximately 10 kb, in 
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an attempt to identify the underlying genetic cause and to reveal potential novel 
candidate loci and genes for BPES-like phenotypes. 
 In total we identified 12 CNVs not previously described in phenotypically normal 
individuals according to the DGV and our in-house reference set, in 9 out of 27 patients 
(33%). An overview of these changes is provided in Table 5.1.1. We found 6 duplications 
and 6 deletions. In 3 patients (cases 7, 8 and 9) a deletion as well as a duplication was 
identified, suggesting the presence of an unbalanced translocation. The identified CNVs 
vary in size from 485 kb to 21.9 Mb. Table 5.1.2 represents the available clinical features 
from 8 out of the 9 patients carrying chromosome imbalances. Four of these patients 
display psychomotor retardation as an additional clinical feature.
 Each of the 12 CNVs was confirmed by a second independent technique, either 
MLPA (patients 1-3, 5, 7-8), FISH (patients 4, 9) or another SNP array platform (patient 
6). In 8 of 9 cases parental DNA was available for segregation analysis. MLPA and FISH 
analysis in these cases determined that chromosomal aberrations arose de novo in 5 
out of 8 individuals (patients 1-4, 8). 
De novo single CNVs
The CNVs identified in cases 1 and 2 were recently described in patients with BPES-
like features, developmental delay and other dysmorphic features (Schinzel et al. 1991; 
Tinkle et al. 2003; Shaw-Smith et al. 2006; Koolen et al 2006; Koolen et al 2008). 
 Patient 1 had an interstitial deletion of 18q12.2q21.1 (14.3 Mb), and displayed 
blepharophimosis, ptosis, epicanthus inversus, and mild dysmorphic features (abnormal 
nose and ears). The patient died at the age of 4. Several cases have been described with 
del(18)(q12.2q21.1) showing a consistent clinical pattern of mild dysmorphic features, 
blepharophimosis, obesity, mental retardation, seizures, behavioral problems, and lack 
of major congenital anomalies (Schinzel et al. 1991; Tinkle et al. 2003).
 In patient 2 an interstitial microdeletion of 17q21.31 (485 kb) was found 
(Fig. 5.1.1), overlapping with the region that was recently described in the new 
microdeletion syndrome 17q21.31 (Shaw-Smith et al. 2006; Koolen et al 2006). This 
new microdeletion syndrome was originally identified by high-resolution genome 
analyses in patients with unexplained mental retardation, and was recently further 
characterized clinically and molecularly (Koolen et al. 2008). The deletions are 
associated with a common inversion polymorphism. Individuals carrying this deletion 
display a recognizable phenotype of blepharophimosis, a characteristic long face with 
pear shaped nose, large ears, hypotonia and mental retardation. Interestingly, the 
phenotype of patient 2, characterized by blepharophimosis, bilateral ptosis, epicanthus 
inversus, telecanthus, broad pear shaped nose, large ears, central and peripheral 
hypotonia, and psychomotor retardation, is in agreement with this recognizable 
17q21.31 microdeletion syndrome. 
 Patient 3 had a small interstitial duplication of 16p13.3 (1.1 Mb). To our 
knowledge, two patients have been reported with a partially overlapping duplication 
of this region, including a patient with an interstitial duplication of 345 kb - 480 kb on 
16p13.3, encompassing the TRAP1 and CREBBP genes that are also duplicated in patient 
3 (Thienpont et al. 2007). The second patient was reported to have a duplication of 
16p13.3 with a minimal and maximal size of 4.5 Mb and 7 Mb respectively (de Ravel 
et al. 2005). The duplicated region of patient 3 overlaps over at least 620 kb with 
the reported duplications. However, the two reported patients display no BPES-like 
features, suggesting that the region of approximately 600 kb that does not overlap is 
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Figure 5.1.1 Case 2 (a) Deletion of chromosome 17q21.31 (485 kb) found with the Illumina’s Sentrix 
HumanHap300 Genotyping Beadchip. (b) MLPA analysis confirmed the deletion. Deleted probes: MAPT 
and KIAA1267. (c) Picture of the eyes of case 2, characterized by blepharophimosis, bilateral upper lid 
ptosis, epicanthus inversus and telecanthus.
responsible for the BPES-like features in patient 3. 
 In patient 4 we detected a novel rearrangement, being an interstitial deletion 
of chromosome 10p12.33p12.31 (4.5 Mb) (Fig. 5.1.2). It was shown to occur de novo 
and it is therefore likely to be causative. The clinical features of this patient include 
blepharophimosis, ptosis, epicanthal folds, ectropion of the lower eyelid, S-shaped 
upper eyelid, synophrys, high palate, broad hands and feet, and an atrial septal defect 
type II. This patient has a normal psychomotor development. 
Inherited single CNVs
In patient 5 a small interstitial duplication of 545 kb on chromosome 11p15.4 was 
detected. This gain was not reported as a variant in the DGV, but was found in the 
phenotypically normal mother of this patient, probably suggesting absence of a causal 
relation between the duplication and the BPES-like phenotype in the child. 
 Furthermore, in case 6 an interstitial duplication of chromosome 9q34.1q34.2 
(1.4 Mb) was found that was not described in the DGV. The mother of this patient 
was shown to carry the same duplication. The phenotype of patient 6 is characterized 
by bilateral ptosis, mild epicanthus inversus, horizontal nystagmus and high 
hypermetropia, while her mother displayed a mild ptosis and strabismus for which she 
underwent surgery. The occurrence of a phenotype in mother and child might suggest 
a causal relationship of the novel duplication and the phenotype.
Complex CNVs
In three cases more complex rearrangements were identified (cases 7, 8 and 9). In these 
patients both a duplication and a deletion were found on different chromosomes, 
suggesting the occurrence of an unbalanced translocation (Table 5.1.1). 
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 Patient 7 was found to carry a terminal duplication of chromosome 10q (21.9 
Mb) and a terminal deletion of chromosome 11q (5 Mb). Recently, a patient was 
described with approximately the same duplication of chromosome 10q and a deletion 
located on chromosome 4q (Bartholdi et al. 2008). This patient displayed the following 
clinical features: blepharophimosis, ptosis, epicanthus inversus, downslanting palpebral 
fissures, generalized hypotonia and developmental delay. The phenotype was ascribed 
to the duplication of chromosome 10q (Bartholdi et al. 2008). Our patient 7 showed 
a similar phenotype, therefore we hypothesize that the duplication of chromosome 
10q might contribute to the BPES-like phenotype in this patient. For patient 7 it 
could not be confirmed whether this complex rearrangement arose from a balanced 
translocation in one of the parents. 
Figure 5.1.2 Case 4 (a) Deletion of chromosome 10p12.33-p12.31 (4.5 Mb) detected with Affymetrix 
GeneChip Human Mapping 262K NspI .(b) FISH analysis confirmed the deletion. Control probe: RP11-390B4 
(red), deleted probe 10p12.31: RP11-177H22 (green). (c) Facial picture of case 4, showing blepharophimosis, 
ptosis, epicanthal folds, ectropion of the lower eyelid, S-shaped upper eyelid, synophrys.
 Patient 8 showed a terminal duplication of chromosome 3q (4 Mb) and a 
terminal deletion of chromosome 13q (5 Mb). FISH analysis revealed the presence 
of an unbalanced translocation in the patient and showed no abnormalities in the 
parents. This patient showed a BPES-like phenotype and some additional dysmorphic 
features. In the ECARUCA database 28 cases were listed with a del(13)(q33.3q34). In 
4/28 blepharophimosis was described as a clinical feature, in 3/28 ptosis, and in 2/28 
telecanthus. No association between BPES-like features and 3q29 could be found in 
literature. 
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 In patient 9 a terminal deletion of chromosome 3p (8.6 Mb) and a terminal 
duplication of chromosome 6p were observed (7.7 Mb) (Fig. 5.1.3a). Her facial 
appearance is characterized by blepharophimosis, ptosis, flattened and broad nose, 
long philtrum (IV-2) (Fig. 5.1.3d). In addition she displays psychomotor retardation. 
Patients with a terminal deletion of the short arm of chromosome 3 have been 
described to display blepharophimosis, epicanthus, upturned nose, long philtrum, 
microcephaly and polydactyly (Malmgren et al. 2007). Both the terminal deletion of 
3p and terminal duplication 6p are associated with BPES-like features according to 
literature (Schinzel 2001). With standard G-banding the deletion and duplication were 
not visible. FISH with DNA probes specific for the subtelomeric region of chromosome 
3p and 6p revealed that this rearrangement arose by an unbalanced translocation 
between chromosome 3p and 6p (Fig. 5.1.3b). Furthermore, another patient of 
this family with similar clinical features was found to have the same unbalanced 
rearrangement using SNP array analysis (III-5) (Fig. 5.1.3d). Subsequently, segregation 
analysis of the 3;6 translocation was performed in other members by FISH analysis 
(Fig. 5.1.3c), and revealed a familial 3;6 translocation. An unbalanced translocation, 
resulting in a terminal duplication of chromosome 3p and a terminal deletion of 
chromosome 6p, was observed in one family member (V-2). This patient showed 
no blepharophimosis, but displayed macrocephaly, Dandy-Walker malformation, 
hypoplasia of the cerebellum, hypertelorism, divergent strabismus, broad and flat nasal 
bridge and low set ears (Fig. 5.1.3d). 
 Previously performed conventional karyotyping revealed no chromosome 
abnormalities in patients 7, 8 and 9. These findings demonstrate that even large 
chromosomal imbalances are not always easily detected with standard G-banding, 




Assuming that the identified CNVs are causative for BPES-like phenotypes, it can be 
postulated that the corresponding chromosomal regions might reveal some relevant 
candidate genes contributing to some specific features. Most of these rearrangements, 
however, are too large to allow pinpointing of major candidate genes. Despite this, 
we used the software tool Anni in order to find functional associations between large 
numbers of genes contained in the identified CNVs and biomedical information from 
literature (Jelier et al. 2007). However, for all these regions no significant candidate 
genes were found. The availability of more BPES-like patients and more subtle 
rearrangements may be useful in the search for candidate genes involved in BPES-like 
phenotypes.
General conclusion
BPES-like features are associated with many syndromes and chromosomal disorders. 
In this study novel rearrangements were identified in 33% of patients with BPES-like 
phenotypes. These changes are presumed to contribute to the phenotype in most 
cases. Overall, we demonstrated that whole-genome high-density array screening is a 
powerful strategy to reveal the underlying genetic defect in BPES-like phenotypes. We 
conclude that patients with all 4 main features of typical BPES should be tested first 
for genetic defects in FOXL2. However, patients with a BPES-like phenotype that can be 
distinguished from typical BPES, should be tested with a genome wide array prior to 
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Figure 5.1.3 Case 9 (a) Terminal deletion of chromosome 3p25.3 (8.6 Mb) and terminal duplication of 
6p24.3 (7.7 Mb) detected with the Illumina’s Sentrix HumanHap300 Genotyping Beadchip. The derivative 
chromosome 3 was not observed by conventional G-banding. (b) FISH analysis revealed the presence of an 
unbalanced 3;6 translocation. Left panel, control probe: CEP3 (red) (Vysis), 6pter probe: GS-196I5 (green); 
right panel, control probe: CEP3 (red) (Vysis), 3pter probe; GS-186B18 (green). (c) Pedigree of the family 
with the segregating t(3;6) analyzed with FISH experiments.  : balanced t(3;6);  : 3p25.3 deletion 
and 6p24.3 duplication;      : 3p25.3 duplication and 6p24.3 deletion. (d) Facial picture of case 9 (IV-2), 
characterized by blepharophimosis, ptosis, flattened and broad nose. Facial pictures of two relatives (III-5, 
IV-13) with the same unbalanced translocation as case 9 are presented. These members show similar 
clinical features. In addition, a facial picture of a relative (V-2) with the opposite unbalanced translocation 
is shown. No BPES-like features are seen in this child.
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Abstract 
Background Sotos syndrome is characterized by overgrowth, facial dysmorphism and 
learning impairment. Haploinsufficiency of NSD1 accounts for approximately 60%-90% 
of the patients. Consequently, a considerable number of patients with features of Sotos 
syndrome remain without a molecular diagnosis. To date, target-gene approaches in 
these patients have not been successful. 
Methods Twenty-six Sotos syndrome-like patients were analyzed with a high resolution 
whole genome SNP array and segregation was studied in the parents. 
Results Four possible pathogenic copy-number variants including deletions of 
10p12.32-p12.31, 14q13.1, Xq21.1-q21.31 and a duplication of 15q11.2-q13.1 were 
detected. They varied in size from 155 kb to 13.36 Mb. The 10p12.32-p12.31 deletion 
revealed a candidate gene (PLXDC2) for overgrowth. The 14q13.1 deletion affected only 
the NPAS3 gene and the patient carrying this deletion displayed mental retardation 
as the main feature. The Xq21.1-q21.31 deletion and the 15q11.2-q13.1 duplication 
encompassed multiple genes of which several could be associated with phenotypic 
expression.  
Conclusion The high resolution genome-wide SNP array approach resulted in a 
detection percentage of 15% of novel abnormalities and is therefore a powerful 
method to attain a molecular diagnosis in Sotos syndrome-like patients. Identified 
candidate genes provide directions for future screening of larger patient cohorts. 
 
Introduction 
Sotos syndrome (SoS; MIM #117550]) is an autosomal dominant overgrowth disorder 
characterized by three cardinal features: height and/or head circumference > 
+2.0 SDS, facial dysmorphism and learning disability [1].  The typical craniofacial 
features include macrodolichocephaly, a broad forehead with a receding hairline, 
a prominent chin and downslanting of the palpebral fissures [2]. SoS is caused by 
haploinsufficiency of the NSD1 gene at 5q35.2-35.3. The detection percentage varies 
but overall NSD1 abnormalities are detected in ~60% - 90% of the cases [3]. Therefore, 
there are a considerable number of patients suspected of SoS but without a molecular 
explanation. The phenotypic spectrum of these patients is usually broad, varying from 
a classical SoS phenotype to patients exhibiting only a few Sotos features. The latter 
group is sometimes referred to as “Sotos-like” [4;5]. 
 In order to identify genetic alterations in SoS patients without NSD1 
abnormalities, several gene-targeted approaches have been performed [6-8].  In 78 
overgrowth syndrome patients in whom NSD1 abnormalities were excluded, the 
NSD-gene-family members NSD2 and NSD3 were screened but no aberrations were 
detected [6]. Furthermore, screening of the NSD1 interacting protein 1 gene (NIZP1) 
did not reveal any sequence abnormalities in 97 patients referred for NSD1 analysis 
(Visser et al, unpublished data) and no NIZP1 deletions were detected in 12 typical 
non-NSD1 SoS patients [7]. In 38 patients with SoS features, a duplication of IGF1R 
was found in a single patient [8]. Recently, RNF135 (MIM #611358) abnormalities were 
identified as the cause of a new overgrowth syndrome in combination with learning 
disability [9]. However, analysis of RNF135 in 160 patients referred for NSD1 screening, 
did not reveal any alterations [10]. These results render the gene-targeted approach 
rather unsuccessful in detecting a molecular diagnosis in these patients. Therefore, in 
this study we have chosen a high resolution genome-wide approach using a Single 
Nucleotide Polymorphism array (SNP array) with the objective to detect pathogenic 
copy-number variants (CNVs) in 26 patients with certain features of SoS. 
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Subjects and methods  
Patients
The present study includes 26 patients described previously by de Boer et al. [11] in 
whom NSD1 mutations or microdeletions were excluded. From family B of the original 
study only the proband (nr. 41) was included. From 3 patients (nr. 21, 29 and 52), DNA 
was no longer available. In patient 17 a duplication of IGF1R had been previously found 
and this patient was therefore excluded from the present analysis [8]. According to the 
clinical scoring system previously used [11], this study included 3 “typical” SoS patients, 
15 from the “dubious” SoS group, and 8 from the “atypical” SoS group. Phenotypic 
details and results of the clinical scoring system are shown in Table 5.2.1. Approval was 
obtained from the Medical Ethical Committee of the Leiden University Medical Center 
and consent was given by the patients and/or their parents or legal guardians. Standard 
deviation scores (SDS) for growth are expressed in reference to the Dutch population 
[12] using the Growth Analyser version 3.5 software (http://www.growthanalyser.
org/). Weight SDS refers to the SDS for weight corrected for height. Target height was 
calculated with a correction for the secular trend as described previously [13]. Growth 
parameters at birth were corrected for gestational age using Swedish references [14]. 
SNP arrays
Genome-wide high density SNP array screening was performed with HumanCNV370-
Duo Genotyping BeadChips (Illumina Inc., Eindhoven, The Netherlands). These chips 
contain ~318.000 SNP probes and ~52.000 non-polymorphic probes per chip, which 
results in a median spacing of 1 probe per 5 kb. Procedures were performed according 
to manufacturer’s protocol (http://www.illumina.com). Fluorescence intensities were 
read with the BeadArray Reader (Illumina) and data-files were analyzed with the 
Beadstudio Data Analysis Software Version 3.2. 
CNV validation
Copy-number polymorphisms were excluded with the Database of Genomic Variants 
(DGV; http://projects.tcag.ca/variation/). Detected CNVs were mapped to the human 
genome assembly (NCBI build 36.1) using the UCSC-genome browser (http://genome.
ucsc.edu/). They were confirmed using a SNP-array from a different manufacturer, i.e. 
the GeneChip Human Mapping 500k array Set (Affymetrix Inc., Santa Clara, CA). These 
chips contain another set of SNP probes, either using the restriction enzyme NspI 
(~262.000 SNPs) or StyI (~238.000 SNPs), and are prepared and analyzed following 
different practical procedures and analysis methods. If available, parental DNA was 
analyzed as well using the Affymetrix-platform. Practical procedures were conducted 
following manufacturer’s guidelines (http://www.affymetrix.com). SNP copy-number 
was assessed using CNAG v2 software [15]. 
X-inactivation study




Genome-wide SNP array was performed in 26 patients with SoS features. In total we 
identified five deletions (patients 6, 39, 45, 54, 58) and one duplication (patient 49) 
which were not found in the DGV. The CNV plots are shown in Figure 5.2.1 and are 
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summarized in Table 5.2.2. Table 5.2.3 lists the genes involved per CNV. Based on the 
size, the de novo character and/or the genes involved, the chromosomal alterations 
identified in patients 39, 45, 49 and 58 were categorized as possible pathogenic. 
 The deletion in patient 6 was inherited from a phenotypically normal mother 
suggesting absence of a causal correlation between the deletion and the phenotype 
in the child. Furthermore, in patient 54 the father (possibly affected) and two of his 
siblings (normal phenotype) were carrier of the deletion detected. Therefore, the 
chromosomal imbalances detected in patients 6 and 54 were considered to be likely 
non-pathogenic and these two patients will not be described here. 
 In patient 39 a 13.36 Mb deletion was found encompassing Xq21.1-q21.31. The 
deletion involved 25 Refseq genes and occurred in the paternally derived chromosome. 
X-inactivation study showed bi-allelic activity, with the paternal chromosome being 
more active (71% versus 29%). Although chromosome analysis at the age of three had 
been described as a normal 46,XX karyotype, with the current techniques the deletion 
was visible in the repeated karyogram (data not shown). 
 In patient 45 a 550 kb deletion was detected at 10p12.32-p12.31 deleting the 
last 12 exons, out of a total of 14 exons, of the Plexin Domain Containing 2 (PLXDC2) 
gene. PLXDC2 encodes a transmembrane protein and is expressed in mouse brain, 
limbs, spinal cord, dorsal root ganglia, lung buds and heart [17]. Unfortunately parental 
DNA was not available to test inheritance. In the DGV, variants were reported in four 
individuals, including loss of exon 1 (variant 9140), loss of exon 2 (variant 2855), loss of 
exon 2 and 3 (variant 9141) and gain of exon 2 (variant 2855) [18;19].
 A 6.53 Mb-sized duplication was found in patient 49 encompassing 15q11.2-
q13.1 and harboring 20 Refseq genes. The proximal and distal breakpoints were 
mapped within two known low copy repeats (LCRs) [20]. Non-allelic homologous 
recombination between LCRs at 15q11-q13 cause interstitial deletions which account 
for approximately 70% of the patients with Prader-Willi syndrome or Angelman 
syndrome [21]. Reciprocal duplications of 15q11-q13 occur less frequent and 
breakpoints are clustered in the same LCRs as Prader-Willi and Angelman syndromes: 
BP1 or BP2 for proximal and BP3 for distal breakpoints [22]. The same breakpoints, BP1 
and BP3 respectively, were found in our patient
 In patient 58 a 155 kb deletion of 14q13.1 was identified comprising the first 
exon of the Neural Pas Domain Protein 3 (NPAS3) gene, which was also detected in his 
mother.  Two of his brothers were tested and both were confirmed to be non-carriers. 
To exclude compound heterozygosity, sequence analysis of NPAS3 was performed in 
our patient but no pathogenic changes were detected (data not shown). NPAS3 has 
two transcript isoforms (NM_022123 and NM_173159) which both include exon 1 and 
encodes for a neuronal transcription factor [23].
Discussion
Studies examining NSD1 abnormalities in SoS patients have refined the clinical 
diagnostic criteria which has resulted in high detection rates for NSD1 abnormalities 
in classical SoS patients. The diagnostic challenge nowadays lays therefore in the 
heterogeneous group of patients with a few phenotypic features of SoS, but without 
NSD1 abnormalities. With a genome-wide approach four possible pathogenic CNVs 
were detected in patients previously diagnosed as “dubious” SoS (patients 39, 45, 
49) and “atypical” SoS (patient 58) [11]. Phenotypic details and possible phenotypic 
expression of the genes involved are discussed per patient below.  
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Patient 39 
This female patient was born as the first child of healthy, non-consanguineous white 
Dutch parents at 35+2 weeks of gestation after premature rupture of membranes and 
gestational diabetes. At birth, weight was 3240 grams (+1.9 SDS) and length 50 cm 
(+1.5 SDS). Parental heights were 192.2 cm (+1.2 SDS) and 168.3 cm (-0.4 SDS) for the 
father and mother, respectively, which results in a target height of 178.2 cm (+1.2 SDS). 
Her motor milestones were within the normal range. Audiologic examination at 2.2 
years of age was normal. At the age of 2.9 years, her height was 107 cm (+3.2 SDS) and 
occipital frontal circumference (OFC) was 54.4 cm (+3.4 SDS). She showed dysmorphic 
features including dolichocephaly, frontal bossing, parietal balding, a high, narrow 
palate (Figure 5.2.2A-C) and there was an advanced osseous maturation of 6 months. 
Two IQ-tests at around three years of age showed an IQ of 57 and 74. Concerning her 
family history, her father’s growth pattern and head circumference were reportedly 
similar, although his OFC measured 60 cm (+1.4 SDS). Two younger siblings of the 
proband showed normal development. Our patient was last seen at the age of 9.4 
years, with a height of 152.4 cm (+2.0 SDS), weight 49.5 kg (+1.2 SDS) and OFC 57.5 
cm (+3.0 SDS). She receives special education. During a recent routine check-up for 
amblyopia, abnormalities of the retina were detected and retinitis pigmentosa was 
suspected. 
 
Figure 5.2.1 Copy-number analysis plots of the CNVs detected. The log R ratio’s (Y-axis) of the SNP probes 
for the detected CNVs and their normal flanking regions are shown. A log R ratio of >0.3 or <-0.3 indicates 
a duplication or deletion respectively. Corresponding chromosomes, chromosomal bands and positions 
(in base pairs) are depicted below each CNV and are according the NCBI Build 36.1 genome assembly in 
the UCSC genome browser.
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An Xq21.1-q21.31 deletion with a size of 13.36 Mb was detected encompassing 25 
genes. In literature several genes in this region have been associated with phenotypic 
expression. Firstly, deletions of Xq21 in male patients were reported to cause a 
contiguous gene syndrome including choroideremia (CHM gene), mental retardation 
(possibly RPS6KA6) and X-linked deafness type 3 (POU3F4 gene) [24]. In our patient 
audiologic testing at the age of two was normal and presently she had no apparent 
hearing loss. However, recently retinal abnormalities were found which might be the 
first signs of choroideremia. The variable phenotypic expression of deleted genes in 
our patient could be explained by the incomplete skewed X-inactivation. 
 Secondly, BRWD3 is another gene possibly related to our patient’s phenotype, 
because loss of function mutations were identified in four male patients with X-linked 
mental retardation, macrocephaly and dysmorphic features [25]. Interestingly, one of 
them showed also tall stature (> +1.9 SDS) and his affected uncle was tall with a final 
height of +1.3 SDS. Thirdly, a gene which might also be associated with tall stature, 
is ITM2A. This gene encodes a transmembrane protein which has been shown to be 
involved in chondrogenesis and a significant association with height was recently 
found in a genome-wide association study [26;27].  
 Thus, although the implication of multiple genes complicates linking individual 
genes to the phenotypic features in our patient, the deleted region contains likely 
candidate genes explaining the retinal alterations, overgrowth and mental retardation. 
Figure 5.2.2 Facial features of the patients carrying a possible pathogenic CNV. Written permission for 
publication of the photographs was obtained. For patient 45 photographs were not available. (a-c) Patient 
39 at the age of 2.9, 4 and 9.4 years respectively. (d) Patient 49 at the age of 51 years. (e) Patient 58 at the 
age of 15.8 years. (f ) Hands and fingers of patient 58. 
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Patient 45 
This male patient was born as the first child of healthy, non-consanguineous white 
Dutch parents at a gestational age of 35+3 weeks with a birth weight of 3500 grams 
(+2.2 SDS).  Mother was hospitalized for preecclampsia, but the delivery was uneventful. 
Parental heights were 185.0 cm (+0.2 SDS) and 179.7 cm (+1.4 SDS) for the father and 
mother, respectively which results in a target height of 193.4 cm (+1.3 SDS).  Although 
his motor development milestones were normal, his gross and fine motor skills were 
assessed as delayed during childhood. He spoke his first words at the age of 30 months 
and talked complete sentences at the age of 60 months. For this language and speech 
development delay he attended special education, after which he proceeded to a 
mainstream elementary school. During childhood he had an increased statural growth 
near the +2.5 SDS curve. Bone age at the age of 2.5 was conform calendar age. At the 
age of 6.2 years his height was 133.1 cm (+2.4 SDS), weight 29.9 kg (+0.6 SDS), OFC 55 
cm (+1.9 SDS) and arm span 131.5 cm (+2.0 SDS). His facial features included frontal 
bossing, a receding hairline and a high arched palate. A simian crease was found in his 
right hand. His IQ was tested to be 84. Chromosome analysis showed a normal male 
46,XY karyotype.
 A small deletion was found, affecting the last 12 exons out of 14 exons of 
PLXDC2. A patient (patient KK) with a 4.3 Mb-interstitial deletion of 10p12.1-p12.31 was 
described, including amongst others PLXDC2 in the deleted region [28]. This patient 
showed also overgrowth with height, weight and OCF > +1.6 SDS, mild dysmorphic 
features and a delay in language development [28]. Patients with larger interstitial 
deletions or 10pter deletions have been reported but they showed postnatal growth 
retardation [29]. In addition to the much larger size of the deletion, involvement of 
PLXDC2 in these deletions could not always be confirmed (Figure 5.2.3). 
Figure 5.2.3 Schematic representation of reported patients with deletions of the short arm of chromosome 
10. On top, the chromosomal bands of 10p are shown in scale with the physical distance in Mb according 
the NCBI Build 36.1 genome assembly in the UCSC genome browser (below). The deletions of patient 45, KK, 
GM3470 and MAR comprise PLXDC2 (horizontal black line), while the deletions of patients MEG, TAT, KAN 
and ROB might include PLXDC2. For each patient, horizontal black bars depict non-deleted chromosomal 
regions. White bars represent the undetermined breakpoint regions and the blank spaces in between the 
deleted region. Mapping data for patient KK was obtained from [26] and for patients GM3470, MAR, MEG, 
TAT, KAN and ROB from [27] and references therein.
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 Due to the missing parental DNA for inheritance studies and the detection 
of variants within PLXDC2 in four control individuals [18;19], the contribution of 
haploinsufficiency of PLXDC2 to a clinical phenotype remains equivocal. However, 
all the more since growth and height data of the four control individuals is lacking, 
phenotypic expression should be considered as well. The findings in our patient 
suggest then that PLXDC2 is a candidate gene to be involved in growth regulation and/
or intellectual development.   
Patient 49
This male patient of Indonesian descent was first seen at the age of 45.2 years. His 
height was 1.78 cm (-0.8 SDS), weight 78.5 kg (+0.3 SDS) and OFC 60 cm (+1.4 SDS). 
The patient presented with a long face, a prominent jaw, a high arched palate and 
strabismus divergens (Figure 5.2.2D). He had a thoracic kyphosis and scoliosis. He 
was institutionalized for his moderate to severe mental retardation. In his forties he 
developed periods of depression followed by severe behavioural problems such as 
screaming, restlessness and aggression. His medical history showed hypertension 
and Parkinsonism and his family history was normal. Chromosome analysis revealed a 
normal 46,XY karyotype. The patient died at the age of 52, due to complications after 
surgery for a femoral fracture. 
 A duplication of 15q11-q13 was identified, which is a region containing 
imprinted and non-imprinted genes. The clinical phenotype of the 15q11-q13 
duplication is variable even within families and is associated with varying levels of 
mental retardation and problems in motor coordination [30]. On physical examination, 
hypotonia, decreased deep tendon reflexes and joint laxity are frequently found. 
Distinct dysmorphic features are not present, although an antimongoloid-slant of the 
eyes and thick or pouting lips have been described [30]. An association with autism 
spectrum disorders has been postulated, but this is not a common feature [30;31]. 
Paternal inherited duplications have been reported to associate with a normal or less 
severe phenotype [30;32], but affected patients have been reported as well [22;33;34]. 
Considering the phenotypic features associated with 15q11-q13 duplications, it is likely 
that the chromosomal imbalance in our patient is the cause of his mental retardation 
and behavioural problems.       
Patient 58
This male patient was born as the 7th child of healthy non-consanguineous white 
Dutch parents at 42 weeks of gestational age after an uneventful pregnancy. At birth, 
weight was 3550 grams (-0.5 SDS) and length 54 cm (+1.2 SDS). His target height was 
186 cm (+0.3 SDS). Although he was hypotonic for which he received physiotherapy 
from 7 till 14 months of age, his motor development milestones were within normal 
range. He followed two years of mainstream elementary school, but continued with 
special education. His IQ was tested to be 76 at the age of 7.3 years. He was last seen at 
the age of 15.8 with a height of 180.3 cm (+0.3 SDS), weight 84 kg (+1.9 SDS) and OFC 
57.4 cm (+0.6 SDS). He did not show any major dysmorphic features, although he had 
short fingers and a simian crease in his left hand. His father died at the age of 40 years, 
due to a ruptured abdominal aneurysm. Both his father and mother attended normal 
elementary schools and followed lower secondary education. He had nine siblings who 
were healthy, but learning problems were prevalent. There was no history of psychiatric 
problems. 
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 A small deletion of the first exon of NPAS3 was identified and his mother was 
confirmed to be a carrier. Previously, a mother and daughter have been described 
who carried a balanced reciprocal translocation t(9;14)(q34;q13) disrupting NPAS3 on 
chromosome 14 without disrupting genes on chromosome 9 [35]. The mother showed 
mild learning disability and was diagnosed with schizophrenia [36]. The daughter 
had severe learning impairment and suffered from schizophreniform psychosis 
[35]. Additionally, a recent study revealed four NPAS3 related haplotypes which were 
associated with bipolar disorder and schizophrenia [37]. The association of NPAS3 with 
these psychiatric disorders remains subject for discussion since our patient and mother 
did not show signs of psychiatric illness. Yet,  there is still a possibility that our patient 
will develop schizophrenia since the onset of schizophrenia in males is usually in their 
late teens and early twenties [38]. Another possibility is that due to the translocation, 
the disruption of NPAS3 resulted in a dominant negative effect and therefore caused 
a more severely affected phenotype [36]. More pronounced behavioural abnormalities 
were also seen in homozygous knock-out mice, while only a non-significant trend was 
observed in the heterozygous mutants [39]. Compound heterozygosity in our patient 
was excluded. 
 The findings in our patient support the postulated association of NPAS3 
with intellectual development, although admittedly the intelligence of the mother 
of our patient was borderline normal. In contrast, they are not in support of a 
causative relation of NPAS3 with psychiatric disorders and more patients with NPAS3 
abnormalities are necessary to elucidate this association. 
Conclusion
A genome-wide SNP array analysis detected four possible pathogenic CNVs in 26 
(15%) patients with features of SoS. This approach is therefore a powerful method to 
provide a molecular explanation in patients with features of SoS but without NSD1 
alterations, although still molecular validation is required to establish a definite causal 
relationship. A candidate gene for overgrowth (PLXDC2) was identified and a deletion 
of NPAS3 in two carriers without psychiatric illness warrants caution of linking this gene 
to schizophrenia. Screening of these genes in larger patient populations is necessary in 
order to further delineate the associated phenotype. 
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Conventional karyotyping by G-banding has been in use since the 1970s as the 
standard technique in many laboratories to detect chromosomal aberrations. With this 
technique it is possible to identify chromosomal rearrangements of at least 5-10 Mb. 
Other techniques have been developed to detect smaller aberrations. These methods, 
such as Fluorescence in situ Hybridization (FISH), Multiplex Ligation-dependent Probe 
Amplification (MLPA) and Quantitative Fluorescence-Polymerase Chain Reaction (QF-
PCR), are useful only for identifying microdeletions and subtelomeric regions or for 
confirming and further characterizing previously identified chromosomal aberrations. 
In recent years a technique to screen the whole human genome in a single experiment, 
the array Comparative Genome Hybridization (aCGH), has been developed. It enables 
the detection of copy number variants (CNVs) (deletions and duplications) that are 
approximately 100 times smaller than those that can be identified by conventional 
karyotyping. The first genome-wide CGH arrays were based on large DNA fragments 
such as bacterial artificial chromosomes (BACs) (Solinas-Toldo et al., 1997; Pinkel 
et al., 1998). The resolution of these arrays depends on the size of the probes. Other 
CGH arrays were developed with small oligonucleotide probes (45-85 - mer) (Agilent 
and Nimblegen) that allowed the detection of smaller CNVs. More recently, the Single 
Nucleotide Polymorphism (SNP) array, which was originally developed for genome 
wide association studies, turned out to be ideal also for the detection of CNVs. These 
oligonucleotide SNP arrays (25-50 - mer) (Affymetrix and Illumina) are based on probes 
containing a SNP. With this oligonucleotide array technique (both aCGH and SNP) the 
resolution has increased to approximately 10 - 100 kb and depends on the genomic 
spacing between the probes.
 Mental retardation (MR) occurs in 2-3% of the population and in approximately 
5% of these patients a chromosomal aberration can be detected by conventional 
karyotyping (de Vries et al., 2005). In contrast, the overall yield of CNVs detected by 
high-resolution array (aCGH and SNP) in MR patients is approximately 17% (Vissers et 
al., 2003; Shaw-Smith et al., 2004; Schoumans et al., 2005; Tyson et al., 2005; Friedman et 
al., 2006; Menten et al., 2006; Rosenberg et al., 2006; Fan et al., 2007; Hoyer et al., 2007). 
We studied 318 MR patients using high-resolution SNP arrays in order to establish the 
frequency of submicroscopic CNVs in patients with idiopathic MR (chapter 2). In this 
cohort we identified different chromosomal aberrations in 22.6% of the MR patients. 
It should be noted, however, that most of the above mentioned reports, including 
our study, represent highly selected patient cohorts. In all these patients conventional 
karyotyping had been performed already and in a smaller group of patients also 
locus-specific FISH and subtelomeric MLPA had been done, however no aberration 
was detected. Testing every MR patient with a SNP array instead of conventional 
karyotyping would further increase the diagnostic power of this method and we have, 
therefore, recommended it as a new diagnostic tool to be included in the workflow 
for MR patients (chapter 2). At present, high-resolution array is being successfully 
implemented in routine clinical diagnostic laboratories. It allows the screening for 
all known microdeletion and microduplication syndromes as well as novel CNVs in a 
single experiment. As a consequence, fewer diagnostic tests are needed to facilitate a 
rapid diagnosis in many patients.
 A major advantage of the SNP array is that it provides information on the 
genotype and enables the detection of regions of loss of heterozygosity (LOH) (chapter 
2). LOH can be the result of a deletion or of uniparental disomy (UPD), which is known 
to cause genomic disorders such as Prader-Willi syndrome and Silver-Russel syndrome. 
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With a SNP array it is possible to distinguish between heterodisomy and isodisomy if 
both parents are hybridized on an array. Furthermore the genotype information can 
be used to identify homozygous regions in offspring from consanguineous parents, to 
resolve questions concerning mix-up of samples and paternity, and to determine the 
parental origin of a deletion. An additional advantage of the genotype information is 
that it serves as an extra control step to confirm a deletion or a duplication. In case of a 
deletion all SNPs appear homozygous because of loss of one allele; duplications show 
four possible genotypes, including AAA, AAB, ABB and BBB. 
 Although it was originally suspected that array analysis would not be able to 
detect mosaicism, it appears that the aCGH and SNP array techniques are actually more 
sensitive in detecting low-level mosaicism than conventional karyotyping (chapter 
2 and 3.4). Usually, an insufficient number of cells is counted unless mosaicism is 
suspected. Also, a single abnormal cell might be interpreted as an artifact of cell 
culture. So, one can easily fail to detect an aberrant subset of cells with conventional 
karyotyping. Furthermore, as shown in chapter 2, 4.2 and 5.1, the array technique is 
more sensitive in detecting unbalanced translocations. Relatively large aberrations (3 
– 21 Mb) are missed by conventional karyotyping because telomeric bands of many 
chromosomes are similar in appearance. 
 In chapter 3.2 and 4.1 we have shown that the SNP array is useful 
in characterizing previously detected microscopically visible chromosomal 
rearrangements. In chapter 3.2 we have described apparently balanced translocations 
and inversions where the SNP array detected additional CNVs. These CNVs were either 
at the breakpoints of the rearrangement or were on chromosomes unrelated to the 
previously detected aberration. In chapter 4.1 we have presented a patient where 
conventional karyotyping detected extra material of unknown origin on the long arm 
of chromosome 9. SNP array analysis detected a duplication of 400 kb, a triplication 
of 2.4 Mb and a duplication of 130 kb of chromosome band 9q34.3. In this case, the 
SNP array proved to be an accurate method for the identification and delineation of 
the chromosomal rearrangement. As there is no technique available at present that 
can detect complex chromosome rearrangements as well as cryptic CNVs in one 
experiment, conventional karyotyping, FISH and high-resolution array screening 
remain essential for unravelling complex karyotypes. 
 The disadvantage of using arrays instead of conventional karyotyping is that 
arrays cannot detect balanced rearrangements. A large prenatal study has shown that 
approximately 0.5% and 0.1% of the antenatal cases carry an apparently balanced 
reciprocal translocation or an inversion respectively (Warburton, 1991). Only 6% of 
these cases are associated with abnormal phenotypes. The abnormal phenotype can 
be caused by the disruption of a gene at the breakpoint or by a small duplication or a 
deletion that is beyond the resolution of the microscope. The SNP array analysis would 
(depending on the resolution) detect the small abnormalities, though the disruption 
of genes would remain undetected. A Dutch retrospective study has shown that of 
all referrals only about 0.78% potentially pathogenic balanced rearrangements would 
remain undetected by array analysis without conventional karyotyping (Hochstenbach 
et al., 2009). Conventional karyotyping, on the other hand, will miss a much higher 
percentage of unbalanced rearrangements if no array analysis is performed. 
 An ideal technique would combine whole-genome high-resolution screening 
for CNVs and the detection of inversions, insertions and translocations. This is possible 
with paired-end mapping, a new sequencing method, whereby aberrations from 
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approximately 3 kb can be identified (Korbel et al., 2007). It involves fragmentation 
of genomic DNA to 3 kb fragments; these fragments are circularized and randomly 
sheared. These products are sequenced and mapped back to the reference sequence. 
Paired-end mapping has already been used successfully in breakpoint mapping of 
balanced chromosome rearrangements (Chen et al., 2009). However, experience with 
this technique in whole-genome screening is limited. More importantly, the costs are 
high and the process is very laborious. A rapid and routine implementation of this 
technique is therefore not to be expected soon.
 Finally, another example of the power of high-resolution arrays is given in 
chapter 5. Two studies in which the SNP arrays were used to detect CNVs in patients 
with phenotypes other than MR are presented. In chapter 5.1 we have reported the 
detection of CNVs in 33% of patients with a BPES-like phenotype. In chapter 5.2 we 
have used high-resolution SNP arrays to detect CNVs in patients with features of the 
SOTOS syndrome. We found chromosomal aberrations in 15% of these SOTOS-like 
patients. 
 The major recurring theme in this thesis is that the clinical consequence of 
novel CNVs is not always immediately evident in many cases (chapter 2, 3.1, 3.2, 3.3, 
5.1 and 5.2). High-resolution array studies have revealed many new microdeletion and 
microduplication syndromes (reviewed by Slavotinek, 2008). There are other recurrent 
deletions and duplications for which the clinical significance is not immediately clear. A 
good example of the difficulty in assigning clinical significance is discussed in chapter 
3.1. A ~600 kb 16p11.2 deletion was initially detected in patients with autism, but later 
it was seen also in patients with MR, in healthy individuals, and finally in obese patients 
(Walters et al., 2010). This suggests that the recurrent 16p11.2 deletion is associated 
with a variable outcome and it is even uncertain whether it is pathogenic. There are 
other well known microdeletion syndromes with a wide phenotypic spectrum (e.g. 
22q11.2) (Edelmann et al., 1999). Since geneticists often assume that only de novo 
CNVs are pathogenic, one of the first steps in a routine diagnostic workflow is to check 
the parents for transmission of a CNV. Besides, it has been shown already that patients 
with known syndromes can inherit this deletion from one of their healthy parents 
(Edelmann et al., 1999). The cause for this phenotypic variability is unknown. Several 
hypotheses have been proposed to explain the variable effect of deletions: stochastic 
variation of gene expression at a lower level (Cook et al., 1998), presence of modifying 
genes on the other undeleted homologue as was demonstrated recently at the locus 
for adult polycystic kidney disease, PKD1 (Rossetti et al., 2009), influence of unlinked 
genes or epigenetic factors that may play a role. Recently, Girirajan and colleagues 
suggested a two-hit model for a recurrent 16p12.1 microdeletion (Girirajan et al., 2010). 
They found that 30% of the affected individuals with a 16p12.1 microdeletion carried 
a second CNV. These results show for the first time two independent chromosomal 
changes in a mentally retarded patient, confirming the multifactorial model proposed 
decades ago. With the increasing resolution of genome analysis similar examples are 
likely to follow soon. The big challenge, however, is to prove the pathogenicity of 
each CNV or genomic variant, which is becoming more difficult with the increasing 
complexity. To gain better insight in the pathogenicity of these CNVs large numbers of 
patients and their families need to be analyzed in great detail. 
 Even before the introduction of G-banding it was clear that two chromosomes 
of a pair were not always alike. As most variants were found in individuals with a 
clinical abnormality, it was not until large newborn studies that it became evident that 
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these variants were benign (reviewed by Wyandt, 2004). With the introduction of the 
whole-genome high-resolution screening technique, a similar problem has appeared; 
this technique is able to detect smaller abnormalities and thereby also new variants 
of unknown clinical relevance (chapters 2 and 3). It has been estimated that up to 
12% of the human genome is involved in CNVs (Redon et al., 2006). Large studies on 
healthy individuals have revealed many new benign CNVs which are collected in the 
Database of Genomic Variants (DGV) (Iafrate et al., 2004; Sebat et al., 2004; Sharp et 
al., 2005; Tuzun et al., 2005; Feuk et al., 2006; Friedman et al., 2006; Hinds et al., 2006; 
Locke et al., 2006; McCarroll et al., 2006; Redon et al., 2006; Conrad and Hurles, 2007). 
This database is a valuable tool for geneticists for comparing CNVs that they find in 
their patients. Although this database is still growing, many rare CNVs identified in MR 
patients are not reported. As more data becomes available in the next few years, it will 
become clear whether CNVs that are at present classified as potentially pathogenic 
are pathogenic or not. Databases like DECIPHER and ECARUCA, which collect CNVs 
detected in patients can help unravel novel disease-causing CNVs much faster. 
 In March 2010 the DGV contained 14478 CNV loci and is still regularly updated. 
The data submitted to this database are not subjected to an editorial screening, the 
only requirements being that the data is published as a scientific manuscript and that 
the CNV was identified in a non-disease control sample. The contributors are therefore 
able to use different methods with a variety of detection rates, error rates, and genomic 
coverage. In some contributing studies no distinction is made between gains and 
losses; these CNVs should therefore be excluded for comparison. Caution should be 
exercised in the interpretation of the submitted CNVs. 
 Manufacturers producing high-resolution array techniques are developing new 
arrays with even higher resolution. Recently we have tested the latest available 2.7M 
(Affymetrix) array. These arrays contain 2.7 million markers, including 400.000 SNP 
probes and 2.3 million CNV probes. Not only the resolution but also the laboratory 
procedures are constantly being improved. In diagnostic laboratories, procedures with 
fewer steps and more automation are highly encouraged, since this means less hands-
on time and less possibility of sample mix-up. However, a higher resolution will, per 
definition, also detect more CNVs of unknown clinical significance. 
 Next generation sequencing technologies will eventually replace the array 
technologies in the genetic diagnostic flow of MR. Sequencing will be able to detect 
mutations as well as deletions, duplications, inversions and translocations. At present, 
sequencing of whole genomes is feasible and in a few years also affordable; however, 
analysis of the data is not yet suitable for a large scale. Bioinformaticians will be 
necessary to solve this problem. Implementation of sequencing will furthermore 
introduce the same problems on an even larger scale, as the whole-genome high-
resolution arrays do at present. Large numbers of new variants will be identified, most 
of which are probably not disease causing and many others that may be associated 
with other unexpected diseases. The challenge to distinguish between harmless 
variants and variants causing or contributing to disease will become even more 
daunting.  
 In the series of articles presented in this thesis we have studied patients with MR 
and/or congenital malformations. The question we have tried to answer by studying 
the genome of the patient is whether we can find a cause for the signs and symptoms 
observed in the patient. The SNP array was successfully used for the detection of novel 
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Conventional karyotyping has been used as the standard cytogenetic technique 
since the 1970s. With conventional karyotyping one can detect aberrations larger 
than 5 – 10 Mb. To identify smaller copy number variants (CNVs) new molecular 
cytogenetic techniques have been developed. One of these techniques is the array 
Comparative Genome Hybridization (aCGH), which is based on the hybridization of 
different fluorescent labelled patient DNA and reference DNA to immobilized DNA 
fragments. The first arrays contained relatively large DNA fragments (100-300 kb) 
and the resolution depended on the size of the probes. Other arrays were developed 
containing oligonucleotide probes of 25 to 60 bp, oligonucleotide aCGH and Single 
Nucleotide Polymorphism (SNP) arrays. The resolution of these arrays does not depend 
on the size of the probes but on the number of probes on a slide. The SNP array, which 
was initially developed for linkage and association studies, is now widely used for the 
detection of submicroscopic CNVs and regions of Loss of Heterozygosity (LOH). 
 With conventional karyotyping one can detect chromosomal aberrations in 
approximately 5% of patients with mental retardation. In chapter 2 we have described 
the use of SNP arrays for the detection of submicroscopic CNVs in patients with 
idiopathic mental retardation (MR). In total, 318 patients were screened using different 
array platforms. Aberrations, including known syndromes, potentially pathogenic 
CNVs, large regions of LOH and mosaic trisomies, were found in 22.6 % of the patients. 
This study has demonstrated that high-resolution whole-genome array techniques 
have a higher diagnostic yield as compared to conventional karyotyping. However, 
it has also shown that the finding of many potentially pathogenic CNVs makes 
diagnosis difficult and it will probably be many years before we can determine which 
CNVs are pathogenic and which are benign. We have implemented the SNP array in 
our diagnostic setting and we now use it as the first step, instead of conventional 
karyotyping, for analysing MR patients. 
 In chapter 3.1 we have further delineated a previously found recurrent 16p11.2 
deletion. Deletions of this region were initially identified in a cohort of patients with 
autism. We identified 13 patients with the same deletion in a group of 4284 MR 
patients. Some of the healthy parents were carriers of the same CNV. These findings 
suggested that the recurrent 16p11.2 deletion is associated with a variable phenotype.
 In chapter 3.2, 13 MR patients with a previously identified apparently balanced 
translocation or inversion were analyzed with the SNP array. Disruption of genes 
at breakpoints of such rearrangements, or the presence of small CNVs around the 
breakpoints or elsewhere in the genome can be the cause of the MR. We detected 
additional CNVs in eight patients; in three patients these were near the breakpoints 
of the rearrangement and in five patients the CNVs were unrelated to the balanced 
rearrangement. With this data we have demonstrated that it is necessary to use 
conventional karyotyping in combination with high-resolution array screening to 
unravel complex karyotypes.
 In chapter 3.3 we have reported five mentally retarded males with a CNV on 
the X-chromosome. We were able to classify the CNVs as pathogenic in only two of 
the patients but it  was difficult to determine pathogenicity for the other relatively 
small duplications. To be able to classify all of them we need to study more patients or 
healthy individuals with (approximately) the same CNVs.
 In chapter 3.4 three cases of mosaicism with a normal cell line and an 
unbalanced autosomal reciprocal translocation are described. Mosaicisms with such 
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cell lines are very rare. The exact mechanism responsible for these karyotypes is not 
clear. We have demonstrated that high-resolution whole-genome arrays can reveal 
more mosaicisms, unbalanced translocations or a combination of both.
 In chapter 4 we have described the use of SNP arrays in unravelling complex 
chromosome aberrations. In chapter 4.1 we determined the size and nature of the 
extra material that had been detected by conventional karyotyping on chromosome 9. 
Fine mapping by SNP array analysis identified a 400 kb duplication, 2.5 Mb triplication 
and 130 kb duplication of 9q34.3. This highlights the value of combining conventional 
karyotyping with the array technologies. In chapter 4.2 a familial translocation 
was detected by SNP array analysis and FISH. Two sibs inherited different derivative 
chromosomes and both showed different phenotypes. The index patient had MR 
and some minor dysmorphic features, while her brother was apparently healthy. This 
chapter underscores the importance of reporting chromosomal imbalances, even if 
they are found in individuals with an apparently normal phenotype.
 That the SNP array is not only useful for the detection of CNVs in MR patients is 
shown in chapter 5. Blepharophimosis- Ptosis- Epicanthus inversus syndrome (BPES) 
is a rare syndrome that includes an eyelid malformation. Mutations in the FOXL2 gene 
are responsible for the majority of BPES cases. However, in a small group of patients 
the cause remains unknown. In 9 out of 27 patients with a BPES-like phenotype we 
identified CNVs that had not been previously identified (chapter 5.1). Sotos syndrome 
includes overgrowth, facial dysmorphism and learning impairment. In 60 – 90 % of the 
Sotos patients haploinsufficiency of the NSD1 gene is responsible for the phenotype. 
In 4 out of 26 patients with a Sotos-like syndrome (without a mutation in NSD1), we 
identified a CNV that had previously not been identified (chapter 5.2). The findings of 
these two studies indicate that the whole-genome screening is a powerful technique 
to search for new candidate genes in different diseases. 
 In chapter 6, the findings of the work described in this thesis are discussed and 
future perspectives are presented. The identification of novel disease causing CNVs in 
MR patients has increased the possibilities for MR diagnosis and genetic counselling. 
Yet, the finding of a high number of potentially pathogenic CNVs introduces a major 
challenge. It is likely that the next generation sequence technologies will eventually 
replace the array technique and will pave the way towards the identification of more 




Conventionele karyotypering met behulp van de lichtmicroscoop is de 
standaardtechniek die sinds de jaren ’70 gebruikt wordt voor het detecteren van 
chromosomale afwijkingen bij patiënten met een verstandelijke beperking (mentale 
retardatie) en aangeboren afwijkingen. Een voordeel van deze techniek is dat alle 
chromosomen in een celkern in één microscopisch veld zichtbaar gemaakt kunnen 
worden en met elkaar vergeleken kunnen worden. Echter, een belangrijk nadeel van 
deze techniek is de lage resolutie. Een afwijking in een chromosoom moet namelijk wel 
rond de 5 – 10 miljoen bouwstenen (baseparen) omvatten om zichtbaar te zijn door de 
microscoop. Conventionele karyotypering kan in ongeveer 5% van de patiënten met 
mentale retardatie een chromosomale afwijking (verdubbeling (duplicatie) of verlies 
(deletie) van gehele of delen van chromosomen) detecteren. Een techniek die kleinere 
afwijkingen kan opsporen is de Fluorescente In Situ Hybridisatie (FISH), deze techniek 
wordt gebruikt voor het opsporen van een specifieke deletie en kan alleen gebruikt 
worden bij verdenking van een klinisch syndroom. Een test die alle uiteinden van de 
chromosomen kan analyseren is de Multiple Ligation-dependent Probe Amplification 
(MLPA). Beide technieken lenen zich echter niet voor analyse van het gehele genoom. 
 Om kleinere chromosomale afwijkingen, de zogenaamde varianten in 
kopieaantal, op te sporen in het hele genoom zijn er in de loop der jaren verschillende 
nieuwe technieken ontwikkeld. Eén van deze technieken is de Single Nucleotide 
Polymorphism (SNP) array. Deze techniek combineert de drie bovengenoemde 
onderzoeken in één experiment. Met de SNP array kan naar honderdduizenden 
plekken verdeeld over alle chromosomen gekeken worden. 
 De array gebaseerde techniek wordt tegenwoordig wereldwijd gebruikt voor 
het opsporen van varianten in kopieaantal bij patiënten met mentale retardatie en 
vervangt al in vele laboratoria de hierboven genoemde technieken (conventionele 
karyotypering, FISH en subtelomeren MLPA) bij deze groep patiënten. 
 In hoofdstuk 2 van dit proefschrift beschrijven we het gebruik van de 
SNP arrays voor het opsporen van varianten in kopie aantal in 318 patiënten met 
onverklaarde mentale retardatie. In 22.6 % van deze patiënten werd een verandering 
gedetecteerd, waaronder bekende syndromen, mogelijk ziekteveroorzakende 
verschillen in kopieaantal, grote gebieden met verlies van heterozygositeit en mozaïek 
trisomieën. Deze studie toont aan dat hoge-resolutie genoom-brede array technieken 
een hogere diagnostische opbrengst hebben dan de conventionele karyotypering. 
Deze bevinding is in overeenkomst met de literatuur. Echter, deze studie laat ook 
zien dat het vinden van mogelijk ziekteveroorzakende varianten in kopieaantal het 
stellen van een diagnose moeilijk kan maken en het in veel gevallen waarschijnlijk 
jaren gaat duren voordat duidelijk wordt of de variant ziekteveroorzakend is of niet. In 
ons laboratorium is de SNP array ingevoerd als diagnostische test en wordt gebruikt 
als eerste test, in plaats van conventionele karyotypering, bij patiënten met mentale 
retardatie en/of aangeboren afwijkingen. 
 De array techniek maakt het mogelijk om grote aantallen patiënten op 
genoom-brede schaal te onderzoeken, waardoor de kans op het ontdekken van 
nieuwe syndromen verhoogd is. In de literatuur verscheen een nieuwe microdeletie, 
die autisme zou veroorzaken, in de korte arm van chromosoom 16, band 16p11.2 
In hoofdstuk 3.1 beschrijven wij dat deze deletie ook voorkomt bij patiënten met 
mentale retardatie. Wij verzamelden 13 patiënten met deze deletie in een groep van 
4284 mentale retardatie patiënten. Bij zeven van de 13 patiënten is een gezonde ouder 
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drager van dezelfde deletie. Deze bevindingen laten zien dat het maken van een 
genotype-fenotype correlatie niet eenvoudig is en suggereren dat de 16p11.2 deletie 
geassocieerd is met een variabel fenotype inclusief autisme, mentale retardatie, en een 
normaal fenotype. 
 Op SNP arrays werd DNA van dertien patienten getest bij wie tijdens 
conventionele karyotypering een ogenschijnlijk gebalanceerde reciproke translocatie 
of inversie was gevonden, hoofdstuk 3.2. Verstoring van genen rond de breukpunten 
van deze afwijkingen, of de aanwezigheid van kleine varianten in kopie aantal rond het 
breukpunt of ergens anders op het genoom kunnen de oorzaak zijn van de mentale 
retardatie bij deze patiënten. We ontdekten varianten in acht patiënten; in drie waren 
deze rond de breukpunten van de translocatie of inversie en in vijf waren er deleties of 
duplicaties ergens anders in het genoom aanwezig. Hiermee toonden we aan dat de 
combinatie van conventionele karyotypering en hoge-resolutie arrays nodig blijft om 
complexe karyotypes te ontrafelen. 
 In hoofdstuk 3.3 beschrijven we zeven varianten, deleties en duplicaties, 
gevonden op het X-chromosoom van mannen met mentale retardatie. Alleen voor 
twee van deze varianten kon vastgesteld worden dat ze pathogeen waren, bij de 
andere relatief kleine varianten was dit niet mogelijk. Om de eventuele klinische 
betekenis van de mogelijk pathogene veranderingen nader te definiëren zullen meer 
patiënten of gezonde personen bestudeerd moeten worden die (ongeveer) dezelfde 
variant vertonen. 
 In hoofdstuk 3.4 worden drie families besproken waarbij één familielid drager 
is van een ongebalanceerde autosomale translocatie in mozaïeke vorm. Naast de 
cellijn met de ongebalanceerde translocatie hebben deze personen een normale 
cellijn. Bij twee van deze personen is de ongebalanceerde translocatie hoogst 
waarschijnlijk na de bevruchting ontstaan. Bij de derde persoon is de moeder draagster 
van de gebalanceerde vorm van de translocatie. Dit is erg zeldzaam en het precieze 
mechanisme voor het ontstaan van dit mozaïek is (nog) niet bekend. 
 In hoofdstuk 4 worden een aantal casussen gepresenteerd. In hoofdstuk 4.1 
hebben we de grootte en oorsprong van een eerder met conventionele karyotypering 
gevonden chromosoom 9 afwijking kunnen bepalen. De SNP array toonde aan dat 
deze afwijking bestond uit een 400 kb duplicatie, een 2.5 Mb triplicatie en een 130 
kb duplicatie op chromosoomband 9q34.3. In hoofdstuk 4.2 beschrijven we een 
familiaire translocatie die gevonden is met behulp van de SNP array en FISH onderzoek. 
Deze cryptische translocatie is niet zichtbaar met conventionele karyotypering. Broer 
en zus erfden allebei een andere ongebalanceerde vorm van de translocatie van 
moeder en hadden allebei een ander klinisch fenotype. De zus is mentaal geretardeerd 
en heeft enkele aangeboren afwijkingen, terwijl haar broer ogenschijnlijk gezond 
is. Dit hoofdstuk onderstreept het belang van het rapporteren van chromosomale 
afwijkingen, ook al worden ze gevonden in gezonde personen.
 Dat de SNP array niet alleen bruikbaar is voor het opsporen van varianten 
in kopie aantal bij patiënten met mentale retardatie laten we zien in hoofdstuk 5. 
Blepharophimosis- Ptosis- Epicanthus inversus Syndroom (BPES) is een zeldzaam 
syndroom dat wordt gekenmerkt door een ooglidvernauwing. Mutaties in het FOXL2 
gen zijn verantwoordelijk voor de meerderheid van de BPES patiënten. Echter, in 
een kleine groep van patiënten blijft de oorzaak onbekend. In 9 van de 27 door ons 
onderzochte BPES-achtige patiënten vonden we een chromosomale verandering 




 Sotos syndroom wordt gekenmerkt door overgroei, een grote schedel, 
een bijzondere vorm van het aangezicht en leerachterstand. In 60-90% van de 
Sotos patiënten is haploinsufficientie (het verlies van één werkend kopie van een 
gen) van het NSD1 gen verantwoordelijk voor het klinisch fenotype. In 4 van de 
26 door ons onderzochte Sotos-achtige patiënten vonden we een chromosomale 
verandering die niet eerder ontdekt was (hoofdstuk 5.2). De bevindingen van de 
twee bovengenoemde studies geven aan dat de genoom-brede array een geschikte 
techniek is voor het vinden van delen van chromosomen die genen kunnen bevatten 
voor verschillende syndromen of ziekten.
 In hoofdstuk 6 worden de in dit proefschrift beschreven resultaten besproken 
en worden toekomstperspectieven voor het diagnostische onderzoek bij mentale 
retardatie en aangeboren afwijkingen beschreven. Het identificeren van nieuwe 
ziekte veroorzakende chromosomale varianten in patiënten met mentale retardatie is 
verbeterd. Daartegenover staat dat het vinden van het hoge aantal mogelijk pathogene 
varianten in kopie aantal een enorme uitdaging heeft geïntroduceerd, namelijk om te 
komen tot een juiste en goed onderbouwde interpretatie van deze varianten in het 
genoom. 
 Het is zeer waarschijnlijk dat uiteindelijk de nieuwe generatie sequencing 
technieken de arrays zullen gaan vervangen en deze zullen op hun beurt weer 
helpen nieuwe mentale retardatie genen en syndromen te identificeren. Echter, het 
aantal varianten in het genoom dat wordt gevonden zal dan nog veel groter zijn, de 
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Figure 1.1 Schematic overview of the Affymetrix platform procedure
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Figure 1.2 Schematic overview of the Illumina platform procedure
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Figure 2.1 37.26 Mb region of LOH on chromosome 20q in case BC311 detected with the Illumina 317K 
BeadChip. Beadstudio logRratio estimate for each individual SNP in the first plot and genotype call for 
every SNP in the second plot. The X-axis shows the position on the chromosome.
Figure 2.2 (a) CNAG copy number analysis for patient CR355 using the Affymetrix 262K GeneChip. LogR-
ratio estimate for each individual SNP in the first plot and for an average of 10 SNPs in the second plot. Both 
plots show a slight increase in logRratio for whole chromosome 13. Blue line in first plot: copy-number 
estimate calculated with the Hidden Markov Model. The X-axis shows the position on the chromosome. 
Green stripes: heterozygous SNP calls. (b) CNAG copy number analysis output for patient CR377 using 
the Affymetrix 262K GeneChip. Both plots show a slight increase in logRratio for chromosome 14. (c) FISH 
experiment (probes LSI13 (green) and LSI21 (red), Vysis) showing a normal cell. (d) FISH experiment show-
ing the presence of a mosaic trisomy 13 in 18% of the 200 cells analyzed.  (e) FISH experiment (probes LSI 
CCNDI, 11q13 (red) and LSI IGH, 14q32 (green), Vysis) showing a normal cell. (f ) FISH experiment showing 
the presence of a mosaic trisomy 14 in 9% of the 200 cells analyzed. (g) Facial picture of patient CR355. 
Facial dysmorphisms included upslant of palpebral fissures, a broad nasal bridge and uplifted earlobes. (h) 
Picture of postaxial polydactyly of the left hand of CR355. (i) Facial pictures of case CR377, 3 years and 7 
months (I, II), and 4 years and 8 months (III). Note marked asymmetry when smiling, asymmetric upslanted 
palpebral fissures, left sided epicanthus, hypertelorism, low-set and small right ear.
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Figure 3.1.1 Phenotypical characteristics of cases with a 16p11.2 deletion. (a) case 2 (overview aged 16 
years (left), face aged 7 years (top) and 17 years, (b) case 3, (c) case 6, (d) case 10, (e) case 11, (f ) case 12, 
(g) father of case 12, (h) case 13,  (i) case 14 (at the age of 9 months (left) and 4 years). Some of the cases 
share facial characteristics (long nose in cases 6, 12 and, father of case 12) (c, f, g); narrow palpebral fis-
sures in cases 6 and 14(c, i); periorbital fulness in cases 2, 3, and 11(a, b, e); ptosis in cases 13 and 14 (h, i). 
Overall however, patients show no common facial features.
Figure 3.1.2 Facial characteristics of cases with an atypical 16p11.2 deletion. (a) case 15, (b) father of case 
15. Note long narrow face, prominent forehead, downslanted and narrow palpebral fissures, and down 
turned corners of the mouth in both.
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Figure 3.3.1 Patient 1 and his brother. (a) Patient 1 with elongated face and flat midface. (b) Scoliosis of 
patient 1. (c) Flat, thin and long feet of patient 1. (d) Brother of patient 1 with similar facial appearance. 
(e) Scoliosis and pectus excavatum of the brother. (f ) Flat, thin and long feet with long first digits of the 
brother. (g) SNP array (Affymetrix Genome-Wide Human SNP Array 6.0) results of patient 1 showing a 12.5 
Mb duplication. Log2ratios for each probe are plotted against the position on the X-chromosome. Intensity 
values are compared with normal males and females resulting in Log2ratios below zero for one copy of 
the X-chromosome for males. Duplicated regions have a Log2ratio of 0, including the pseudoautosomal 
regions 1 and 2 (PAR 1 and 2) at Xp22.3 and Xq28.
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Figure 3.3.2 Patient 3. (a) Facial appearance showing oval eyes, short nose and a relative small chin. (b) 
SNP array (Affymetrix GeneChip Human Mapping 262K NspI and 238K StyI) results showing the 2.71 Mb 
deletion and 6.22 Mb duplication. Intensity values are compared with normal males resulting in Log2ratios 
of zero for one copy of the X-chromosome. Log2ratios for each probe are plotted against the position on 
the X-chromosome.  
Figure 3.4.2 Case 1. (a) SNP array analysis revealed a duplication of 10.11 Mb on chromosome 10 and (b) a 




Figure 4.1.1 Cytogenetic and molecular results. (a) Partial karyotype showing both chromosomes 9. Right: 
abnormal chromosome 9. (b) MLPA analysis revealing an aberration of the 9q probe. Red peaks: control 
panel; blue peaks: patient. (c) SNP array analysis of the patient revealed an aberration on the long arm of 
chromosome 9 of approximately 2.93 Mb. The threshold for deletions and duplications is, respectively, 1.6 
and 2.4. (d) SNP array copy number plot focused on the duplicated region of chromosome 9, showing a 
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Figure 4.1.2 (a) FISH analysis with RP11-270D17 (green) and GS-135I17 (red) observed a duplication for 
both the probes confirming the 400 kb and 130 kb duplication, respectively. (b) Hybridization with RP11-
413M3 (green, centromeric side of chromosome 9q) and RP11-48E05 (red, telomeric side of chromosome 
9q) revealed the presence of four red and four green signals. The signals for the chromosome with the 
triplicated region showed that the middle repeat is inverted (green-red-red-green-green-red). (c) For probe 
RP11-48E05 the centromeric signal was of double intensity as compared to the telomeric signal. For probe 
RP11-413M3 (green) the telomeric signal was stronger than the centromeric signal. This indicates that the 
repeats of the triplication are normal in the proximal and distal region and inverted in the central region.






Figure 4.2.1 Pictures of the index patient and her apparently healthy brother. (a) (b) Facial picture of the 
index patient at the age of 3 (a) and 4 (b) years. Note frontal bossing, hypotelorism and thin and long face. 
(c) Facial picture of her brother at the age of 2 years.
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Figure 4.2.2 Cytogenetic and molecular analysis of the familial t(3;21)(p26.3;q22.3). (a) Conventional kary-
otyping revealed no abnormalities for chromosomes 3 and 21 in the index patient. The arrow indicates 
the aberrant chromosome 21. (b) SNP array analysis (Affymetrix GeneChip Human Mapping 262K NspI) 
results for the index patient demonstrating a 3 Mb duplication on the short arm of chromosome 3 and a 5 
Mb deletion on the long arm of chromosome 21. Genes involved on both regions, UCSC Human Genome 
Browser (http://genome.ucsc.edu), Mar 2006 build (hg18). (c) FISH analysis confirmed the presence of the 
derivative chromosome 21 (black arrow), originating from a translocation between 3p (green; GS-1186B18; 
Flint) and 21q (red; GS-63H24; Flint). Control probes used for centromere chromosome 3 (red; CEP3; Vysis) 
and satellites of chromosome 13 and 21 (green; a-sat 13/21; Cytocell). (d) FISH analysis for the mother 
of the index patient demonstrated that she is carrier of the balanced t(3;21)(p26.3;q22.3) (black arrows) 
(probes: GS-1186B18, GS-63H24, CEP3 and a-sat 13/21). (e) FISH analysis for the brother of the index pa-
tient showing the derivative chromosome 3 (black arrow) (probes: GS-1186B18, GS-63H24, CEP3).
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Figure 5.1.1 Case 2 (a) Deletion of chromosome 17q21.31 (485 kb) found with the Illumina’s Sentrix Hu-
manHap300 Genotyping Beadchip. (b) MLPA analysis confirmed the deletion. Deleted probes: MAPT and 
KIAA1267. (c) Picture of the eyes of case 2, characterized by blepharophimosis, bilateral upper lid ptosis, 
epicanthus inversus and telecanthus.
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Figure 5.1.2 Case 4 (a) Deletion of chromosome 10p12.33-p12.31 (4.5 Mb) detected with Affymetrix 
GeneChip Human Mapping 262K NspI .(b) FISH analysis confirmed the deletion. Control probe: RP11-390B4 
(red), deleted probe 10p12.31: RP11-177H22 (green). (c) Facial picture of case 4, showing blepharophimosis, 
ptosis, epicanthal folds, ectropion of the lower eyelid, S-shaped upper eyelid, synophrys.
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Figure 5.1.3 Case 9 (a) Terminal deletion of chromosome 3p25.3 (8.6 Mb) and terminal duplication of 
6p24.3 (7.7 Mb) detected with the Illumina’s Sentrix HumanHap300 Genotyping Beadchip. The derivative 
chromosome 3 was not observed by conventional G-banding. (b) FISH analysis revealed the presence of an 
unbalanced 3;6 translocation. Left panel, control probe: CEP3 (red) (Vysis), 6pter probe: GS-196I5 (green); 
right panel, control probe: CEP3 (red) (Vysis), 3pter probe; GS-186B18 (green). (c) Pedigree of the family 
with the segregating t(3;6) analyzed with FISH experiments.  : balanced t(3;6);  : 3p25.3 deletion 
and 6p24.3 duplication;      : 3p25.3 duplication and 6p24.3 deletion. (d) Facial picture of case 9 (IV-2), 
characterized by blepharophimosis, ptosis, flattened and broad nose. Facial pictures of two relatives (III-5, 
IV-13) with the same unbalanced translocation as case 9 are presented. These members show similar 
clinical features. In addition, a facial picture of a relative (V-2) with the opposite unbalanced translocation 
is shown. No BPES-like features are seen in this child.
